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Abstract
The goal of an early phase clinical trial is to find the regimen (dose, combina-
tion, schedule, etc.) satisfying particular toxicity or (and) efficacy characteristics.
Designs for trials studying doses of a single cytotoxic drug are based on the funda-
mental assumption “the more the better”, that is, the toxicity and efficacy increase
with the dose. This monotonicity assumption can be violated for novel therapies
and for more advanced trials studying drug combinations or schedules. It also be-
comes common to consider a more complex endpoint rather than a binary one as
they can carry more information about the drug. Both the violation of the mono-
tonicity assumption and the complex outcomes give rise to important statistical
challenges in designing novel clinical trials which require an extensive attention.
In the first part of this thesis, we consider a specific class of combination trials
which involve novel therapies and can benefit from the monotonicity assumption.
We also propose a general tool evaluating the performance of novel designs in the
context of complex clinical trials. Further, we consider a problem of Bayesian
inference on restricted parameter spaces. We propose novel loss functions for pa-
rameters defined on the positive real line and on the interval demonstrating their
performances in standard statistical problems. Based on the obtained results, we
propose a novel allocation criterion for model-based designs that results in a more
ethical allocation of patients.
In the second part of this thesis, we consider a more general setting of early phase
trials in which an investigator has no (or limited) information about the monotonic
i
orderings of regimens’ responses. Using an information-theoretic approach we
derive novel regimen selection criteria which allow the avoidance of any parametric
or monotonicity assumptions. We propose novel designs based on these criteria
and show their consistency. We apply the proposed designs to Phase I, Phase II
and Phase I/II clinical trials and compare their performances to currently used
model-based methodologies.
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Clinical trials are an integral part of drug development. A clinical trial is defined
as a prospective study comparing effects of interventions in a human being. In the
specific context of drug trials, four different phases of testing are conventionally
identified (Friedman et al., 2015):
• Phase I, first in human clinical trials, primarily evaluating the basic safety
of a drug
• Phase II, evaluating whether a drug has the desirable biological activity/activities
• Phase III, confirmatory trials, assessing the effectiveness of a drug and com-
paring it to a standard of care or a placebo
• Phase IV, a post-marketing phase, which identifies and evaluates long-term
effects of a drug
Phase III and Phase IV clinical trials are usually conducted using a large number
of patients and have been extensively studied in the literature (see e.g. Chow and
Liu, 1999, and references therein). Commonly, Phase III clinical trials investigate
1
one or two dosing regimens that were found to be promising in terms of toxicity
and efficacy during Phase I and Phase II clinical trials (Friedman et al., 2015).
Therefore, successes in later phases depend, to a great extent, on the knowledge
about the novel compound obtained in early phase clinical trials, which are argued
to be one of the most important steps in the drug development. A well-designed
early phase study is therefore essential to provide valuable information (Chevret,
2006). This underlines the need for effective statistical methods for the accurate
selection of optimal dosing regimens. Early phase clinical trials are, however, con-
ducted using a small number of patients or healthy volunteers and face particular
ethical restrictions due to the limited knowledge about adverse events associated
with a new drug. This raises many statistical challenges which need to be ad-
dressed appropriately. Due to its great importance, the methodology for early
phase clinical trials is a growing field and is attracting a lot of attention both
from statisticians and clinicians (Chevret, 2006). In this thesis, we propose novel
methods for early phase clinical trials prompted by emerging practical needs. The
proposals in this thesis are mainly motivated by statistical challenges arising in
the context of oncology studies. However, the majority of novel methodologies
presented are generic and can be applied beyond cancer trials and beyond early
phase designs.
Early phase clinical trials are commonly called dose finding clinical trials as they
aim to identify the optimal (in some sense) dosing regimen of a drug. In recent
years, the term “doses” has expanded to not only be understood as doses of a single
drug but as different treatment levels which can be, for example, the combinations
of several drugs or schedules of administration (Bornkamp, 2017). For the sake of
terminology, we will refer to a “dose” as a dose of a single agent, and we use the
term “regimen” as a generic name of the objects of study in an early phase clinical
trial. Depending on the context, the regimen can be dose, combination, dose-
schedule, combination-schedule. Goals of early phase regimen finding oncology
clinical trials are described below.
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Phase I clinical trials are the first studies in humans evaluating the toxicity of
regimens. There is limited e affects a human body, and the initial step here is
to find “safe” regimens. Given a discrete set of regimens, the goal of Phase I
clinical trial is to identify the maximum tolerated regimen (MTR) defined as the
regimen having the maximum acceptable level of toxicity γt (Friedman et al.,
2015) where t stands for toxicity and γt might be a percentage, a score or a medical
characteristic depending on the trial’s endpoint. Phase I clinical trials are usually
referred to as regimen escalation trials. It is a common practice to summarise
the data about the regimen’s toxic severity in a single binary outcome, a limiting
toxicity, conventionally called dose-limiting toxicity, DLT, (Le Tourneau et al.,
2009). In this case, γt is a maximum acceptable proportion of patients suffering
toxicity. Then, the MTR defines the set of regimens that have an acceptable
probability of DLT and can be studied in subsequent phases. We will use terms
maximum tolerated dose (MTD) and maximum tolerated combination (MTC) in
contexts of single agent and combination trials, respectively.
Once the set of safe regimens is defined, the second step is to ensure that at least
one of them has a desirable therapeutic effect (Yin, 2013). To answer this question,
the efficacy of regimens is evaluated in Phase II clinical trials. Given a discrete set
of regimens, the goal of Phase II clinical trial is to find the regimen corresponding
to a pre-specified efficacy level γe (where e stands for efficacy), which, again, can
be a percentage, a score or a medical characteristic. Phase II clinical trials are
usually referred as regimen ranging trials. Upon the completion of Phase II trials,
the regimens (usually one or two) for a Phase III confirmatory clinical trial are
selected (Friedman et al., 2015).
For many years Phase I and Phase II clinical trials were conducted separately.
However, there was a recent shift to integrate these phases into a single study.
This integration allows for the acceleration of development of the trial and a re-
duction in costs (Yin, 2013). The integrated trial also provides more observations
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for both toxicity and efficacy endpoints and can result in a more reliable recom-
mendation for Phase III study, particularly, for novel agents (Wages and Conaway,
2014). The goal of a Phase I/II clinical trial evaluating both toxicity and efficacy
simultaneously is to find the optimal biologic regimen (OBR) corresponding to
pre-specified levels of toxicity and efficacy.
Despite different formulations of research problems, the goals of all these trials are
similar from the statistical perspective. The common goal of an early phase study
is to find the regimen having characteristics “as close as possible” to the target γ
which can be either a scalar (e.g. γt or γe) or a vector (e.g. (γt, γe)
T). We would
use the term target regimen (TR) to emphasise that a particular design can be
applied to different types of trials.
1.2 Motivation
The primary motivation behind methods proposed in this thesis is the growing
complexity of early phase clinical trials. It is becoming more common to con-
sider more complex dosing regimens rather than doses of a single agent only. For
instance, therapies using a combination of drugs have become the mainstream ap-
proach to diseases such as cancer (Khalil et al., 2016) and tuberculosis (Kerantzas
and Jacobs, 2017). It was found that administering several agents simultaneously
can noticeably improve their safety profiles and therapeutic effects. However, po-
tential synergistic (or antagonistic) effects give rise to additional challenges in
designing early phase combination trials compared to single agent ones. A lot of
dose finding trials are based on the fundamental assumption “the more the bet-
ter”, that is, the toxicity of the drug increases with the dose. This is also known
as the monotonicity assumption (Clertant and O’Quigley, 2017). This means that
clinicians can naturally order doses according to the monotonically increasing tox-
icity. This, however, might not hold for combinations. Consider two dual agents
combinations: T1 and T2. Assume that, relative to T2, the combination T1 has a
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higher dose of the first compound, but a smaller dose of the second compound. In
the vast majority of trials, clinicians cannot define which of these combinations is
more toxic prior to the trial (Wages et al., 2011). The same argument holds when
considering efficacy levels of combinations.
The schedule of administration can add an additional complexity as well (Kodama
et al., 2009). As an illustration, consider a six days course of treatment and two
dose-schedules: (i) 10 mg a day every day and (ii) 20 mg a day every two days.
The total amount of drug received by a patient is the same by the end of six
days, but it is unclear which of these dose-schedules is more toxic. A smaller dose
is expected to reduce toxicity, but a more regular administration is expected to
increase it. Again, clinicians cannot define which of these effects is greater in many
clinical trials.
The problem of unknown ordering of toxicities and efficacies can also appear in
the single agent context. While the paradigm “the more the better” holds for
cytotoxic agents, it can be violated for molecularly targeted agents (MTA) which
include hormone therapies, signal transduction inhibitors, gene expression mod-
ulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin
delivery molecules, among others. For MTAs either dose-efficacy or dose-toxicity
relationships can have a plateau (Morgan et al., 2003; Postel-Vinay et al., 2011;
Robert et al., 2014; Paoletti et al., 2014) or a dose-efficacy relationship can exhibit
an umbrella shape (Conolly and Lutz, 2004; Lagarde et al., 2015).
The problems in all of these advanced clinical trials are similar in their nature as
they suffer from the unknown ordering of regimens and cannot fully benefit from
the monotonicity assumption. Additionally, more complex outcomes rather than
binary ones are becoming of growing interest in clinical trials as they can carry
more information about the profile of a drug (see e.g. Thall and Cook, 2004; Lee
et al., 2010, 2017). To conduct more complex clinical trials, specific methods for
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the adequate identification of the TR are essential. In this work, we propose novel
designs that are able to address either some or all of the stated challenges and
extend several well-established early phase designs in order to guarantee a more
accurate and ethical regimen selection.
1.3 Outline of Thesis
In Chapter 2 we consider several types of combination trials which can benefit from
the monotonicity assumption. We show, however, that the straightforward appli-
cation of standard Phase I dose escalation model-based designs may fail to address
the goals specific to the combination context and propose an alternative. Further,
we generalise the non-parametric optimal benchmark O’Quigley et al. (2002), a
tool to evaluate the performance of regimen finding designs, to the setting of com-
plex trials with multiple endpoints having discrete or continuous distributions.
In Chapter 3 we consider a problem of estimation in restricted parameter spaces
that arise in many areas of regimen finding. We stress that standard criteria for the
choice of estimators and for the allocation of patients might not be a proper choice
in the context of early phase clinical trials. We demonstrate the performance of
the proposed estimator in some classic statistical problems and construct a novel
allocation criterion for a Phase I model-based design which improves its ethics.
In Chapter 4 the general setting of regimen finding clinical trials with the mono-
tonicity assumption violation and multinomial outcomes is considered. We propose
a class of novel designs which relax the monotonicity assumption and can be ap-
plied in complex Phase I, Phase II and Phase I/II trials. We demonstrate their
applications motivated by actual clinical trials.





Designs and Optimal Benchmarks
2.1 Background
Historically, Phase I oncology clinical trials investigated increasing doses of a
single cytotoxic compound, e.g. chemotherapy or radiotherapy. Based on their
mechanism of action, it is known that a higher dose has higher toxicity and the
monotonicity assumption is satisfied. The algorithm-based “3+3” dose escalation
design (Carter, 1973; Storer, 1989) was one of the first methods used to conduct
dose escalation studies of cytotoxic cancer treatments in humans. Despite an enor-
mous number of papers showing that the 3+3 design is inferior to model based
alternatives (see e.g. O’Quigley et al., 1990; Ratain et al., 1993; Kang and Ahn,
2001, 2002), it is still the most common design used in a clinical practice (Ro-
gatko et al., 2007; Le Tourneau et al., 2009; Chiuzan et al., 2017) due to its
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simple escalation/de-escalation rules which do not require any support from a
statistician. The 3+3 design uses the information from the most recently enrolled
patients only and ignores earlier data obtained in the trial. This results in a sys-
tematic underestimation of the MTD, an unethical allocation of patients (patients
are assigned to low doses far from the target toxicity) and a high risk of erroneous
conclusions (Reiner et al., 1999). Instead, more statistical approaches that use all
available information have been shown to lead to noticeable improvements in the
probability of correct MTD selection (Wheeler, 2017). Below we recall the core
of model-based dose escalation designs that formed the basis of many of regimen
escalation methodologies.
2.1.1 Continual Reassessment Method Type Designs
Consider a single agent Phase I clinical trial with binary toxicity outcome, dose-
limiting toxicity (DLT) or no DLT, N patients and m dose levels d1, . . . , dm. Let Yij
be a binary (Bernoulli) random variable taking value yij = 0 if patient i has
experienced no DLT given dose dj and yij = 1 otherwise. This random variable is
characterised by toxicity probability pj such that pj = P (Yij = 1), i = 1, . . . , N .
It is assumed that the toxicity probability is an increasing function of dose, p1 <
. . . < pm. The goal of the trial is to find the MTD, the dose corresponding to the
target level of toxicity, γt.
Original Continual Reassessment Method One of the first model-based
dose escalation designs that borrows information across doses was the Bayesian
Continual Reassessment Method (CRM) by O’Quigley et al. (1990). Relying on
the monotonicity assumption, the idea of the method is that the identification
of the MTD can be efficiently achieved by means of a working model without
characterizing the true dose-toxicity relationship.
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Assume that toxicity probability pj has the functional form
pj = ψ(dj, θ) (2.1.1)
where θ ∈ Rd is a d-dimensional vector of parameters and dj is a scalar unit-less
dose level (also refereed as standardised levels). Denote the prior distribution of θ
by f0(·). Assume that n patients have been already assigned to doses d(1), . . . , d(n)
and binary responses y1, . . . , yn were observed, respectively. The CRM updates the
posterior distribution of θ using Bayes’s Theorem
fn(θ) =
fn−1(θ)φ(d(n), yn, θ)∫




i=1 φ(d(i), yi, θ)∫
Rd f0(u)
∏n
i=1 φ(d(i), yi, u)du
(2.1.2)
where
φ(d(i), yi, θ) = ψ(d(i), θ)
yi(1− ψ(d(i), θ))1−yi .








Patients in the dose escalation trial are assigned cohort-by-cohort, where a cohort
is a small group of typically 1 to 4 patients. Then, the dose dj that minimises
|pˆ(n)j − γt|, (2.1.4)






, among all d1, . . . , dm is rec-
ommended for the next group of patients. The procedure is repeated until the
maximum number of patients, N , has been treated. Note that the original CRM
implementation plugs the mean value of θ in the model ψ(dj, θˆ) instead of using
the posterior mean (2.1.3). While no noticeable differences in these approaches
are found for a 1-parameter model (Iasonos et al., 2016), a difference can, how-
ever, be expected using models with more parameters. Therefore, we will use the
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estimator (2.1.3).
There have been many developments building on the CRM since its original pro-
posal. O’Quigley and Shen (1996) have considered a likelihood approach to CRM
and Shen and O’Quigley (1996) have formulated the conditions of its consistency
(the probability that the design would select the true MTD tends to 1 as N →∞).
Korn et al. (1994); Zohar and Chevret (2001); O’Quigley (2002) have consid-
ered early stopping rules to accommodate practical challenges of implementations
in actual clinical trials. Cheung and Chappell (2002); Lee and Cheung (2009);
O’Quigley and Zohar (2010); Cheung (2011) have investigated choices of stan-
dardised levels d1, . . . , dm and parameters of the prior distribution f0. Cheung and
Chappell (2000) have proposed a modification called the time-to-event CRM which
accommodates late-onset toxicities and leads to conducting a trial in a timely man-
ner. Cheung (2005) has shown that the CRM does not lead to counter-intuitive
escalation/de-escalation decisions that would not be accepted by clinicians. The
CRM was subsequently extended to contexts of more complex trials, for example,
to Phase I combination trials (Wages et al., 2011) and to Phase I/II dose finding
trials (Braun, 2002).
While it is generally agreed that the Bayesian CRM design leads to an accurate
MTD selection, the choice of ψ(dj, θ) is debated (Iasonos et al., 2016). The common
parametric forms of the model function are given below.
Choice of the Working Model in Model-based Designs The common
choice for the 1-parameter working dose-toxicity model is
ψ(dj, θ) = d
exp(θ)
j (2.1.5)
or ψ(dj, θ) = d
θ
j where θ is a scalar parameter (O’Quigley and Shen, 1996). The use
of 1-parameter models is motivated by challenging estimation given small sample
sizes.
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On the other hand, it is argued that the 1-parameter model (2.1.5) does not re-
flect the anticipated dose-toxicity relation (Neuenschwander et al., 2008). Instead,
the logistic function was suggested as an appropriate alternative with a clinically
relevant interpretation. Whitehead and Williamson (1998) proposed to use the
2-parameter logistic model
ψ(dj, θ1, θ2) =
exp(log(θ1) + θ2dj)
1 + exp(log(θ1) + θ2dj)
(2.1.6)
where θ1, θ2 are scalar parameters. There are variants of the logistic model: with
parameter θ1 being known and fixed and with both θ1 and θ2 being unknown. The
same parametric model was also used by Babb et al. (1998). This model is seen to
be appropriate in the context of actual clinical trials and is extensively employed
in practice (Neuenschwander et al., 2008) despite potential inconsistency problems
raised by Iasonos et al. (2016). Paoletti and Kramar (2009) have compared several
model choices of ψ(·) in a comprehensive simulation study. Routinely, models
with more than two parameters are not routinely considered in the setting of dose
escalation trials.
Regardless of the choice of working model, the dose escalation designs above are
based on the “strict” assumption of monotonicity (the toxicity strictly increases
with the dose). In Section 2.2 we consider particular types of combination trials
for which the monotonicity assumption holds in a “non-strict” sense - the toxi-
city does not decrease with the dose. While such trials can potentially benefit
from application of single-agent dose escalation designs, we show that they do not
address all goals of combination trials and might lead to misleading conclusions.
Consequently, we propose modifications to model-based designs to accommodate
the combination specific setting.
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2.1.2 An Optimal Benchmark for Studies with a Binary
Endpoint
A variety of dose finding methods for Phase I clinical trials aiming to find the MTD
were developed in the literature since the proposal of the CRM. A conventional
way to assess the performance of a design is to conduct an extensive simulation
study. One of the key characteristics of any regimen finding method is its accuracy
which is usually computed as the proportion of times the true target regimen (e.g.
the MTD) is selected (also referred as the proportion of correct selections - PCS).
The majority of novel proposals are studied in scenarios chosen by investigators
themselves. This, clearly, adds subjectivity to the assessment of a method’s oper-
ating characteristics as one can always find scenarios in which the TR selection is
easier than in others.
To solve this problem, O’Quigley et al. (2002) proposed the non-parametric opti-
mal benchmark that provides an upper limit of accuracy (in terms of the PCS) for
dose finding methods based on a binary toxicity endpoint. The benchmark uses
the complete information concept which assumes that outcomes of each patient
can be observed at all dose levels (in contrast to an actual trial in which a pa-
tient can be assigned to one dose only). The benchmark shows how “difficult” the
TR identification is in the chosen scenario and provides the objective context for
the performance evaluation of the design under investigation. Since its proposal,
the benchmark has proven its great usefulness to assess newly proposed designs
comprehensively (see e.g. Paoletti and Kramar, 2009; Yin and Yuan, 2009). Ad-
ditionally, based on the benchmark, Cheung (2013) derived sample size formulae
for the CRM.
In the setting of a Phase I single agent trial with a binary endpoint aiming to iden-
tify the MTD, the benchmark was proposed as follows. For a given patient the
complete information consists of the vector of outcomes at all dose levels assuming
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that p1, . . . , pm are known. In other words, for a given patient one knows the max-
imum toxicity probability that this patient can tolerate. Formally, the information
about the response of patient i at all dose levels is summarised in a single value
ui ∈ (0, 1), profile of the patient, which is drawn from a uniform distribution,
U(0, 1). The value ui was also defined as a tolerance of patient i by Finney (1952)
who, historically, was one of the originators of the idea of having an increasing
series of probabilities generated by shareholding a continuous distribution which
formed a basis for the complete information concept. For instance, ui = 0.3 means
that patient i can tolerate doses dj with pj ≤ 0.3, but would experience a DLT
if given dose dj′ with pj′ > 0.3. It follows that ui is transformed to yij = 0 for
doses with pj < 0.3 and to yij = 1 otherwise. The procedure is repeated for N
patients which results in the vector of responses corresponding to each dose level
yj = (y1j, . . . , yNj), j = 1, . . . ,m. Let T (yj, γt) be a summary statistic for the dose
level dj upon which the decision about the MTD selection is based. Convention-
ally, T (yj, γt) is chosen such that its minimum (or maximum) value corresponds to
the estimated MTD. Therefore, dj for which T (yj, γt) is minimised (maximised) is
selected as the MTD in a single trial. The procedure is repeated for S simulated
trials and then proportions of each dose selections are computed.
In a context of Phase I clinical trial with a binary endpoint





is a conventional choice for the MTD selection criterion. Wages and Varhegyi
(2017) proposed a Web application for the benchmark evaluation using this crite-
rion.
Motivated by more complex studies, for instance, Phase I/II clinical trials eval-
uating binary toxicity and binary efficacy endpoints simultaneously (Thall and
Russell, 1998) or Phase I trials with multiple grades of toxicities (Lee et al., 2011),
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Cheung (2014) generalized the benchmark to both of these cases. This has broad-
ened the benchmark application significantly. However, there are a growing num-
ber of Phase I and Phase I/II clinical trials involving continuous endpoints, but
no corresponding benchmark exists. For example, Bekele and Thall (2004); Yuan
et al. (2007); Ivanova and Kim (2009); Bekele et al. (2010); Ezzalfani et al. (2013);
Wang and Ivanova (2015) considered a continuous toxicity endpoint while, for ex-
ample, Bekele and Shen (2005); Hirakawa (2012); Yeung et al. (2015, 2017) studied
Phase I/II trials with binary toxicities and continuous efficacies.
In Section 2.3, we propose a new benchmark which can be applied to dose find-
ing studies with continuous outcomes and shares the same concept of the com-
plete information as the original approach. We demonstrate the application of the
benchmark in contexts of recently proposed Phase I and Phase I/II dose finding
designs.
2.2 Designs for Combination Trials Involving
an Immunotherapy
2.2.1 Problem Formulation
The monotonicity assumption upon which the CRM type designs are based can
be violated for MTAs, e.g. an immunotherapy. For example, the majority of
Phase I trials of immune-checkpoint protein blockers, such as anti-programmed-
death-receptor-1 (PD1), have never actually reached the MTD (see e.g. Robert
et al., 2014; Patnaik et al., 2015; Yamamoto et al., 2017). At the same time,
immunotherapies have been shown to have a strong anti-tumour activity and a
better safety profile than cytotoxic cancer therapies (Disis, 2010; Kyi and Postow,
2014). It was also found that the therapeutic effect of an immunotherapy can
be noticeably improved by combining it with a backbone chemotherapy or other
targeted agents (Sharma and Allison, 2015). Therefore, there are many Phase I
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combination trials investigating either (i) the added value of an immune checkpoint
blocker to a backbone therapy or (ii) the added value of a new agent to an immune
checkpoint blocker (Pardoll, 2012). In both cases, one agent, called a standard of
care, is administered at a fixed dose and another agent is dose-escalated. While
such setting allows for the straightforward adaptation of single agent designs, it
also hides potential difficulties.
The conventional goal of Phase I drug combination trial is to find the maximum
tolerated combination (MTC). However, many studies of immunotherapies have
never actually reached the maximum tolerated level as stated above. An im-
munotherapy can also have a complex mechanism of its interactions with other
compounds (Sharma and Allison, 2015). Consequently, when considering combi-
nation trials involving an immunotherapy, the information beyond the conventional
(and only) objective of a Phase I study can be also important for a more accurate
choice of the combination(s) to study in subsequent phases.
We focus on the setting that covers two important types of Phase I clinical trials
with corresponding research questions added to the MTC selection:
1. The standard of care is a toxic agent (e.g. chemotherapy) and is given at the
full (single agent) dose and an immune-checkpoint blocker is dose-escalated.
A clinician would tolerate only a slight increase τ in the toxicity of combi-
nation compared to the toxicity of the standard of care (Paller et al., 2014)
and the question whether “the increase in toxicities is acceptable?” should
be tested.
2. The standard of care corresponds to a low toxicity level (e.g. an immune-
checkpoint blocker) and is given at the full (single agent) dose and either a
toxic agent or an MTA is dose-escalated.
(a) An interest is to determine a plateau region between the estimated MTC
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and the standard of care which would help to define the therapeutic index
(a ratio of the dose that produces highest acceptable toxicity to the dose
needed to produce the desired therapeutic response) more accurately. A
plateau is defined by not exceeding the difference in associated toxicities by
more than τ .
(b) A clinician has an expectation of an additional toxicity τ over the stan-
dard of care under the assumption of compounds independence. An interest
lies in checking for an interaction effect defined as an additional toxicity
over τ .
The objectives of these trials are (i) to identify the MTC, (ii) to quantify the ex-
pected difference between single and combination treatments and (iii) to determine
the shape of the dose-toxicity relationship. These clinical trials share a common
interest in the comparison of toxicity levels associated with the estimated MTC
and the standard of care alone but they differ in their motivation. To unify nota-
tion, we study the extra toxicity (ET) beyond the expected difference τ . We show
that standard single agent dose-escalation methods currently used for such trials
may fail to address secondary questions of the trial.
To achieve all objectives, we suggest to adapt two modifications to the Bayesian
model-based design. We propose to include the standard of care given alone as a
control arm and, to randomise each patient to the control arm or to the combi-
nation selected by the Bayesian model-based design. We demonstrate that such
randomisation procedure leads to a reliable statistical evaluation of the ET (added
over the standard of care) and of the general interaction effects between com-
pounds. We also show that the Emax model provides a well-established tool to
detect and to evaluate different patterns in the dose-toxicity relationship and its
parameters match the information needed to address stated objectives.
It is important to mention that the question of using the control group in Phase I
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trials is widely debated in the literature (e.g. Saad et al., 2017). The main argu-
ment against is the monotonicity assumption that makes comparing toxicity levels
unnecessary and results in considering the control group as not contributing to the
goal of the trial (the MTC selection). However, this assumption has been found
to be inappropriate for many immunotherapies. Importantly, patients allocated
to the control arm receives the standard of care which makes the randomisation
an ethically viable option. It will be also demonstrated that modelling the data
observed for the control group simultaneously with the escalated arm contributes
to toxicity estimates for all dose levels and can serve the MTC selection objective
as well.
2.2.2 Motivating Trials
The proposed design is motivated by two recent combination trials that could
potentially benefit from its implementation.
Gemcitabine is a standard chemotherapy for an advanced pancreatic cancer (Agli-
etta et al., 2014) which has a narrow therapeutic index (Crane et al., 2002). Treme-
limumab is a fully humanized monoclonal antibody against CTLA-4 that may al-
low effective immune responses against tumour cells. In several clinical studies,
anti-CTLA4 agents have been shown to induce durable tumour responses through
modulation of the immune system in patients with metastatic melanoma (Buch-
binder and Desai, 2016). The hypothesis was that the combination of these two
agents “might provide a synergistic anti-tumour activity without increasing tox-
icity” (Aglietta et al., 2014). Gemcitabine 1000 mg/m2 was administered in all
patients while escalating doses of tremelimumab (6, 10 and 15 mg/kg) were se-
quentially tested to identify the MTC. This trial was conducted using the 3+3
design, leading to a high risk of erroneous conclusions due to the assumption of
the increasing dose-toxicity relationship. Furthermore, as the expected probabil-
ity of the DLT for Gemcitabine is more than 20%, any (if the dose-response curve
is flat) or no combination (if the dose-response curve is steep) can be the MTC.
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Finally, the highest dose was recommended for further investigations, but the ques-
tion whether the toxicity is increased over a clinically meaningful difference τ was
never formally tested.
Sorafenib is a treatment for advanced cellular cell carcinoma. However, its efficacy
remains limited as the time to progression is around six months. Despite this
agent is being prescribed at the MTD (800mg/kg), its therapeutic index makes
it possible to reduce the dose in case of adverse reactions (Wilhelm et al., 2006).
SPLASH is a dose-escalation study of Avelumab in combination with sorafenib in
patients with advanced cellular cell carcinoma that is about to be initiated at the
Hospital Gustave Roussy. While Avelumab will be given at a fixed dose, Sorafenib
will be escalated from 200 mg/kg up to 800mg/kg. The MTD is defined as the
highest dose having the probability of DLT during cycle 1 closest to 25%. The
expected DLT probability for Avelumab alone is 8%.
2.2.3 Randomisation and Emax Model
Framework Consider a clinical trial in which combinations of agents A and B
are studied. The drug A is a standard of care given at the fixed dose, a, and B
is dose-escalated. We specify increasing doses of B: 0 = b0 < b1 < b2 < . . . < bm.
Then, d˜0 = {a, b0}, d˜1 = {a, b1}, . . . , d˜m = {a, bm} are m+1 combinations available
in the trial, where d˜0 corresponds to the agent A given as a single agent and is
subsequently referred to as the control arm, and the combinations d˜1, . . . , d˜m are
referred to as the investigational arms. A clinician observes binary outcomes, DLT
and no DLT. Let pj be the probability for a patient to experience a DLT given
the combination d˜j. It is assumed that toxicity is a non-decreasing function of
combination, p0 ≤ p1 ≤ . . . ≤ pm and reliable prior information for the toxicity
probability of the control arm, p0, is available.
Let γt be the maximum acceptable toxicity probability. The primary goal of
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using estimated toxicity probabilities pˆ0, . . . , pˆm. The secondary goal, specific to
combination trials, is to test if the difference of toxicity probabilities associated
with the estimated MTC and the standard of care is as expected. The ET is
defined in terms of the expected difference, τ . One would conclude the ET when
the probability that the difference in the two estimated risks of toxicity exceeds τ
is larger than some credible level α. Formally, if the ET is present one would like
the probability
P ≡ P (P (pˆj? − pˆ0 ≥ τ) > α) (2.2.1)
to be equal to 1. In contrast, if there is no ET, the probability (2.2.1) is desired
to be equal to 0.
Note that as only one drug is varied, the problem can be considered as a uni-
dimensional MTC search and the CRM (Section 2.1.1) can be applied. It, however,
is designed for the MTC selection only, therefore, we introduce two design features
into it.
Randomisation between control and investigational arms Patients in
dose-escalation trials are assigned cohort-by-cohort. According to the original al-
location rule, the CRM design tends to assign the majority of patients in the
neighbourhood of the MTC. This leads to a sparse allocation of patients on other
combinations and on the control arm. This will make it difficult to test for dif-
ferences in toxicity risk associated with the estimated MTC and the control arm.
We introduce the following randomisation procedure between the investigational
(combinations) and control (standard of care) arms.
Denote the cohort size by c = c1+c2 and let c1 be the number of patients in cohort
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assigned to the estimated MTC by CRM according to the criterion (2.1.4), and c2
be the number of patients in cohort assigned to the control arm, d˜0. This results
in at least N2 =
c2
c1+c2




the investigational arm by the end of the trial. For instance, taking c1 = 3 and
c2 = 1 (denoted by 3:1), one will end up with at least 25% of the total sample
size being assigned to the control. Note that the model-based design is allowed
to select the control arm as the estimated MTC if the associated toxicity is the
closest to the target γt. This facilitates avoiding exposing patients to high toxicity
if the first combination has an unacceptable DLT probability. Therefore, the total
number of patients on the control arm can be more than c2
c1+c2
N .
Importantly, in the proposed design the values of c1 and c2 are fixed before the
trial. While the choice of these values is investigated in Section 2.2.6, their choice
can be also guided by a prior information that a clinician has about the standard
of care. For example, if a clinician is certain about the toxicity risk associated
with the standard of care, one can allocate more patients to the investigational
arms and use lower value of c2.
The modified allocation rule (the randomisation of patients between control and
investigational arm) raises an important question of the suitable choice of the
parametric model ψ(dj, θ) which is discussed below.
4-parameter Emax model In the context of the single agent trial, the 1-
parameter power model is argued to be an appropriate choice (Iasonos et al.,
2016). There are, however, at least two reasons why 1-parameter models are not
suitable for the type of trials considered here.
Firstly, the parametric form (2.1.5) implies the “strict” monotonicity assumption -
the toxicity increases as dose increases. It does not allow modelling a plateau in
the combination-toxicity relations. Therefore, one can expect that such a model
would tend to finding the ET regardless the scenario which is undesirable in the
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considered combination trials.
Secondly, one of the main arguments behind using a 1-parameter model (and,
consequently, the main critique of models with more parameters) is that the CRM
design tends to collect observations in the neighbourhood of the MTC only. This
means that the approximation of the dose-toxicity relation is of interest in the
neighbourhood of one point only. Clearly, 1-parameter models are rich enough to
achieve it. Note, however, that given the randomisation step proposed above, the
majority of patients will be now assigned in the neighbourhood of two points: the
control arm and the estimated MTC. Therefore, more flexible models are essential
to consider.
Motivated by the ability to model a plateau in a combination-toxicity relation, we
propose to use the 4-parameter Emax model






where E0 is the toxicity probability associated with the control arm, Emax + E0
is the maximum toxicity probability attributable to the combination, ED50 is the
combination which produces E0+
Emax
2
toxicity and λ is the slope factor. Following
the assumption of the non-decreasing toxicity probability, we specify λ ≥ 0. To
adjust the single agent model to the combination setting, the unit-less variable dj,
corresponding to the same toxicity probability as the combination d˜j, is used. To
construct dj one needs to represent them in terms of prior estimates of toxicity
probabilities pˆ
(0)





















50 are point prior estimates of model parameters.




Therefore, by definition, pˆ0(0) ≡ Eˆ(0)0 that leads to d0 = 0. Modelling E0 directly
guarantees that the sequential update of other parameters does not contribute to
the toxicity probability estimation on the control arm. In this case, the model
takes the trivial form
ψ(d0, ·) = E0.
Intuitively, it reflects that the toxicity probability of the standard therapy does
not depend on the mechanism of its interaction with compound B.
The parameters of the Emax model allows to model the toxicity on the control
arm and the plateau. Modelling a plateauing dose-toxicity relationship (e.g. im-
munotherapies) is not possible with other working models, e.g. two-parameter
logistic form. We investigate the choice of the parametric model in the numerical
study below.
2.2.4 Simulation Setting
We explore the performance of the Bayesian model-based dose-escalation method
incorporating randomisation to the control arm into the Emax model by simu-
lations in different scenarios. Motivated by a recent combination trials review
by Riviere et al. (2015) we consider a setting with N = 48 patients and m = 7
combinations. We set the target toxicity probability γt = 0.25, the expected dif-
ference τ = 0.05 and the confidence level α = 0.90.
Three main characteristics, (i) the proportion of correct selections (PCS), (ii) the
proportion of times the ET is concluded and (iii) a goodness-of-fit measure, are
considered. A goodness-of-fit measure is used to capture the overall shape of the







√√√√∑mj=0(pj − pˆ(s)j )2∑m
j=0(pj − pˆoptj )2
(2.2.2)
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where S is the number of replications, pˆ
(s)
j is the toxicity probability estimate for
combination d˜j obtained by the design in s
th simulation and pˆoptj is the toxicity
probability estimate for combination d˜j obtained by the non-parametric optimal
benchmark approach described in Section 2.1.2. The normalisation facilitates com-
parisons betwen different scenarios as the optimal benchmark incorporates their
specificities. The value of the NMSE being equal to 1 corresponds to the curve
estimated as precise as by the optimal benchmark.
Prior Specification The standardised levels, dj, are constructed using the
skeleton pˆ(0).
pˆ(0) = [0.08, 0.25, 0.35, 0.45, 0.55, 0.65, 0.70, 0.75]T.
The first value, 0.08, corresponds to the mean prior toxicity probability for the
control arm. The prior MTC being the first combination ensures that the trial is
started at the lowest combination. Other values are obtained by taking an adequate
spacing between prior values. It has been shown by O’Quigley and Zohar (2010)
that the CRM design is robust and efficient in this case. In contrast to the skeleton
that is the same regardless which parameter model is used, the prior distributions
of the model parameters needs to be calibrated such that all competing designs
carry the same amount of the prior information.
To ensure that the proposed approach and competitive designs are evaluated un-
der comparable set-ups the credible intervals for the prior toxicity probabilities
associated with the control arm and the prior MTC are used. Taking into account
that one usually has a reliable information about the standard therapy, but lim-
ited information about combinations, we specify prior distributions to satisfy the
following conditions:
1. The control arm d˜0: the expected toxicity probability is pˆ
(0)
0 = 0.08 and the
upper bound of the 95% credibility interval is 0.25.
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2. The prior MTC d˜1: the expected toxicity probability is pˆ
(0)
1 = 0.25 and the
upper bound of the 95% credibility interval is 0.80.
Following these conditions the prior distributions of the Emax model parameters
are specify as
E0 ∼ B(0.8, 10− 0.8), Emax|E0 ∼ U[0, 1− E0], ED50 ∼ Γ(0.4, 0.4), λ ∼ Γ(1, 1)
(2.2.3)
where B(u, v) denotes the Beta distribution with parameters u, v and Γ(u, v) de-
notes the Gamma distribution with the mean u
v
and the variance u
v2
. As the
choice of prior distributions may have quite a significant impact on the estimates
of parameters, we first rely on the elicitation given in Equation (2.2.3), but also
investigate the robustness to different prior distributions in Section 2.2.6. We refer
to the design using the Emax model with proposed randomisation as “EmaxR”.
Cohort Size for the Control Arm and Combination Skipping The co-
hort size is fixed to be c1 = 3 for the investigational arm and c2 = 1 for the
control arm. Therefore, at least 12 patients (25% of the total sample size) will
be allocated to the standard therapy and at most 36 patients are allocated to the
investigational arm. We allow combinations to be skipped. Other randomisation
ratios, 2 : 1 and 4 : 1, and an impact of no skipping constraint are studied in
Section 2.2.6.
Scenarios Nine qualitatively different scenarios, depicted in Figure 2.1, are
used to study the performance of the proposed approach. Scenarios 1-5 are con-
sistent with the prior information about the control arm. Scenario 1 corresponds
to a commonly used logistic dose-toxicity shape while scenario 2 considers a flat
dose-toxicity curve with the MTC being d˜7 and no ET beyond τ . In scenario 2,
the model monotonicity assumption implies that the toxicity probability on the
control has the largest difference with combination d˜7 and the model is expected
to have a tendency to claim the ET. Then, scenario 2 is used to test if the ran-
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Figure 2.1: Considered combination-toxicity scenarios. The MTC is marked by a
triangle.
domisation to the control arm together with the Emax model can prevent false
conclusions regarding the ET. Scenarios 3-4 correspond to steep dose-toxicity re-
lationships that have a plateau around and outside the target toxicity probability,
respectively. These scenarios are used to investigate under what conditions it is
easier to find the ET. Scenario 5 also corresponds to a sharp increase in toxicities,
but for medium combinations having unacceptably high toxicity such that there
is no ET between the MTC and the control arm.
Scenario 6 reflects the case of a misspecified prior toxicity probability for the
control arm - the true toxicity probability for d˜0 is below the prior value. The
prior information dictates that there is no ET between the MTC and the control
(0.11 − 0.08 < τ = 0.05), although it is present. In scenarios 7-9 the toxicity
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probability for the control is underestimated by the prior information and the
control arm has a toxicity probability close to the maximum acceptable one. Both
cases with (scenario 8) and without (scenarios 7, 9) ET are considered.
Competing Models The performance of the proposed approach is compared
to designs that are currently used for the considered types of trials: the 1-parameter
power model
pj(dj, θ) = d
θ
j
denoted by P1 and the 2-parameter logistic model given in Equation (2.1.6) with-
out randomisation denoted by L2. We also explore the possibility of randomisation
to the control arm using the 2-parameter logistic model denoted by L2R. As there
are only at most 36 patients on the investigational arm in the randomised setting
against 48 in the non-randomised one, we also consider the 2-parameter logistic
model without randomization and N = 36. This would allow spotting the influ-
ence of the randomisation on the operating characteristics. Prior distributions for













are chosen to satisfy approximately two conditions on prior distribution of d˜0
and d˜1 formulated above. While these prior parameters are chosen to satisfy
condition on two combination only, the difference can be found for the rest of
combinations. Figure 2.2 shows the prior distributions of the toxicity probability
on each combination imposed by the specified parameters’ prior distributions for
Emax, L2 and P1 models.
As expected the prior distributions of the toxicity probability associated with
combinations d˜0 and d˜1 have similar characteristics for all models. At the same
time, the differences can be found for other combinations. Emax and L2 being
26


















































Figure 2.2: Mean values (black circles) and 95% credible intervals (dashed lines)
of toxicity probabilities for each combination using Emax, L2 and P1 models.
more flexible models allow for a more informative prior distribution of the toxicity
probability associated with the standard of care while leaving the distributions
of the rest of combinations vague. At the same time, the prior by P1 cannot
achieve the same as one parameter is used only and the distribution of the toxicity
probability associated with the standard of care cannot be imposed independently
of the other combinations.
The characteristics of all models compared are evaluated in R (R Core Team,
2015) using the bcrm-package by Sweeting et al. (2013). To accommodate the
randomisation to the control arm and the Emax model corresponding modifications
to the package were made. For all methods 104 replicated trials were used. The
posterior distribution of parameters were found using JAGS (Hornik et al., 2003).
The number of burn-in iterations is 2000, the number of production iterations is
104 and two chains were used.
2.2.5 Operating Characteristics
Proportion of Correct Selections The results of the comparison are sum-
marized in Table 2.1 (scenarios 1-5) and Table 2.2 (scenario 6-9), with each figure
representing the proportion of each combination selections. The last columns cor-
responds to the mean proportion of toxicity outcomes (DLTs).
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Table 2.1: Operating characteristics of EmaxR, L2R, L2 and P1 models in sce-
narios 1-5: proportions of each combination selections and mean proportions of
toxicity outcomes (DLTs). The MTC selection is in bold. Results are based on
104 replications.
d˜0 d˜1 d˜2 d˜3 d˜4 d˜5 d˜6 d˜7 DLTs
Scenario 1
Toxicity 0.08 0.10 0.12 0.15 0.25 0.40 0.45 0.47
EmaxR 0.0 2.1 8.8 24.9 43.1 13.6 3.8 3.7 19.1
L2R 0.0 1.8 8.3 26.5 44.6 13.8 3.1 2.0 19.2
L2(N = 36) 0.4 0.6 4.4 29.7 45.4 15.6 2.4 1.5 25.2
L2 0.4 0.1 3.5 24.9 52.6 16.4 2.1 1.3 25.1
P1 0.0 1.0 4.2 16.5 51.4 20.4 5.5 1.0 29.2
Scenario 2
Toxicity 0.080 0.090 0.095 0.100 0.105 0.110 0.112 0.115
EmaxR 0.0 0.3 0.5 0.9 0.5 1.6 1.9 94.4 10.2
L2R 0.0 0.6 0.8 1.5 1.8 1.6 2.5 91.2 10.1
L2(N = 36) 0.1 0.3 0.8 0.3 0.9 1.1 2.0 94.5 11.0
L2 0.3 0.1 0.3 0.5 1.8 1.0 0.5 95.6 11.4
P1 0.0 0.0 0.0 0.0 0.0 0.6 0.8 98.7 11.3
Scenario 3
Toxicity 0.08 0.25 0.26 0.265 0.27 0.27 0.27 0.27
EmaxR 2.4 44.3 13.9 7.3 7.1 5.0 4.1 15.9 21.2
L2R 2.8 44.7 15.8 10.1 7.6 4.4 2.5 12.1 21.3
L2(N = 36) 5.3 25.5 13.4 10.1 10.6 7.53 5.7 21.9 25.3
L2 5.1 27.0 13.0 9.4 11.5 7.1 6.1 20.7 25.3
P1 0.0 0.0 0.5 0.5 13.4 18.9 17.9 44.7 26.6
Scenario 4
Toxicity 0.080 0.250 0.500 0.510 0.520 0.525 0.530 0.535
EmaxR 5.1 82.1 11.5 0.9 0.3 0.1 0.0 0.0 24.4
L2R 4.1 86.4 8.4 0.9 0.3 0.0 0.0 0.0 24.6
L2(N = 36) 20.7 72.0 6.1 0.7 0.3 0.1 0.0 0.0 28.4
L2 20.9 75.0 4.0 0.1 0.0 0.0 0.0 0.0 26.9
P1 20.2 71.7 7.4 0.7 0.0 0.0 0.0 0.0 31.0
Scenario 5
Toxicity 0.080 0.085 0.090 0.100 0.50 0.50 0.50 0.50
EmaxR 0.0 1.9 7.8 57.1 31.2 1.6 0.1 0.4 18.8
L2R 0.0 1.5 9.5 56.4 30.2 1.4 0.8 0.3 18.2
L2(N = 36) 0.0 0.0 4.1 59.7 31.7 1.5 0.5 0.4 26.1
L2 0.1 0.1 1.4 62.7 35.5 0.2 0.1 0.0 25.1
P1 0.0 0.0 0.0 54.9 36.4 7.0 1.2 0.5 33.2
Overall, both randomised models EmaxR and L2R result in nearly the same PCS
with differences no more than 4% across scenarios. The models that do not employ
randomisation have a comparable performance in scenarios 1, 2, 4 and 6. In the
rest of scenarios, P1 is less conservative and selects more toxic combinations more
often than L2. The non-randomised designs select the MTC more often if the
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Table 2.2: Operating characteristics of EmaxR, L2R, L2 and P1 models in sce-
narios 6-9: proportions of each combination selections and mean proportions of
toxicity outcomes (DLTs). The MTC selection is in bold. Results are based on
104 replications.
d˜0 d˜1 d˜2 d˜3 d˜4 d˜5 d˜6 d˜7 DLTs
Scenario 6
Toxicity 0.020 0.030 0.050 0.080 0.090 0.100 0.110 0.115
EmaxR 0.0 0.0 0.0 0.0 0.4 1.1 1.2 97.2 8.3
L2R 0.0 0.0 0.0 0.0 1.0 1.1 1.9 96.1 8.7
L2(N = 36) 0.0 0.0 0.0 0.0 0.6 0.9 0.8 97.5 10.9
L2 0.0 0.0 0.0 0.1 0.1 0.2 0.5 99.3 11.3
P1 0.0 0.0 0.0 0.0 0.0 0.1 1.1 98.8 11.3
Scenario 7
Toxicity 0.20 0.23 0.40 0.40 0.40 0.40 0.40 0.40
EmaxR 12.7 64.3 15.1 4.7 1.7 0.7 0.5 0.4 25.8
L2R 9.4 67.2 15.7 5.3 1.4 0.3 0.4 0.3 25.8
L2(N = 36) 19.0 52.0 18.3 4.5 2.0 1.7 1.4 1.1 30.1
L2 15.0 62.5 15.1 3.6 1.8 0.8 0.8 0.5 29.2
P1 0.2 28.0 29.2 23.5 14.1 3.87 0.8 0.4 35.2
Scenario 8
Toxicity 0.17 0.20 0.25 0.35 0.40 0.40 0.40 0.40
EmaxR 5.1 40.3 29.5 16.1 5.9 1.7 0.8 0.5 23.6
L2R 2.8 45.3 31.5 12.7 4.9 1.8 0.8 0.20 23.3
L2(N = 36) 4.5 27.5 34.3 19.1 7.3 3.1 1.5 2.7 29.0
L2 4.5 24.9 41.1 19.1 6.5 1.9 1.1 0.9 28.6
P1 0.0 3.4 30.2 37.5 18.7 7.27 1.7 1.1 32.3
Scenario 9
Toxicity 0.25 0.255 0.26 0.265 0.27 0.27 0.27 0.27
EmaxR 21.6 37.6 10.0 7.9 4.7 4.3 2.3 11.6 25.5
L2R 19.6 43.3 12.9 7.2 5.2 2.4 2.1 7.3 26.1
L2(N = 36) 10.1 20.7 12.5 10.5 10.1 6.3 5.8 24.0 26.0
L2 10.1 22.9 12.7 10.3 9.5 8.0 6.4 20.0 26.3
P1 0.3 6.5 15.0 26.7 28.1 12.8 6.9 3.7 26.6
MTC is located in the middle of the curve - scenarios 1, 5 and 8. For instance,
L2 outperforms its randomised version L2R by 6-10% in these scenarios. The
decrease in the PCS can be mainly explained by the reduced number of patients
on the investigational arm as the differences between L2R and L2(N = 36) vary
in the range 1-3%. While randomisation entails a minor drop in these scenarios,
it might also result in a notable increase in the PCS if the MTC is located at
the beginning of the curve - scenarios 3, 4 and 7. Considering L2R and L2,
randomisation leads to a more accurate MTC selection by 17%, 11% and 5%,
respectively. These differences increase to 19%, 14% and 15% compared to L2(N =
29
36). Note that the misspecified prior distribution for the control arm (scenarios
6-9) does not affect the MTC selection noticeably. Note that the inclusion of
randomisation to the control leads to decrease the proportion of toxicity outcomes
almost in all scenarios. For instance, it is decreased by up to 6% in scenario 1 that
results in nearly two fewer patients experienced adverse events. The decrease in
number of DLTs in the approaches with randomisation can be explained by the
fact that the standard of care d˜0 has the lowest DLT probability and at least 25%
of patients are allocated to it. At the same time, the design without randomisation
tends to allocate the majority of patient to the investigational arms having greater
probabilities of toxicity.
In scenarios 2 and 6, the MTC is the highest combination and all models select it
correctly in more than 90% of replications with L2R having the least PCS: 91.2% in
scenario 2 and 96.1% in scenario 6. In scenario 9 where the control arm is already
associated with the maximum acceptable toxicity, the randomised designs select
the control arm by nearly 10% more often than L2. Generally, the randomised
designs select combinations in the beginning of the curve (d˜1− d˜3) more often with
nearly 70% of d˜0, d˜1, d˜2 selections against 45% for L2 and 22% for P1.
Probability to find the ET While both 4- and 2-parameter models with
randomisation were shown to have comparable performances in terms of the PCS,
major differences can be found in Table 2.3 in which the upper line represents the
proportion of times ET is found (Pˆ) and the lower line shows the NMSE.
Comparing randomised designs, EmaxR results in greater proportions of correctly
identified ETs in scenarios 1, 3, 4, 6 and 8 by 2-7%. In scenarios with no ET (2, 5,
7 and 9), EmaxR finds the ET less often than L2R by 2-9%. Note, however, that
both approaches wrongly conclude the ET in the majority of trials under scenario
5. They struggle to capture the jump in toxicity risks between d˜3 and d˜4, and
overestimate the MTC toxicity probability (see also Figure 2.3 and Figure 2.4)
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Table 2.3: Operating characteristics of EmaxR, L2R, L2 and P1 models. The upper
line: proportions of times the ET is found. The lower line: NMSE. Scenarios with
no ET are underlined. Results are based on 104 replications.
Sc 1 Sc 2 Sc 3 Sc 4 Sc 5 Sc 6 Sc 7 Sc 8 Sc 9
EmaxR
Pˆ 74.7 16.3 66.7 71.5 67.9 24.2 12.2 29.3 6.6
NMSE 1.7 2.0 2.2 3.5 3.1 1.4 2.5 1.7 3.7
L2R
Pˆ 71.8 14.4 59.7 64.1 75.0 20.9 21.3 31.4 11.8
NMSE 2.0 2.2 7.2 4.4 3.4 1.5 4.4 3.1 7.2
L2 (N = 36)
Pˆ 47.0 13.7 35.8 35.3 43.5 13.7 25.1 21.3 32.3
NMSE 1.8 2.0 6.3 5.1 3.0 1.4 6.3 4.0 8.9
L2
Pˆ 61.5 15.8 50.1 50.2 64.7 18.1 37.5 30.2 43.5
NMSE 2.0 2.5 7.7 5.8 3.6 1.6 7.6 4.5 9.0
P1
Pˆ 99.9 93.6 99.7 99.7 99.4 95.3 99.8 99.9 99.7
NMSE 2.1 2.6 7.8 6.1 3.8 2.1 7.8 4.5 9.2
for the illustration of fitted curves). It is also challenging for both models to
determine the ET in scenarios 6 and 8 when the prior distribution for the control
arm is misspecified. EmaxR correctly identifies the ET in 24% and 30% of trials.
At the same time, the prior misspecification is not being an issue in scenarios 7
and 9 with no ET as EmaxR finds the ET in 12% and 6% of trials, respectively.
Regarding the designs with no randomisation, P1 almost always finds the ET re-
gardless the underlying scenario. As expected the strict monotonicity assumption
imposed by the power model results in these (often) incorrect conclusions. The
model L2 does not share the same pattern and it is able to find the ET with a low
probability if it is not present (for example, scenario 2). At the same time, the in-
clusion of randomisation in L2 leads to a large increase in proportions of correctly
identified ET by 10-14% in scenarios 1, 3 and 4. Again, comparing approaches
with the same number of patients on the investigational arm these proportions
differ by 25-30%. In the rest of scenarios (6 and 8) with the ET, L2 and L2R have
similar characteristics and outperform L2 (N = 36) by 5-10%. In the majority of
scenarios with no ET, using L2R instead of L2 leads to a decrease in the proportion
of incorrect conclusions about the ET, for example, by 16% and 32% in scenarios 7
and 9, respectively. There is only one example when randomisation increases the
probability to find the ET while it is not there - scenario 5.
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Goodness-of-fit Comparing the ability of models to fit the combination-toxicity
curve, EmaxR being the most flexible model results in the NMSE smallest values
in all scenarios with the largest difference in scenario 3 − 2.2 against 7.2 for L2R,
and the smallest difference in scenario 6 − 1.4 against 1.5 for L2R. Similarly, P1,
the least flexible alternative, results in the greatest NMSE values in all scenarios.
L2 shows a better fit than P1, which can be improved further by randomisation
to the control. Low values of the NMSE for L2 with the reduced number of pa-
tients can be explained by the decreased accuracy of the non-parametric optimal
benchmark.

































































Figure 2.3: Mean values (solid lines) and 90% credible intervals (shadowed area)
of toxicity probabilities for each combination obtained by fitted EmaxR (green),
L2R (blue) and L2 (red) models in scenarios 1-4. True toxicity curves are marked
by dashed-dotted lines. Results are based on 104 replications.
Further differences in the ability of these models to detect dose-effects are given
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in Figure 2.3 and Figure 2.4 presenting mean values of toxicity probabilities and
corresponding 90% credible interval. The mean values for estimated probabilities
by EmaxR (green), L2R (blue) and L2 (red) are given by solid lines while the
credible intervals are given by shadow areas of the corresponding colour. The true
toxicity probabilities are marked by dashed-dotted lines.
EmaxR corresponds to the best fit of the toxicity curve and to the narrowest
credible interval among all alternatives in all scenarios. The fitted curves of L2R
and L2 are similar for the first combinations, but probability estimates obtained
by L2R are more accurate due to the shift toward the true toxicity probability
curve for the rest of combinations.
2.2.6 Sensitivity Analysis
Prior Distributions In this section the influence of different sets of prior dis-
tributions is studied. Since an investigator usually has a reasonable prior for E0
and the detection of a plateau should be determined by the data alone (hence an
uninformative prior on the Emax parameter is imposed), we consider cases of less
informative prior for ED50 and more informative one for λ
ED50 ∼ Γ(0.25, 0.25), λ ∼ Γ(3, 3) (2.2.4)
and more informative prior for ED50 and less informative for λ
ED50 ∼ Γ(1, 1), λ ∼ Γ(0.05, 0.05). (2.2.5)
We compare previously used prior distributions given in Equation (2.2.3) to the
prior distributions given in Equation (2.2.4) denoted by EmaxR (λ) and the set
given in Equation (2.2.5) denoted by EmaxR (ED50). The summary of the oper-
ating characteristics using different prior distributions are given in Table 2.4.
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Figure 2.4: Mean values (solid lines) and 90% credible intervals (shadowed area)
of toxicity probabilities for each combination obtained by fitted EmaxR (green),
L2R (blue) and L2 (red) models in scenarios 5-9. True toxicity curves are marked
by dashed-dotted lines. Results are based on 104 replications.
In the majority of scenarios the choice of prior did not influence the PCS by more
than 4% with scenarios 1, 3 and 8 being exceptions. In cases where the MTC
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Table 2.4: Operating characteristics of EmaxR using different prior distributions.
Scenarios with no ET are underlined and the most noticeable differences across
scenarios are in bold. Results are based on 104 replications.
Sc 1 Sc 2 Sc 3 Sc 4 Sc 5 Sc 6 Sc 7 Sc 8 Sc 9
Proportion of correct selections
EmaxR 45.1 94.4 44.3 82.1 57.1 97.2 64.3 29.5 21.6
EmaxR (λ) 43.8 93.3 41.3 85.5 58.7 99.7 64.1 27.3 22.7
EmaxR (ED50) 35.3 96.5 52.9 85.5 54.0 99.8 63.4 16.5 24.8
Proportion of toxicity outcomes
EmaxR 19.1 10.2 21.2 24.4 18.8 8.3 25.8 23.6 25.5
EmaxR (λ) 19.2 10.3 21.1 24.7 19.1 8.2 25.9 23.5 25.7
EmaxR (ED50) 19.1 10.5 21.1 24.5 19.3 8.4 25.4 23.5 26.1
Pˆ
EmaxR 74.7 16.3 66.7 71.5 67.9 24.2 12.2 29.3 6.6
EmaxR (λ) 74.0 12.7 71.1 78.4 80.0 28.5 15.6 31.2 10.0
EmaxR (ED50) 68.1 9.2 66.3 70.5 61.5 23.6 16.2 20.4 11.2
NMSE
EmaxR 1.7 2.0 2.2 3.5 3.1 1.4 2.5 1.7 3.7
EmaxR (λ) 1.9 1.8 2.2 3.3 3.7 1.4 2.5 1.7 3.6
EmaxR (ED50) 2.0 2.2 2.2 4.3 3.2 1.9 3.0 2.3 3.1
lies in the middle of the curve (scenarios 1 and 8), the informative prior for ED50
results in nearly 10% loss in the PCS. Conversely, in scenario 3 where the MTC
is located at the beginning of the curve, the PCS was greater. At the same time,
the proportion of toxicity outcomes are not influenced by the prior choices in all
scenarios.
The proportion of times the ET is found is again not affected by the choice of prior
in scenarios 1-4, 6-7 and 9 with the difference between competing models below
10%. Major differences in Pˆ can be found in scenario 5 in which the informative
prior for λ leads to 20% more false conclusions than the informative prior for ED50.
At the same time, it is generally harder for EmaxR (ED50) to detect the ET with
the largest difference of 10% in scenario 8. While NMSE is not largely affected by
the choice of prior distributions, EmaxR (ED50) results in slightly greater values
in scenarios 1-2, 4 and 6-8 with the greatest difference of 1 in scenario 4.
Overall, the choice of prior does not seem to have a noticeable impact in the
majority of the scenarios, but EmaxR (λ) seems to be more robust and results
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in better toxicity curve fittings. Therefore, an informative prior for λ and an
uninformative prior for ED50 appear to be preferable choices.
Randomisation Ratio and No Skipping Constraint The randomisation
was shown to be the key factor in improving the fit of the dose-toxicity curve and
in establishing the ET. We now consider the impact of different randomisation
ratios on the performance of the design. We also investigate the impact of the “no
skipping constraint”. The prior given in Equation (2.2.3) is used and the summary
of the operating characteristics is given in Table 2.5.
Table 2.5: Operating characteristics of EmaxR using different randomisation ra-
tios and no skipping constraint. Scenarios with no ET are underlined and the
most noticeable differences across scenarios are in bold. Results are based on 104
replications.
Sc 1 Sc 2 Sc 3 Sc 4 Sc 5 Sc 6 Sc 7 Sc 8 Sc 9
Proportion of correct selections
EmaxR(2:1) 43.5 91.6 44.1 84.2 58.5 97.2 62.7 28.2 27.7
EmaxR(2:1) No Skip 46.9 90.7 44.8 83.7 57.2 96.7 62.3 27.1 29.2
EmaxR(3:1) 45.1 94.4 44.3 82.1 57.1 96.8 64.3 29.5 21.6
EmaxR(3:1) No Skip 45.7 90.4 47.1 83.8 55.9 97.2 66.5 31.0 21.5
EmaxR(4:1) 43.3 94.6 45.1 86.8 57.1 98.1 66.5 29.1 19.1
EmaxR(4:1) No Skip 44.0 88.4 48.2 89.2 58.8 98.0 69.2 29.7 19.5
Proportion of toxicity outcomes
EmaxR(2:1) 17.5 9.9 19.7 22.9 18.2 8.1 25.2 22.5 25.8
EmaxR(2:1) No Skip 17.6 9.5 19.9 22.5 17.8 8.5 24.8 22.4 25.5
EmaxR(3:1) 19.1 10.2 21.2 24.4 18.8 8.3 25.8 23.6 25.5
EmaxR(3:1) No Skip 18.8 9.9 21.5 24.3 18.9 7.9 25.6 23.1 25.5
EmaxR(4:1) 20.4 10.7 23.2 26.8 20.9 8.6 27.6 25.1 26.9
EmaxR(4:1) No Skip 19.5 10.3 23.1 26.0 20.7 8.9 26.8 24.4 26.8
Pˆ
EmaxR(2:1) 73.5 11.4 63.1 71.9 68.3 19.9 7.8 17.6 4.8
EmaxR(2:1) No Skip 69.1 12.1 63.8 69.6 69.1 20.0 8.5 16.7 4.6
EmaxR(3:1) 74.7 16.3 66.7 71.5 68.0 24.2 12.2 29.3 6.6
EmaxR(3:1) No Skip 75.6 12.2 68.7 72.8 71.3 24.1 11.0 27.2 7.7
EmaxR(4:1) 76.3 11.6 64.5 72.1 72.3 20.5 11.9 24.4 9.9
EmaxR(4:1) No Skip 74.5 14.4 69.2 69.9 66.1 20.9 13.1 23.1 9.9
NMSE
EmaxR(2:1) 1.7 2.1 3.4 3.3 3.2 1.7 2.4 1.6 3.6
EmaxR(2:1) No Skip 1.7 2.1 3.3 3.5 3.5 1.7 2.5 1.6 3.5
EmaxR(3:1) 1.7 2.0 2.2 3.5 3.1 1.5 2.5 1.7 3.7
EmaxR(3:1) No Skip 1.6 2.0 3.4 3.3 3.2 1.7 2.4 1.6 3.7
EmaxR(4:1) 1.6 1.9 3.2 3.4 3.3 1.5 2.5 1.7 3.7
EmaxR(4:1) No Skip 1.7 2.0 3.1 3.6 3.4 1.6 2.6 1.6 3.6
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Comparing models with the same randomisation ratios, no skipping constraint has
a minor influence on characteristics of EmaxR in all scenarios. In the majority
of cases, the difference in the PCS does not exceed 4% with scenario 2 being an
exception. In this case, N = 48 is not always enough to test all combinations and
reach the MTC given a large cohort size (c = 5). For EmaxR(4:1) no skipping
constraint also increases Pˆ by 5% in scenario 3 with the MTC being at the begin-
ning of the curve and decreases it by 6% in scenario 5 with the MTC being the
medium combination.
Considering different randomisation ratios with combinations skipping, all ap-
proaches result in the comparable PCS in all scenarios with EmaxR(2:1) in sce-
nario 9 being an exception. The increased number of patients on the control (16
patients) leads to a higher PCS when the MTC is a standard therapy itself. At the
same time, a smaller number of patients on the investigational arm might result
in a substantial loss in the ability to detect the ET, for example, in scenario 8, Pˆ
decreased by 10% compared to EmaxR(3:1). Note that EmaxR(4:1) also results in
a less accurate ET detection in this case as there are fewer patients on the control
arm. Moreover, ratio 4:1 results in more toxicity outcomes as more patients are
assigned to the standard of care. There is no noticeable difference in the NMSE
across ratios. Overall, the operating characteristics remain unchanged for various
randomisation ratios in the majority of scenarios, but the ratio 3:1 seems to be a
reasonable trade-off between the MTC selection and the plateau detection.
2.3 A Benchmark for Studies with Complex
Endpoints
To assess the goodness-of-fit across different scenarios in the previous section, the
non-parametric optimal benchmark was used. It is, however, applicable to trials
with a single binary endpoint only. Below, we generalise the benchmark to trials
with (possibly multiple) continuous endpoints.
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2.3.1 A Benchmark for a Continuous Endpoint
Consider a Phase I clinical trial with continuous outcome Yij at dose dj for patient i
having a cumulative distribution function (CDF) Fj(y). The goal of the trial is find
the target dose (TD) which minimises (or maximises as defined by an investigator)
some decision criterion T (·, γt). We will further suppress the γt notation from
T (yj). In simulations, the CDF Fj is chosen by a statistician and specifies the
distribution of outcomes for a given dose dj, and the set of CDFs corresponding
to doses d1, . . . , dm defines a simulation scenario. This simple fact is going to be a
central part of our proposal. To illustrate the construction of the novel benchmark
step-by-step, we use a setting studied by Wang and Ivanova (2015) throughout
this section.
Example 1. Wang and Ivanova (2015) considered a setting with m = 6 doses and
a biomarker for toxicity measured on a continuous scale. In one of the simulation
scenarios presented, it is assumed that toxicity outcome Yij given dose level dj has
normal distribution N (0.1j, (0.1j)2), j = 1, . . . , 6. Then, the CDF Fj is the CDF
of a normal random variable with corresponding parameters
Φ(·, µj = 0.1j , σ2 = (0.1j)2).
These CDFs will be used to obtain the benchmark in this scenario.
Let us denote the quantile transformation as
F−1j (x) = inf{y|Fj(y) ≥ x}, 0 < x < 1. (2.3.1)
Then,
Probability Integral Transform. If U ∼ U(0, 1) is a uniform random variable
on the unit interval, then Fj is the cumulative distribution function of a random
variable F−1j (U).
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This result is commonly used for the inverse transform sampling (e.g. see Bekele
and Shen, 2005, for an example in dose finding) to generate random variables with
CDF Fj.
Assume that the information about a patient’s toxicity profile is summarised in
a single value ui drawn from U(0, 1). For patient i with profile ui, the quantile
transformation yij = F
−1
j (ui) is applied to obtain a continuous outcome that this
patient would have given dose dj, j = 1, . . . ,m. Different dose levels are modelled
by applying the corresponding quantile transformation. This results in a vector of
responses (yi1, . . . , yim), also called the complete information about patient i. The
same procedure is repeated for all patients i = 1, . . . , N which results in the vector
of responses for each dose level yj = (y1j, . . . , yNj), j = 1, . . . ,m.
Example 1 (Continued). Following the setting by Wang and Ivanova (2015),
assume that the first patient has a toxicity profile u1 = 0.40. The benchmark
answers the question ”how would patient 1 respond to dose level dj with the re-
sponse having distribution N (0.1j, (0.1j)2)”. Applying the corresponding quan-
tile transformation, the response of patient 1 given the dose level d1 is equal to
y11 = Φ
−1(u1 = 0.40, µj = 0.1, σ2 = 0.12) ≈ 0.075. Subsequently, the complete
information about patient 1 consists in the vector of responses at all dose levels
d1, . . . , d6
(0.075, 0.149, 0.224, 0.299, 0.373, 0.448).
The complete information for 5 patients with randomly generated profiles u1, . . . , u5
is given in Table 2.6.
Recalling the decision criterion T (yj) on which the TD selection is based, the dose
level dj such that T (yj) is minimised (or maximised) is selected as the TD in a
single trial. For instance, if the goal of the trial is to find the dose having the
average level of toxicity γt, the decision criterion given in Equation (2.1.7) can be
used. The benchmark can be constructed for different decision criteria and then
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d1 d2 d3 d4 d5 d6
u1 = 0.40 0.075 0.149 0.224 0.299 0.373 0.448
u2 = 0.25 0.033 0.065 0.098 0.130 0.163 0.195
u3 = 0.92 0.241 0.481 0.722 0.962 1.203 1.443
u4 = 0.67 0.144 0.288 0.432 0.576 0.720 0.864
u5 = 0.31 0.050 0.101 0.151 0.202 0.252 0.302
Mean 0.109 0.217 0.325 0.434 0.542 0.650
Variance 0.007 0.029 0.065 0.116 0.181 0.261
can be used to evaluate any design under investigation.
Example 1 (Continued). The goal of the trial considered by Wang and Ivanova
(2015) is to find the dose with the mean response closest to the target response γt.
The criterion of choosing the dose which maximises the probability of the average
level of toxicity µj to be in the ε neighbourhood of γt was considered. Let gj(·|yj) be






The TD is the dose for which the criterion T (yj) is maximised. Following the
original framework, γt = 0.1 and ε = 0.01 are chosen. Using the complete in-
formation generated in Table 2.6 and the density function of Normal distribution
with corresponding mean and variance parameters yields: T (y1) = 0.09; T (y2) =
0.04; T (y3) = 0.02; T (y4) = 0.01; T (y5) = 0.01 and T (y6) = 0.01. The value of
the criterion is maximised for d1 which is selected as the TD in this single trial.
The procedure is repeated for s = 1, . . . , S simulated trials to obtain the proportion
of correct selections. The evaluation of the method by Wang and Ivanova (2015)
using the proposed benchmark is provided in Section 2.3.3.
Algorithm 1 provides the step-by-step guidance on how the benchmark can be
constructed based on S simulated trials.
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Algorithm 1 Computing a benchmark for a single continuous endpoint
1. Specify CDFs Fj for all doses dj, j = 1, . . . ,m and define the decision
criterion T (·)
2. Generate a sequence of patients’ profiles {ui}Ni=1 from uniform distribu-
tion U(0, 1).
3. Transform ui for dose level dj using yij = F
−1
j (ui), i = 1, . . . , N , j = 1, . . . ,m
and store yj = (y1j, . . . , yNj).
4. Compute T (yj) for all j = 1, . . . ,m, find dose J for which T (yJ) is maximised
(minimised) and set Zs = J .
5. Repeat steps 2-4 for s = 1, . . . , S simulated trials
6. Use Z¯(j) =
∑S
s=1 I (Zs = j) /S as the selection proportion of dose dj,
j = 1, . . . ,m
The proposed benchmark can be applied to a wide range of distributions as it
requires the quantile information only, which is routinely available for many dis-
tributions in various statistical software (for example, qbinom, qnorm, qexp , etc
in R (R Core Team, 2015)). Note that the Probability Integral Transform can be
also applied to discrete random variables in which case the quantile transforma-
tion F−1j (·) is given explicitly. It is easy to see that F−1j (·) of a Bernoulli random
variable in Algorithm 1 results in the original benchmark construction proposed
by O’Quigley et al. (2002). Importantly, the benchmark employs the concept
of the complete information implying that a statistician conducting simulations
knows distributions at all dose levels. This means that the proposed benchmark
can be applied to more complex regimen finding trials (e.g. combination or dose-
schedule studies) straightforwardly as the complete information concept, proposed
by O’Quigley et al. (2002), does not suffer from the uncertainty in the monotonicity
ordering.
The novel benchmark can be also applied to clinical trials with multiple endpoints.
This construction is provided below.
2.3.2 A Benchmark for Multiple Endpoints
In the setting with several endpoints, the correlation between them is important.
Below, we describe the algorithm generating correlated outcomes in the bench-
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mark framework. The approach described below has been known for a long time
(Tate, 1955; Molenberghs et al., 2001). We apply it to an arbitrary distribution
of outcomes to generate the complete information vector. We start with the case
of binary toxicity and continuous efficacy responses that has attracted a lot of
attention in the literature recently (see e.g. Hirakawa, 2012; Yeung et al., 2015,
2017).
Consider a Phase I/II clinical trial with toxicity outcome Y
(1)
ij and efficacy outcome
Y
(2)




j , respectively, at dose level dj for patient i. We will
use the setting studied by Bekele and Shen (2005) to illustrate the construction of
the benchmark for multiple endpoints throughout this section.
Example 2. Bekele and Shen (2005) considered a setting with m = 4 dose levels,
an efficacy outcome at dose dj having Gamma distribution Γ(λjω, ω) where λjω is
the shape parameter, ω = 0.1 is the rate parameter (i.e., the mean equals to λj),
and a DLT outcome having probability pj. In one of the simulation scenarios the
following parameters are assumed λ1 = 25, λ2 = 60, λ3 = 115, λ4 = 127
and p1 = 0.01, p2 = 0.10, p3 = 0.25, p4 = 0.60. Then, F
(1)
j is the CDF of
a Bernoulli random variable with parameter pj and G(·, λjω, ω) is the CDF of a
Gamma random variable with parameter λj, j = 1, 2, 3, 4.
The toxicity/efficacy profile of patient i is given by two characteristics: u
(1)
i ∈ (0, 1)
corresponding to toxicity and u
(2)
i ∈ (0, 1) corresponding to efficacy. Firstly, we




i ) with the mean µ = (0, 0)





where ρ is the correlation coefficient. In simulation studies, the correlation coeffi-
cient, ρ, is specified by a statistician as part of the scenario. By applying the CDF
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one can obtain two correlated random variables having uniform distributions.





marginally as described in Section 2.3.1 and responses for patient i given the












i ). This results in
the complete information vector of toxicity and efficacy outcomes at all dose level











1j , . . . , y
(2)
Nj) are obtained for each dose level
dj, j = 1, . . . ,m.
Example 2 (Continued). The correlation coefficient considered by Bekele and
Shen (2005) is ρ = 0.25. The bivariate normal vector with mean µ = (0, 0)
and covariance matrix Σ is initially generated: (x1, x2) = (−0.892, 0.292). Then,
the first patient has a toxicity profile u
(1)
1 = Φ(−0.892) = 0.186 and an effi-
cacy profile u
(2)





1 = 0.186, p1 = 0.01) = 0 and to the efficacy response
G−1(u(2)1 = 0.615, λ1ω = 2.5, ω = 0.1) = 26.3 . Subsequently, the vector of the
complete toxicity information is (0, 0, 1, 1) and the vector of the complete efficacy
information is (26.3, 74.6, 121.8, 134.3). The complete information for 5 patients








5 is given in Table 2.7.
Similar to the single endpoint case, the TD selection is based on a pre-specified




j ), which takes the minimum (maximum) value for
the most desirable dose level. This would, however, involve the information for
all endpoints of interest and can have more complicated structure. In the context
of the Phase I/II clinical trial the decision criterion is also known as a trade-off
function (see e.g. Thall and Cook, 2004).
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d1 d2 d3 d4
u
(1)
1 = 0.186 0 0 1 1
u
(2)
1 = 0.615 26.3 74.6 121.8 134.3
u
(1)
2 = 0.390 0 0 0 1
u
(2)
2 = 0.214 12.2 48.4 87.3 97.3
u
(1)
3 = 0.618 0 0 0 0
u
(2)
3 = 0.898 45.7 104.7 159.3 173.5
u
(1)
4 = 0.456 0 0 0 1
u
(2)
4 = 0.545 23.6 70.0 112.9 128.1
u
(1)
5 = 0.683 0 0 0 0
u
(2)
5 = 0.869 42.5 99.9 153.5 167.4
Number of toxicities 0 0 1 3
Mean (efficacy) 30.1 79.5 127.5 140.2
Standard Deviation (efficacy) 13.8 23.0 29.5 30.8
Example 2 (Continued). Bekele and Shen (2005) defined the TD as the dose with
the highest expected efficacy while being safe (pj < 0.35) and efficacious (λj > 5).


























j (·|y(1)j ) and g(2)j (·|y(2)j ) are probability density functions of a toxicity prob-




j , respectively, and θ
(1), θ(2)
are threshold probabilities. This decision criterion is used to construct the bench-
mark in this setting. Applied to the benchmark, the integrals in Equation (2.3.4)
are computed using density functions of Beta and Normal random variables for
toxicity and efficacy outcomes, respectively. Using summary statistics given in Ta-

















4 ) = 0.
The criterion is maximised for dose level d3 which is selected as the TD in this
single trial. The procedure is repeated for s = 1, . . . , S simulated trials to obtain
the proportion of correct selections. The evaluation of the method by Bekele and
44
Shen (2005) using the proposed benchmark is provided in Section 2.3.4.
Similarly, the benchmark can be applied to an arbitrary number of endpoints. For
instance, consider a Phase I/II trial in which toxicity and efficacy are evaluated
in four cycles. Then, the profile of patient i is given by u
(1)
i , . . . , u
(8)
i each drawn
from U(0, 1) and the rest of the construction remains unchanged. The procedure
to generate the benchmark for K endpoints is given in Algorithm 2.
Algorithm 2 Computing a benchmark for multiple outcomes
1. Specify K ×K covariance matrix Σ and define objective function T (·).
2. Generate xi = (x
(1)
i , . . . , x
(K)
i ), i = 1, . . . , N from N (µ,Σ) where
µ = [0, . . . , 0]1×K .
3. Compute ui = (u
(1)
i , . . . , u
(K)
i ), i = 1, . . . , N applying CDF Φ to each compo-
nent of xi.








i ) for k = 1, . . . , K at





1j , . . . , y
(k)
Nj)
5. Compute T (y
(1)
j , . . . ,y
(K)
j ), j = 1, . . . ,m, find dose level J for which T (·) is
maximised (minimised) and set Zs = J .
6. Repeat steps 2-5 for s = 1, . . . , S simulated trials
7. Use Z¯(j) =
∑S
s=1 I (Zs = j) /S as the selection proportion of dose dj,
j = 1, . . . ,m
In the following section, we illustrate the implementation of Algorithm 1 (Section
2.3.3) and Algorithm 2 (Section 2.3.4) in different clinical contexts.
2.3.3 Application to a Phase I Trial with Continuous
Toxicity
A dichotomization of the toxicity endpoint (DLT/no DLT) in Phase I clinical trials
restricts the available information about the drug’s toxicity. In fact, a continuous
toxicity endpoint can provide more information about a drug’s profile (Wang et al.,
2000; Bekele and Thall, 2004; Wang and Ivanova, 2015).
Recently, Wang and Ivanova (2015) proposed the Bayesian Design for Continuous
Outcomes (BDCO) which can be applied to clinical trials with a continuous toxicity
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endpoint. In short, BDCO assumes that outcome Yij given dose dj to patient i has
normal distribution N (µj, σ2j ) where µj is considered as a random variable itself.
Based on the posterior distributions of µj, BDCO is driven by the probability that
µj is within ε of the target, γt:
pij = P (γt − ε ≤ µj ≤ γt + ε) . (2.3.5)
The design targets the dose which maximizes the probability in Equation (2.3.5).
Below, we apply the proposed benchmark to the setting considered in the original
paper using this decision criterion and compare its performances to BDCO.
Recalling the setting by Wang and Ivanova (2015), we consider six scenarios with
six dose levels d1, . . . , d6, a sample size of N = 36, parameter ε = 0.01 and
two cases: (i) the case of equal variances in which outcome Yij has normal dis-
tribution N (0.1j, 0.22) and (ii) the case of unequal variances corresponding to
normal distribution N (0.1j, 0.12j2). In each of six scenarios the target values
γt = {0.1, 0.2, 0.3, 0.4, 0.5, 0.6} are used, respectively. As a consequence, the target
dose is dose d1 in scenario 1, d2 in scenario 2, and so on.
Table 2.8 shows the proportions of each dose selections corresponding to the BDCO
against the respective benchmark. The results of the BDCO are extracted from
Table 2 in the original article, and the benchmark is evaluated using S = 106 trial
replications.
Under scenarios 2-5, the proportion of correct selections using the benchmark is
87%, which illustrates that they have the same level of “complexity”. Conversely,
the benchmark shows that it is easier to find the TD if it is either the first or the
last dose. Under all scenarios with equal variances, the BDCO has the accuracy
close to the benchmark. The ratio of the probability of correct selection of the
BDCO relative to the benchmark ranges between 92% and 98% in these cases.
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Table 2.8: Comparison of the BDCO design against the respective benchmark in
six scenarios considered by Wang and Ivanova (2015).
Design Variance Proportion of selections




0.91 0.10 0.00 0.00 0.00 0.00
Benchmark 0.94 0.06 0.00 0.00 0.00 0.00
BDCO
Unequal
0.97 0.03 0.00 0.00 0.00 0.00




0.07 0.86 0.08 0.00 0.00 0.00
Benchmark 0.07 0.87 0.07 0.00 0.00 0.00
BDCO
Unequal
0.04 0.84 0.11 0.01 0.00 0.00




0.00 0.07 0.83 0.09 0.00 0.00
Benchmark 0.00 0.07 0.87 0.07 0.00 0.00
BDCO
Unequal
0.00 0.16 0.65 0.16 0.02 0.00




0.00 0.00 0.08 0.81 0.11 0.00
Benchmark 0.00 0.00 0.07 0.87 0.07 0.00
BDCO
Unequal
0.00 0.00 0.27 0.50 0.18 0.04




0.00 0.00 0.00 0.09 0.80 0.11
Benchmark 0.00 0.00 0.00 0.07 0.87 0.07
BDCO
Unequal
0.00 0.00 0.02 0.34 0.45 0.20




0.00 0.00 0.00 0.00 0.10 0.90
Benchmark 0.00 0.00 0.00 0.00 0.07 0.93
BDCO
Unequal
0.00 0.00 0.00 0.07 0.40 0.54
Benchmark 0.00 0.00 0.00 0.02 0.27 0.71
Under scenarios with unequal variances, the benchmark demonstrates that it is
harder to find the TD if the corresponding variance is high. For example, the
benchmark leads to 86% of correct selections under scenario 2 and 45% under
scenario 5. Again, it appears that it is easier to find the TD if it is the first or
the last dose for any methods. BDCO shows a high accuracy in scenario 1-5 with
unequal variances. The correct probability ratios never go below 91% and even
reach nearly 100% under scenario 5. In the former case, BDCO recommends the
TD in 45% of replications (as well as the benchmark), but it recommends the
highest dose d6 systematically less often - 20% against 29% by the benchmark.
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This implies that BDCO leads to more conservative decisions. Scenario 6 confirms
this finding in which the correct probability ratio equals 76% which, however, is
still high.
Overall, BDCO selects the correct dose uniformly less often than the benchmark in
all scenarios (as expected), but the efficiency of the design is high. The minimum
ratio of the probabilities of correct selections is 76% which corresponds to the
scenario with highly variable outcomes. This indicates that parameters of the
BDCO are adequately calibrated and the BDCO in the proposed form is able to
find the MTD in many different scenarios.
2.3.4 Application to a Phase I/II Trial with Continuous
Efficacy and Binary Toxicity
Similarly to a continuous toxicity outcome, the continuous efficacy endpoint can
provide a better guidance on the TD selection than a dichotomized one. One of the
first designs proposed for Phase I/II clinical trials considering continuous efficacy
outcomes is by Bekele and Shen (2005) who developed a Bayesian approach to
model toxicity and (continuous) biomarker of efficacy jointly. We denoted this
design by BS.
Bekele and Shen (2005) introduced a latent normal random variable which is
related to the observed binary toxicity. A bivariate normal distribution allows
for different strengths of the dependence between toxicity and efficacy. Dose
escalation/de-escalation decision rules are based on the posterior distributions of
both toxicity and efficacy endpoints. The design was shown to have good oper-
ating characteristics in many scenarios. Therefore, the majority of subsequently
proposed designs (e.g. see Hirakawa (2012) and Yeung et al. (2015)) were com-
pared to it. Below, we provide the comparison of the design by Bekele and Shen
(2005) against the respective benchmark.
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Recalling the framework by Bekele and Shen (2005) we consider an efficacy out-
come at dose dj having Gamma distribution Γ(λjω, ω) with rate parameter ω = 0.1
and a DLT outcome having probability pj. A total of six scenarios and four dose
levels per scenario are explored using the total sample size N = 36. The parame-
ters of λj and toxicity probability pj are given in Table 2.9. In each scenario a weak
association, ρ = 0.25, between the toxicity endpoint and the efficacy biomarker is
used. The TD is defined as the dose with the highest expected efficacy while being
safe (pj < 0.35) and efficacious (λj > 5).
Table 2.9 shows proportions of each dose selections of the BS design against the
respective benchmark. The results for BS are extracted from Table 1 of the original
work which uses 1000 replications, and the benchmark is evaluated using S = 106
trial replications.
Table 2.9: Comparison of the BS design against the respective benchmark in six
scenarios considered by Bekele and Shen (2005).
Design Proportion of selections
d1 d2 d3 d4 None
Scenario 1
(λj , pj) (25,0.01) (70,0.10) (115,0.25) (127,0.60)
BS 0.00 0.03 0.95 0.02 0.00
Benchmark 0.00 0.08 0.92 0.00 0.00
Scenario 2
(λj , pj) (5,0.50) (70,0.70) (90,0.80) (135,0.85)
BS 0.06 0.00 0.00 0.00 0.94
Benchmark 0.02 0.00 0.00 0.00 0.98
Scenario 3
(λj , pj) (25,0.03) (46,0.05) (90,0.10) (135,0.15)
BS 0.00 0.00 0.02 0.98 0.00
Benchmark 0.00 0.00 0.01 0.99 0.00
Scenario 4
(λj , pj) (20,0.05) (75,0.05) (75,0.35) (75,0.65)
BS 0.00 0.83 0.17 0.00 0.00
Benchmark 0.00 1.00 0.00 0.00 0.00
Scenario 5
(λj , pj) (60,0.05) (65,0.50) (80,0.70) (95,0.85)
BS 0.94 0.06 0.00 0.00 0.00
Benchmark 0.97 0.03 0.00 0.00 0.00
Scenario 6
(λj , pj) (2,0.03) (2,0.03) (2,0.03) (2,0.03)
BS 0.01 0.00 0.00 0.00 0.99
Benchmark 0.01 0.00 0.00 0.00 0.99
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Under scenarios 1, 3 and 5 with increasing dose-efficacy relationships, the BS design
performs with a high accuracy and the proportions of correct selections are close
to the benchmark. Interestingly, the BS design recommends the TD d3 3% more
often than the benchmark under scenario 1. Given the number of replications for
the BS and the benchmark, 3% difference is significant. This can be an indication
that the prior distribution used by BS is in favour of d3. It would also explain
the relatively lower performance under scenario 4 in which the BS recommends
the target dose d2 in 83% of trials against 100% by the benchmark. The BS
recommends the dose with the same efficacy, but noticeably greater toxicity in 17%
of trials. An alternative explanation of the difference in proportions of selections
under scenario 4 can be a plateau in the dose-efficacy relation that is not modelled
by the BS. Nevertheless, the ratio of correct probabilities is 83% demonstrating
good operating characteristics of the BS design.
Under unsafe scenario 2 and inefficacious scenario 6, the BS design comes to the
correct conclusion in nearly the same proportions of trials as the benchmark. This
shows the ability of the BS design to avoid unethical selections due to either high
toxicity or low activity.
Overall, the benchmark confirmed that the BS design is flexible and can recom-
mend the TD under many different scenarios. It also gives some possible clue to
the super-efficient performance under scenario 1 and to potential challenges that
the BS design can face in plateau dose-efficacy scenarios.
2.4 Discussion
In the first part of this chapter, the Bayesian model-based dose-escalation methods
incorporating randomisation to the control arm into the Emax model were studied
and compared to currently used model-based alternatives. The proposed approach
shares the following features:
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• The design can identify the ET between the toxicity probabilities at the
MTC and the single agent more frequently than alternative approaches
• The randomisation step allows establishing whether effects observed for com-
binations are associated with the interaction of drugs or with one of the
therapies in the combination only.
• The cost of randomisation to the control arm is presented by a small reduc-
tion in proportions of correct selections in some scenarios.
• The sensitivity analysis suggests that the proposed design is robust to rea-
sonable choices of prior distributions and to allocation ratios between inves-
tigational and control arms.
Summarising, although the control arm is not routinely used in oncology early
phase clinical trials, it is advocated to be included in combination trials of the
considered types.
Importantly, the following limitation of the proposed design should be taken into
account:
• As the classical Bayesian CRM design, the proposed design might have a
large variance of number of patients on the MTC as indicated by Oron and
Hoff (2013).
Therefore, it is hard to guarantee the specific level of power in the frequen-
tist hypothesis testing framework that can also be of the great usefulness.
Consequently, the design that could maximise the power of such a test might
be also of a practical interest.
• A risk of overfitting in trials with fewer combinations in the trials
In the considered simulation study motivated by the actual trial, fitting
the Emax model has not lead to overfitting as the number of combinations
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is higher than the number of parameters. However, the considered Emax
model requires four parameters to be estimated. In the context with fewer
combinations studied in a trial, the proposed design can result in overfitting
of the combination-toxicity curve.
In the second part of this chapter, we formulated the novel benchmark for dose
finding studies. In essence, the novel benchmark is similar to the original proposal
by O’Quigley et al. (2002) as the information about a patient is summarised in
a single value, but can be also applied to studies with continuous outcomes. In
the era of an increasing complexity of clinical trials, the procedure evaluating an
adequacy of novel dose finding methods is crucial. It is shown that
• the proposed benchmark provides an accurate upper limit on the performance
of model-based dose finding designs;
• the benchmark is able to reveal some inadequacy in the model/parameter/prior
specifications or, alternatively, to confirm the design;
• the benchmark assesses the complexity of scenarios and can serve as a stan-
dardization of scenarios of various difficulty.
Therefore, it should be definitely recommended for the complete analysis of dose
finding designs as it helps to evaluate them in a more comprehensive way.
Finally, it is important to mention that while the benchmark is a useful tool to
assess the performance of any given dose finding methods, it does not capture
all aspects of the evaluation. For instance, it does not provide information on a
patient allocation distribution or a mean number of DLTs. Developments in this
direction will be of great value for the complete design assessment.
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Chapter 3
Loss Functions in Restricted
Parameter Spaces
In many applications, for example, in clinical trials, when considering a problem
of parameter estimation, the support of this parameter often is either naturally
restricted (e.g. probability, variance, exponential distribution parameter) or an in-
vestigator can restrict it based on previously obtained knowledge (e.g. treatment
effects on children given the data for adults). The knowledge about restricted
space can carry important information that an experimenter has and can poten-
tially improve the estimation (Mahmoudi and Zakerzadeh, 2011). There are also
areas in which estimates on bounds of the restricted space are highly undesirable
as they can lead to severe consequences. For instance, it can be worse to under-
estimate the potentiality of an event having life-threatening consequences than to
overestimate it (Norstrom, 1996). An erroneously low estimated risk-level can lead
to the absence of necessary initiative to reduce it.
Considering dose finding trials, once the estimate is obtained the decision to which
dose the next patient should be allocated is commonly made based on the absolute
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distance (2.1.4) or the squared distance between the estimate pˆj and the target γt.
These decision rules, however, do not take into account that both the probability
estimate and the target γt lie in the restricted space (unit interval). We show
why a simple logit transformation of these probabilities might not easily solve the
problem. In this chapter, we consider a general Bayesian estimation problem in
restricted parameter spaces and a problem of an appropriate loss function choice.
Subsequently, we demonstrate how the proposed loss functions can be used as a
criterion for allocation of patients in dose escalation trials.
3.1 Background
One of the ways to incorporate the information about a restricted space is to em-
ploy a Bayesian approach and to define a (uniform) prior distribution on the re-
stricted space (Hartigan, 2004). However, once a posterior is obtained the squared
error loss
Lq(ϑ, d) = (ϑ− d)2 (3.1.1)
where d is a decision the statistician has to take in order to approximate an un-
known ϑ, called parameter, is often used to summarise a posterior distribution.
The squared loss function (3.1.1) ignores the information about the restricted pa-
rameter space and is recognised to lead to suboptimal solutions (see e.g. Stein,
1964; Brown, 1968, for alternative loss functions for a scale parameter). Research
on improving the Bayes estimator under the squared loss function (a posterior
mean) for a scale parameter has subsequently attracted a great deal of attention
in the literature (Arnold, 1970; Zidek, 1973; Brewster, 1974; Brewster and Zidek,
1974; Kubokawa, 1994).
To illustrate potential inconsistencies the squared error loss can lead to when
estimating a parameter on a positive real line, consider two inferential procedures
based on two independent experiments:
1. Estimate µ ∈ (−∞,+∞) given i.i.d. observations Xi ∼ N (µ, σ2), where σ2
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is known;
2. Estimate σ ∈ (0,+∞) given i.i.d. observations Yi ∼ N (µ, σ2), where µ is
known.
The unknown parameters of interest (denoted by ϑ in Equation (3.1.1)) are µ and
γ, respectively. Using the squared error loss (3.1.1), the decision µ = 0 in the
first experiment and σ = 0 in the second are equally penalised, while this should
not be the case. The claim of σ = 0 implies that the Y ’s are degenerate random
variables, an extremely strong statement which should be penalised similarly to
the decision µ = +∞ or σ = +∞. The squared error loss function imposes an
infinite penalty to a boundary decision in the first experiment and does not in the
second one. While the decision σ = 0 is usually prevented by a proper choice of
the prior, the squared loss function does not imply that it should be avoided and
associated with a severe penalty. In contrast, an appropriate loss function imposes
such a penalty and can be also used to prevent boundary decisions.
In addition, since the loss function (3.1.1) does not penalise boundary values, it
was found to be unacceptable in many application areas: see Norstrom (1996);
Soliman (2002) for examples in reliability analysis, Karimnezhad et al. (2014) in
environmental sciences. To avoid boundary values of a scale parameter, Norstrom




where ϑ, d ∈ (0,+∞) (3.1.2)
which was used by many researchers (Kiapour and Nematollahi, 2011; Karim-
nezhad and Moradi, 2016).
The precautionary loss function covers the case of the scale parameter. There are,
however, many applications in which the parameter of interest is restricted to an
interval (a, b) and similar problems of severe consequences of boundary decisions
can appear. The question of an appropriate loss function choice for a parameter ϑ
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defined on the interval (a, b) has received less attentions in the statistical literature
compared to a scale parameter. At the same time, its importance is acknowledged
in many fields (see e.g. Aitchison, 1992; Pawlowsky-Glahn and Egozcue, 2001;
Mateu-Figueras et al., 2013, for examples in compositional data analysis). More-
over, despite the variety of literature on families of loss functions for parameters
restricted to an interval and on corresponding improved Bayes estimators (see e.g.
Kubokawa, 1994; Marchand and Strawderman, 2005), they seem to be rarely ap-
plied in practice due to their complexity and a lack of closed-form solutions. The
choice of loss functions for parameters defined on the interval and on the positive
real line is yet under-represented area in the Bayesian literature and the usual
mean still remains a common summary statistic.
The contribution of the first part of this chapter is twofold. Firstly, we provide
a unified approach to define symmetry of a loss function when a parameter space
is restricted to a particular open subset based on an appropriate definition of the
distance. We outline that distances on their corresponding parameter spaces share
the same property - an infinite penalisation of the bounds which is also known as
the balance property (Mahmoudi and Zakerzadeh, 2011). We also recall two other
desirable properties of loss functions: convexity and invariance. Secondly, we pro-
pose several loss functions which are as simple as the squared loss function (3.1.1),
have explicit solutions for the corresponding Bayes estimator and include the infor-
mation about the restricted parameter space in the corresponding Bayes estimator.
In particular, we propose the scale invariant generalisation of the the precaution-





for the parameter ϑ ∈ (a, b). We show that the Bayes estimator corresponding
to the interval squared loss function includes the Bayes estimator of the squared
loss function (3.1.1) and of the precautionary loss function as limiting cases. It
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is found that the interval squared and precautionary loss functions are both sym-
metric on corresponding parameter spaces and can be useful in application areas
where conservative estimates are preferred. We generalise the approach for the
multivariate parameter space and demonstrate how Bayes estimators obtained
using the proposed loss functions behave in three classic problems of Bayesian
estimation compared to standard approaches.
3.2 Scale Symmetry
3.2.1 A Historical Anecdote: Galileo on Scale Symmetry
In the Spring of 1627, a peculiar controversy 1 arose in one of Florence intellectual
circles, where noble gentlemen used to entertain erudite talks:
Un cavallo, che vale veramente cento scudi, da uno e` stimato mille scudi e da un
altro dieci scudi: si domanda chi abbia di loro stimato meglio, e chi abbia fatto
manco stravaganza nello stimare.
The problem translates into: “A horse, whose true worth is one hundred scudi2,
is estimated by someone to be one thousand scudi and by someone else to be
ten scudi: the question is, who gave a better estimate, and who instead gave a
more extravagant estimate?”. It is formulated in a letter from Andrea Gerini to
Nozzolini, an erudite priest. Gerini wanted Nozzolini’s opinion on a sentence by
Galilei (1627), according to whom
. . . li due stimatori abbiano egualmente esorbitato e commesse eguali stravaganze
nello stimare l’uno mille e l’altro dieci quello che realmente val cento,
which translates to: “The two estimators have been equally exorbitant and are
1the italic is a translation of a commentary to Galilei (1627) appearing in the edition of
Galilei’s works mentioned in the bibliography, from which all of the quotes are taken, following
Sca`rdovi (1980).
2a monetary unit, literally, a shield
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responsible for an equal extravagance by estimating, one thousand the former and
ten the latter, what is really worth one hundred”.
In the intense correspondence following the initial letters, Nozzolini argues that
the estimates should be evaluated according to the arithmetic proportion, whereas
Galileo insists that the correct method of judging is by the geometric proportion.
The crux of the problem is that the estimand is a positive quantity, for which the
geometric proportion seems more appropriate, as wittingly argued by Galileo in
another letter:
Se uno stimasse alta dugento braccia una torre, che veramente fusse alta cento,
con quale esorbitanza nel meno pareggera` il signor Nozzolini  l’altra nel piu` ?
which translates as: “If one were to overestimate a one-hundred arm high tower
as two-hundred arm high, what underestimate would Nozzolini consider as equally
deviating?”
3.2.2 Scale Symmetry, Convexity and Scale Invariance
Let us start with the following definition for the parameter define on the whole
real line.
Definition 1. A loss function L(ϑ, d) is symmetric if, for every d1, d2 and ϑ ∈ R1
(ϑ− d1)2 = (d2 − ϑ)2 (3.2.1)
implies L(ϑ, d1) = L(ϑ, d2).
Definition 1 implies that two decisions defined on the real line should be equally
penalised by a symmetric loss function L(·, ϑ) if they stand on the same squared
distance from ϑ. Note that for d1 < d2 Equation (3.2.1) can be rewritten as
ϑ = d1+d2
2
. It follows that if ϑ is the arithmetic mean of d1 and d2 then these deci-
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sions should be equally penalised. Clearly, the squared error loss of equation (3.1.1)
is symmetric on the real line by definition.
Then, Galilei’s claim of eguali stravaganze for a positive parameter ϑ can be ex-
pressed in modern terminology as the requirement of the scale symmetric loss
function, as in the following definition.








implies L(ϑ, d1) = L(ϑ, d2).






log d1 + log d2
2
.
In other words, if ϑ is the geometric mean of d1 and d2, then these decisions
should be equally penalised by a scale symmetric loss function. As in Definition 1
of symmetry for the real line, two decisions are symmetric if the parameter ϑ is
their appropriate mean – geometric in this case as opposed to arithmetic. This
fact will be used for our proposal of the symmetry definition on the interval.
The definition of the squared distance on the positive real line, R+ (Mateu-Figueras
et al., 2013)
D+(ϑ, d) = (log ϑ− log d)2 (3.2.3)
is known in Statistics as Brown’s loss function (Brown, 1968). Its motivation is to
rescale the positive real line to the whole real line via the log transformation and
to use the squared error loss function. Here, the logarithm function is a natural
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choice for a positive random variable.
Note that
D+(ϑ, d1) = D+(ϑ, d2) (3.2.4)
implies either d1 = d2 or Equation (3.2.2). Therefore, we can also restate Defini-
tion 2 in terms of (3.2.4).
The Euclidean distance on the real line and D+ on the positive real line share
the same property - they infinitely penalise boundary values on corresponding
parameter space. In case of ϑ ∈ R, the squared distance Lq(ϑ, d) takes an infinite
value when d = ±∞. For similar reasons, we require that an appropriate loss
function for a scale parameter should go to infinity as the decision approaches the
natural boundaries of the parameter space, to reproduce the behaviour at ±∞ of
the squared error loss function. A loss function with this property are also called
balanced according to Mahmoudi and Zakerzadeh (2011).
We recall one more property of loss functions for a parameter on the positive real
line - the scale invariance.
Definition 3. Loss function L(ϑ, d) is scale invariant if for every c > 0 and every
pair (ϑ, d).
L(ϑ, d) = L(cϑ, cd)
It follows that the squared loss function (3.1.1) is not scale symmetric, is not scale
invariant and does not penalise all boundaries for a scale parameter.
3.2.3 Symmetric Loss Functions on the Positive Real Line
The inadequacy of difference-based loss functions, like the squared error loss, for
estimating certain positive quantities has often been recognized (James and Stein,
1961; Stein, 1964). Several alternative loss functions have been proposed, the
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and Brown’s loss function (Brown, 1968) itself, D+(ϑ, d) given in Equation (3.2.3).
One can check that all of functions above are scale invariant, but only Brown’s
loss function is scale symmetric and infinitely penalises the boundary decisions.
Unfortunately, Brown’s loss function is not convex, a feature of loss functions
which is often required to represent risk aversion and for the sake of regularising
the associated minimisation problems. An unpleasant consequences is that, the
Bayes estimator associated with Brown’s loss function is usually difficult to com-
pute. Below we propose simple alternative loss functions which share the desirable
properties of a loss function on the positive line and have explicit Bayes estimators.












which are scale symmetric, scale invariant, convex, and which tend to infinity at





which can be considered as a modification of the squared error loss function. The
numerator is again the squared distance, but the denominator guarantees the
infinite penalisation for d = 0. It is easy to see that the loss function (3.2.8)
is a scale invariant version of the precautionary loss function (3.1.2). The graphs
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of loss functions L1(ϑ, d), Lsq(ϑ, d) and D+(ϑ, d) as functions of d for fixed ϑ = 0.4
are given in Figure 3.1.










Figure 3.1: Scale symmetric loss functions L1 (dashed), Lsq (solid) andD+ (dotted)
for d ∈ (0, 3) and ϑ = 0.4.
Note that loss functions of similar-looking forms which have been considered in the
literature, for example, the normalized squared loss Lnq (3.2.5) and the relative
squared error loss (Savchuk and Tsokos, 2011) Lrq(θ, d) =
(d−ϑ)2
ϑ
, do not tend to
infinity at the boundary and are not scale symmetric.
3.2.4 Scale Means and Scale Variances
Within the Bayesian approach, ϑ is a random parameter with a distribution which
conveys the uncertainty in the given state. In such a case, a point summary of
the distribution of ϑ minimising the risk (i.e. the expected loss) associated with
the given loss function is often required. Such a minimiser of an expected loss is
usually called a Bayes estimator. When a scale symmetric loss function is used,
we propose to call such minimisers scale means. In case of convex loss functions,
such as the novel loss function given in Equation (3.2.7) and the loss function in
Equation (3.2.8) , the minimisation can be performed explicitly.
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Theorem 1. Let ϑ be a positive random variable with a posterior density func-
tion f and such that E(ϑk) <∞ and E(ϑ−k) <∞, where E denotes the posterior
mean with respect to f and k > 0. Then,
(a) Expectation of the loss function Lk(ϑ, d) in Equation (3.2.7) with respect to f













(b) Expectation of the precautionary loss function (3.1.2) is minimised by the




for which the following bound holds: dˆsq ≥ E(ϑ).
Proof. (a) The expectation of the loss function (3.2.7) with respect to the posterior
density function f takes the form










− 2 = dkE (ϑ−k)+ dk−1E (ϑk)− 2.
















and in the special case of k = 1, dˆ1 =
√
E(ϑ)/E(ϑ−1).
(b) Similarly to the previous point, the expectation of the precautionary loss
function (3.1.2) with respect to the posterior density function f taken the form






d2 − 2dE(ϑ) + E(ϑ2)
d
.




This results in dˆsq =
√
E(ϑ2). Using the Jensen inequality (Jensen, 1906) for ϑ2




) ≥ E2 (ϑ) .
Applying the squared root to the both sides of the inequality the result immediately
follows.
In a more fundamental Bayesian approach, a Bayes estimator is regarded only as
a convenient summary of the posterior, and a loss function as a way to prescribe
what kind of summary is appropriate. Typically, the posterior expectation is used
as the Bayes estimator, implying that the squared loss function is being used. A
second step is usually taken to accompany the Bayes estimator with a measure
of uncertainty of the posterior distribution. If the posterior mean is used, the
posterior variance is often presented. However, if a scale symmetric loss function
is considered to be appropriate then it is also reasonable to present the achieved
minimum of the posterior expected loss as the second summary of the posterior
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distribution. For the given loss functions (3.2.7) and (3.1.2), particularly simple
expected posterior losses can be obtained. For the loss function (3.2.7), the scale












The approach used above for a positive parameter can be generalised to the pa-
rameter defined on the interval (a, b). The issue of a restricted parameter space is
not usually discussed in the choice of the loss function and corresponding Bayes
estimator: bounds are taken into account through the prior specification only, then
the squared loss function and posterior mean (the corresponding Bayes estimator)
are used. Such solutions can be suboptimal if boundary decisions are to be avoided.
Below, we define the property of the symmetry on an interval and show that the
novel definition generalises the cases of parameters on the whole real line and on
the positive real line. We provide the loss function with desirable properties which
is, again, a generalisation of the squared loss function and the precautionary loss
function.
3.3.1 Symmetric Loss Functions on Interval
Let us consider an inferential problem for which the parameter of interest lies in





where a < x < b. Note that, for a = 0 and b = 1, transformation (3.3.1) reduces
to the logit transformation. Following the same line of reasoning as in Section 3.2,
we introduce the following definition of the symmetric on (a, b) loss function (or
simply the interval symmetric loss function).
Definition 4. A loss function L(ϑ, d) is symmetric on the interval (a, b) if, for





implies L(ϑ, d1) = L(ϑ, d2).
In other words, two decisions d1 and d2 should be penalised equally if the arith-
metic mean of their logit transformation is equal to the logit transformation of ϑ.
Lemma 1 justifies the use of the logit transformation (3.3.1).
Lemma 1. Definition 4 is equivalent to Definition 1 when a → −∞ and
b → +∞ and equivalent to Definition 2 when a → 0 and b → +∞.
Proof. Condition (3.3.2) for a < d1 < d2 < b can be rewritten
ϑ = f(a, b, d1, d2) ≡ ab− d1d2 +
√
(d1 − a)(b− d1)(d2 − a)(b− d2)
a+ b− d1 − d2 .
Obviously, ϑ is a symmetric function of d1 and d2. Considering two limits
lim
a→−∞, b→+∞






f(a, b, d1, d2) =
√
d1d2,
it can be seen that the definitions are equivalent.
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It follows from Lemma 1 that Definition 4 is a convenient generalisation of the
definition of the symmetry.
3.3.2 An Interval Symmetric Loss Function and Its
Minimiser
As in the case of a positive parameter and scale symmetric loss functions, the
approach by Brown (1968) of specifying the squared loss function after rescaling
the interval (a, b) to the real line via, for example, the logit transformation (3.3.1)






On the unit interval this loss function is equivalent to so-called Aitchison distance
proposed by Aitchison (1992) for parameters defined on a simplex. However, the
loss function (3.3.3) is not convex and its minimisation problem does not have an
explicit solution. As an alternative, we propose the following loss function
Liq(ϑ, d) =
(d− ϑ)2
(d− a)(b− d) . (3.3.4)
which is interval symmetric and tends to infinity when the decision d tends to




d(1− d) . (3.3.5)
The graph of the corresponding loss function for the fixed ϑ = 0.5 and for different
values of d is given in Figure 3.2.
Note that the loss function (3.3.5) for a = 0 and b = 1 looks similar to the well-
known loss function (Ferguson, 2014)
(d− ϑ)2/(ϑ(1− ϑ))
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Figure 3.2: An example of the interval symmetric loss function (3.3.4) for a = 0,
b = 1, ϑ = .5 (solid line) and ϑ = .25 (dashed line) and different values of d ∈ (0, 1).
which, however, does not have the desirable property of assigning infinite penalties
to boundary decisions.
The decision which minimises the interval symmetric loss function (3.3.4) is given
explicitly in Theorem 2.
Theorem 2. Let ϑ ∈ (a, b) be a random variable with a posterior density func-
tion f and E(ϑ2) <∞ where E(·) denotes the expectation with respect to f . Then,
(a) Expectation of the interval symmetric loss function Liq in Equation (3.3.4)
with respect to f is minimised by the Bayes estimator
dˆiq =
ab− E(ϑ2) +√(E(ϑ2)− ab)2 − (a+ b− 2E(ϑ))(2abE(ϑ)− (a+ b)E(ϑ2))
a+ b− 2E(ϑ)
(3.3.6)
(b) Estimator (3.3.6) minimises the expectation of squared loss function (3.1.1) in
the limiting case a→ −∞ and b→ +∞, and the expectation of precautionary loss
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function Lsq (3.1.2) in the limiting case a→ 0 and b→ +∞.
Proof. (a) The expectation of the loss function Liq in Equation (3.3.4) with respect
to the posterior probability density function takes the form
E (Liq(ϑ, d) =
d2 − 2dE(ϑ) + E(ϑ2)
(d− a)(b− d) .




which takes the form
b(d2 − E(ϑ2)) + a (d2 − 2b(E(ϑ)− d)− E(ϑ2)) + 2d (E(ϑ2)− dE(ϑ))
(d− a)2(b− d)2 = 0.
Solving this equation results in the Bayes estimator given in Equation (3.3.6).
(b) Taking the limits
lim
a→−∞, b→+∞




dˆiq(a, b, ϑ) =
√
E(ϑ2),
it is easy to see that the obtained estimators are equivalent to the minimisers of the
squared loss function Lq and of the precautionary loss function Lsq, respectively.
Note that diq → a+b2 as E(ϑ)→ a+b2 .
3.3.3 Multivariate Generalisations
The definition of symmetry can be generalised to cases of parameters belonging to
subsets of Rm by applying the same ideas to different restricted parameter spaces
as in Definition 5.
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Definition 5. Let ϑ = (ϑ(1), ϑ(2), . . . , ϑ(m))T be a parameter lying in one of the
parameter spaces ϑ ⊂ Rm listed below. Let di = (d(1)i , d(2)i , . . . , d(m)i )T, i = 1, 2
be two vectors of decisions defined on the same parameter space. A loss function
L(ϑ,d) is a multivariate ϑ−symmetric if the equality
L(ϑ,d1) = L(ϑ,d2)
is implied by each triple ϑ,d1,d2 ∈ ϑ satisfying the following respective equality of
distances:





















































2 − logit(aj ,bj)ϑ(j)
)2
;
(d) when ϑ = {ϑ : ϑ(1) > 0, ϑ(2) > 0, . . . , ϑ(m) > 0;∑mi=1 ϑ(i) = 1} (symmetry
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The definition of the symmetric loss function in each case employs a distance cor-
responding to the particular restricted space. While the distances in (a)-(c) are
natural extensions of the previously used, the definition in (d) is less straightfor-
ward. Definition 5(d) uses the Aitchison distance again as it is argued to have
desirable properties of the metric on the simplex Sm (Billheimer et al., 2001).
Following Definition 5, Lemma 2 similar to Lemma 1 holds.
Lemma 2. Let ϑ = (ϑ(1), ϑ(2), . . . , ϑ(m))T be a vector of parameter of interest such
that ϑ(1) ∈ (a1, b1), ϑ(2) ∈ (a2, b2), . . . , ϑ(m) ∈ (am, bm) and denote a vector of cor-








Then, Definition 5(c) is equivalent to Definition 5(a) when ai → −∞ and bi →∞
for all i = 1, . . . ,m and to Definition 5(b) when ai = 0 and bi → ∞ for all
i = 1, . . . ,m.
Following Brown (1968), the distances in Definition 5 could be taken as corre-











At the same time, some convex alternatives could be considered when leading to
simple solutions of minimisation problems. However, the search of the symmetric
multivariate generalisation of the proposed loss functions Lk, Lsq and Liq seems
to be non-trivial. We propose the following loss functions for parameters with
non-negative components.
Proposition 1. Let ϑ = (ϑ(1), ϑ(2), . . . , ϑ(m))T ∈ Rm+ be a vector of unknown

















are additive multivariate generalisations of the loss function (3.2.7) and the loss
function (3.1.2),respectively, which infinitely penalise the boundary decisions.




sq penalise the boundaries infinitely and a de-
sirable performance of the corresponding estimators can be expected. However,




















instance, d˜1 = (
10471
1280
, 2)T, d˜2 = (6, 6)

















= 5.5. The same is true
for L
(m)
sq . Even if the whole loss functions are not symmetric, they are “component-













































































































Figure 3.3: Contour plots of loss functions D(2)+ , L(2)1 , L(2)sq for the case m = 2 and
ϑ = (1, 2)T.




Below, the performance of the Bayes estimators corresponding to the proposed
loss functions in three classic examples is demonstrated. The mean squared error
(MSE) is chosen to compare the different estimators on common grounds. Note
that, in general, it is not favourable to the new proposals, since the MSE is derived
from the squared error loss.
3.4.1 Estimation of a Probability
An important example of a parameter defined on the unit interval is a probability.
In the presence of a binary random sample with an unknown probability of success,
Beta prior distribution B(1, 1) is often assumed. Having observed x successes out of




B(x+ 1, n− x+ 1)
where B(·, ·) is Euler’s Beta function. The estimator corresponding to the squared





Another widely used estimator is the so-called “add two successes and two failures”





Below we compare these approaches to the newly proposed estimator (3.3.6).
The symmetric optimal Bayes estimator (3.3.6) in the case a = 0 and b = 1 can
be written as
dˆ =
E(ϑ2)−√E(ϑ2)(1− 2E(ϑ) + E(ϑ2))
2E(ϑ)− 1
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where ϑ is an unknown success probability, over which a posterior distribution is
given. It is assumed that the extremes of the interval are not possible values for the
parameter. The first and second moments of Beta distribution can be computed










For the comparison, simulated trials with sample size N = 15 are considered. On
a grid of values ϑ ∈ (0, 1), data from a binomial distribution with N = 15, and
p = ϑ were simulated. For each value of ϑ, 104 simulated data sets were used. In











k corresponds to s
th simulation and k = q, iq, AC corresponds to the
estimation method. The results are given in Figure 3.4.









































Figure 3.4: MSE, variance and bias for the restricted estimator pˆiq (solid), the
squared error loss function estimator pˆq (dashed) and the Agresti-Coull estimator
pˆAC (dotted). Results are based on N = 15 observations and 10
4 replications.
The proposed estimator pˆiq outperforms (in terms of the MSE) the Bayes estimator
obtained with the squared error loss function pˆq in the interval ϑ ∈ (0.2, 0.8). The
cost of this advantage is the worse performance on the intervals close to the bounds
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as the proposed form of the loss function penalises the boundary decisions and
drives estimates away from them. However, the proposed estimator outperforms
the Agresti-Coull estimator pˆAC on the same intervals ϑ ∈ (0, 0.2) and ϑ ∈ (0.8, 1).
Thus, the proposed estimator provides a reasonable trade-off between currently
used estimators pˆq and pˆAC outperforming pˆAC on bounds and pˆq away from them.
In addition to the MSE, associated confidence intervals and coverage probabilities
are extensively studied in the literature (see e.g. Brown et al., 2001). In particu-
lar, coverage probabilities were shown to have an erratic behaviour and often to
go below their nominal level. Corrections were proposed by Agresti and Coull
(1998). Confidence intervals can also be constructed around the newly proposed
point estimator pˆiq. The following confidence intervals are compared via simulated
coverage probabilities in Figure 3.5:
[1] Normal approximation of the confidence interval centred around pˆk, as sug-
gested by Brown et al. (2001)
CI
(k)





where 1− α is the confidence level and k = q, iq, AC.

















[3] Approximate confidence interval using the delta-method (Resnick, 2013) cen-
tred around newly proposed pˆiq
CI
(iq)


















Figure 3.5: Left panel: Coverage probabilities of CI
(iq)





N (purple line) using [1], the normal approximation interval. Right panel:
Coverage probabilities of CI
(iq)
D (blue line) and CI
(AC)
W (purple line) using [2], the
Wilson, and [3], the delta-method, confidence intervals respectively. Results are
based on N = 15 observations and 104 replications.
As it was originally found by Vollset (1993); Newcombe (1998), the coverage prob-
abilities have an erratic behaviour for different values of the true probability ϑ.
Using the normal approximation confidence interval, the coverage probability of
CI
(q)





N also fluctuate but never go below 0.95 for N = 15. While





N might be below 0.95 (Brown et al., 2001), it would be generally true that
their coverage probabilities are greater than those of CI
(q)
N for larger intervals of ϑ
and are more robust. In addition, a comparison between the normal approxima-
tion method (left panel of Figure 3.5) and the Wilson and delta method intervals
(right panel of Figure 3.5) supports the suggestion by Brown et al. (2001) that the
normal approximation gives a simple way to construct confidence intervals with -
on average - better coverage probabilities than alternative methods.
76
3.4.2 Restricted Estimation of a Normal Distribution
Mean
In the following example, it is demonstrated what benefits the proposed form of
loss function (3.3.4) can provide in a Bayesian framework in the presence of the
additional information that the true parameter lies in an interval (a, b).
The problem of restricted mean estimation has been known for a long time (e.g.
Bartholomew, 1965) and has been extensively studied in the literature (see e.g.
Casella and Strawderman, 1981; Bickel, 1981; Gatsonis et al., 1987; Kumar and
Tripathi, 2008). The previously proposed estimators were constructed using the
squared error loss function and compared using a Bayes risk (Marchand et al.,
2011). Interestingly, despite the variety of the literature on the problem and
the fact that the Bayes estimator with respect to the uniform prior distribution
on (−a, a) outperforms uniformly the “unrestricted” Bayes estimator under the
squared error loss function (Hartigan, 2004), the sample mean estimator is still
widely used in practice. For this reason we propose our simple alternative and
compare it to commonly used estimators.
Consider the problem of estimating the mean µ of a normal sample of i.i.d.
Xi ∼ N (µ, σ2), i = 1, . . . , n where σ2 is known. Assume it is known that
the parameter µ belongs to the interval (−a,+a) where a > 0. An example is
the estimation of the treatment effect in paediatric studies of a drug that has been
already tested in the adult population. For instance, a clinician might be sure that
a toxicity biomarker for the same doses cannot be less than for adults.
As stated above, the common way to incorporate this information in the Bayesian
framework is to restrict the prior distribution of the parameter µ to the interval
(−a,+a) and then to use the squared error loss to obtain the Bayes estimator.
Thus, the information about the restricted space is ignored when obtaining a
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summary statistic, while the proposed form of loss function (3.3.4) allows to incor-
porate it together with the prior distribution. Furthermore, in practice the prior
information can be often ignored as well and the sample mean estimator (corre-
sponding to the Jeffrey’s prior) is used. Therefore, a comparison of the proposed
loss function and the currently used approaches (with and without incorporating
the prior information) is of interest.
Consider samples of size N = 15 and Bayes estimators as follows:
• Bayes estimator under Jeffrey’s prior g(µ) ∝ k√ n
σ2
for µ and the squared
error loss function. Denoted by J ;
• Bayes estimator under the uniform prior U(−a,+a) for µ and squared error
loss function. Denoted by U1.
• Bayes estimator in Equation (3.3.6) under the uniform prior U(−a,+a) for
µ and the interval symmetric squared error loss function. Denoted by U2.
Alternatively to U2, the Bayes estimator U
′
2 defined by (3.3.6), but with a wider
interval (−1.25a,+1.25a) is also applied to investigate how a less strict penalisation
of the bounds influences the estimation. This wider interval could be interpreted
as a conservative way to incorporate information about the parameter location.
Two cases a = 2 and a = 4 are considered. The parameter σ2 = 4 is assumed to be
known in both cases. As before, the MSE is used as a measure of the comparison.
The results for 104 replications for each value of µ are given in Figure 3.6.
Incorporating the interval information in the Bayes estimator allows for improve-
ment if the true value of the parameter µ is not close to the bounds. In the case
a = 2 estimator U2 outperforms U1 on the interval µ ∈ (−1,+1) and in the case
a = 4 on the interval µ ∈ (−3,+3). The same holds for estimator U ′2, however,
its MSE never falls below the level of the MSE corresponding to J . Clearly, the
wider interval improves estimation on the bounds, at the cost of the higher MSE
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Figure 3.6: MSE corresponding to different values of the restricted mean parameter
µ with (a) a = 2 and (b) a = 4 and Bayes estimator U1 (solid), U2 (dashed), U
′
2
(dotted) and the simple mean estimator J (solid dashed). Results are based on
104 replications.
in the middle. Note that the wider interval a = 4 corresponds to less amount of
the additional information and to a smaller benefit in the MSE comparing U1, U2
and U ′2 against J . Overall, the Bayes estimator corresponding to the interval sym-
metric loss function avoids the boundary decisions, improves the estimation if the
parameter lies away from bounds and can be recommended for the application if
boundary decisions lead to severe consequences.
3.4.3 Estimation of the Parameters of Gamma
Distribution
An important example of the multidimensional restricted parameters estimation
is Gamma distribution with positive shape and scale parameters α1, α2 > 0. A
Bayesian inference for this problem has been studied, for example, in Miller (1980)
and methods for approximate computation of Bayes estimators were proposed
using the Lindley approximation (Lindley, 1980).
We consider the function L
(2)
sq given in Equation (3.3.9) to obtain Bayes estima-
tors for the parameters. As the loss function (3.3.9) is the sum of the univariate
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precautionary loss functions (3.1.2), the following estimators are used
αˆi =
√
E(α2i ), i = 1, 2 (3.4.3)
where the expectation E is taken with respect to the posterior density function.
Let us consider an experiment with sample size N = 15. The parameters of
Gamma distribution are varied over a grid, α1, α2 ∈ (0, 10) and the performance
of the different approaches are compared by simulations. The two approaches
compared use the same prior distribution for parameters α1 and α2 using the
following Bayes estimators:
1) Bayes estimator under the squared loss function - the posterior mean
2) Bayes estimator under the multivariate precautionary loss function - the scale
posterior mean (3.4.3).
We use non-informative Gamma prior distribution with parameter (10−4, 10−4)
for both α1 and α2 and an approximate computation method proposed by Lind-
ley (1980). We emphasise the choice of the prior distribution is out of scope and
the goal is to compare two Bayes estimators under equal conditions. The differ-
ences between MSEs corresponding to the method 1) and to the method 2) for
parameters α1 and α2 in 10
4 replicated trials is given in Figure 3.7.
The differences in the MSEs for both parameters are positive for all values of the
true parameters α1 and α2. It means that the Bayes estimator from method 2)
is associated with a smaller MSE than the Bayes estimator from method 1). The
difference in the MSE increases as a true value of parameter increases. This result
makes the proposed estimator and the associated loss function L
(2)
sq good candidates
for the further investigation in multidimensional estimation problems.
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Figure 3.7: Differences in the MSEs for parameters α1 and α2 using Bayes estimator
under the squared error loss function and the Bayes estimator under L
(2)
sq . Results
are based on 104 replications.
3.5 A Modified Allocation Rule for the
Continual Reassessment Method
The absolute distance criterion (2.1.4) used by the Bayesian CRM (Section 2.1.1)
implies that each next patient should be allocated to the estimated MTD. While
this is expected to result in the assignment of as much as possible patients to
the MTD, it can also lead to not exploring a dose-toxicity relation enough and
to “locking-in” (selecting regardless further outcomes) on suboptimal doses (Oron
and Hoff, 2013). Furthermore, an investigator should take into account another
ethical constraint and avoid the allocation of patients to highly toxic doses. Finally,
following the arguments above, the absolute distance criterion might not be a
reliable measure of the distance between objects (pˆj and γt) defined on the unit
interval. In this section, we show how both statistical and ethical counterparts
can be taken into account in the allocation criterion using the proposed interval
symmetric loss function (3.3.4).
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3.5.1 Motivation
Following Section 2.1.1, consider a Phase I clinical trial with two doses (d1, d2)
and a binary endpoint. The goal of the trial is to find the MTD which has a
probability of DLT closest to the target, say γt = 0.30. Assume that 10 patients
were assigned to each dose and 2 and 4 toxicities were observed, respectively. Then,
a typical question in a sequential trial is: “which dose should be administered to
the next patient”. As described in Chapter 2, a conventional criterion for many
dose-escalation designs is to assign the next patient to dose dj corresponding to
the point estimate pˆj closest to γt using either the absolute distance (2.1.4) or the
squared distance
(pˆj − γt)2 . (3.5.1)
Assume that in the example above, the probabilities p1 and p2 are considered as
random variables having Beta distributions B(2, 8) and B(4, 6) and one uses the
means as point estimates: pˆ1 = 0.2 and pˆ2 = 0.4. Following the criterion (3.5.1),
the next patient can be assigned to either of doses as both probabilities are equally
close to the target. At the same time, one can argue that these doses are not
“equal” for at least two reasons. On the one hand, the criterion (3.5.1) ignores the
uncertainty in the estimates. Indeed, the probability of being within 5% of γt is
larger for p2
P (p2 ∈ (0.25, 0.35)) > P (p1 ∈ (0.25, 0.35)) . (3.5.2)
The larger variance of p2 favours the decision to assign the next patient to d2. On
the other hand, assigning the patient to a dose with the estimated toxicity risk
of 0.4 can be unethical as it potentially exposes a patient to an excessive toxicity.
It is usually of interest to balance these two concerns - an investigator aims to
decrease an uncertainty, but also tends to avoid exposing patients to doses far
from the MTD. In the illustration above, the conventional absolute (or squared)
distance criteria fails to address both of these concerns.
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The question of safety was firstly addressed in the allocation rule by Babb et al.
(1998) using the Escalation with Overdose Control (EWOC) design. The EWOC
uses the following criterion for patients allocations (Cheung, 2011)
E
(
α(γ − pi)+ + (1− α)(pi − γ)+
)
(3.5.3)
where (x)+ = max(0, x) and α is a parameter of asymmetry. Criterion (3.5.3)
imposes that more toxic doses should have more severe penalty than less toxic
doses. While the EWOC design was shown to result in a low mean number of DLTs,
it also leads to the underestimation of the MTD in many scenarios (Wheeler et al.,
2017). Therefore, some modifications were proposed. The main idea beyond the
modifications is to use a varying parameter αi in the criterion (3.5.3) for allocating
patient i rather than a fixed value α. Particularly, Tighiouart et al. (2010) used
α2 = . . . = α9 = 0.25, αi = min (αi−1 + 0.05, 0.50) . (3.5.4)
We will denote the corresponding design by TAR. Wheeler et al. (2017) proposed
toxicity-dependent feasibility bound design (TDFB) which uses
αi+1 = min
(






where αmin and S are parameters chosen by an investigator. These designs, how-
ever, prioritise the ethical issue (avoiding the overdosing of patients) and do not
fully address the statistical issue (minimising the uncertainty in the MTD esti-
mate).
Another design aimed to resolve both uncertainty and safety concerns is the
Bayesian Logistic Regression Model (BLRM) proposed by Neuenschwander et al.
(2008). To address the statistical part, BLRM uses the whole distribution of the
DLT probability, while the ethical part is addressed via a penalty for overly toxic
intervals. The allocation is determined by a loss function computed for each dose.
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For instance, the loss function for γt = 0.33 takes the form
L =

1 if p ∈ (0.00, 0.26)
0 if p ∈ (0.26, 0.41)
1 if p ∈ (0.41, 0.66)
2 if p ∈ (0.66, 1.00)
(3.5.6)
Given the posterior distribution fn after n patient have been observed, the ex-
pected value of the loss function for each dose is computed and the next patient
is assigned to the dose corresponding to the minimum value of the loss. While
this approach has been proven to be useful in practice, it requires several addi-
tional parameters (the values of the loss function and corresponding intervals) to
be carefully calibrated.
In this section we propose a new criterion for allocation of patients in a dose
escalation trial which is based on the interval symmetric loss function (3.3.4). The
criterion takes into account both the variance of the probability distribution and
the ethical concerns of an investigator. It requires only one parameter, which has
a simple and intuitive interpretation, to be specified. This parameter controls
the mean number of toxicity outcomes explicitly. We incorporate the proposed
criterion into the Bayesian CRM using the 1-parameter power model (2.1.5) and
compare operating characteristics to the standard CRM, EWOC type designs and
BLRM.
3.5.2 Criterion
Derivation Following the construction of the interval symmetric loss func-




p(1− p) . (3.5.7)
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The criterion (3.5.7) takes its minimum value δ(·) = 0 at p = γt, and, as shown
above, its distinguishing property is an infinite penalisation of the boundary deci-
sions. In the context of dose escalation trials, it means that doses corresponding to
p = 0 and p = 1 would be never selected. The denominator of the criterion (3.5.7)
also corresponds to the variance of a binary event probability. Therefore, it follows
that the uncertainty is incorporated into the criterion’s point estimate directly and
the criterion (3.5.7) can be considered as a statistic. Applying it to the illustration
example above helps to address the uncertainty issue: δ(pˆ1 = 0.2, γt = 0.3) = 1/16
and δ(pˆ2 = 0.4, γt = 0.3) = 1/24 leading to selecting d2 for the next patient as
follows from Inequality (3.5.2).
The target toxicity γt is always below 0.5 in Phase I clinical trials. Consequently,
if one considers two point estimates which stand on the same squared distance
(γt−ν)2 from the target γt (for 0 < ν < γt), the criterion (3.5.7) favours the higher
probability estimate. This might conflict with the ethical constraint. Indeed, it was
shown above that the novel criterion is symmetric on the unit interval implying
that overly toxic and overly safe doses are equally penalised. To address needs
of Phase I trial, we generalise the interval symmetric loss function to allow the
asymmetric penalisation by including an asymmetry parameter a as follows
δ(p, γt) =
(p− γt)2
pa(1− p)2−a . (3.5.8)
The asymmetry parameter 0 ≤ a ≤ 2 corresponds to the penalisation of overly
toxic doses and (2− a) to the penalisation of overly safe doses. The constant 2 is
chosen to preserve the same rate of p in both nominator and denominator which
guarantees that δ → 0 when p → γt for any value of γt. Clearly, 0 ≤ a < 1
implies a more severe penalty for selections of more toxic doses. Applying the
criterion (3.5.8) using a = 0.5 one can obtain that
δ(pˆ1 = 0.2, γt = 0.3, a = 0.5) < δ(pˆ2 = 0.4, γt = 0.3, a = 0.5)
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implying that dose d1 should be selected due to the penalty for overly toxic dose
selections. We refer to the proposed allocation criterion as to the Convex Infi-
nite Bounds Penalisation (CIBP) approach. Illustrations of the standard crite-
rion (3.5.1) and of CIBP using a = 1 and a = 0.5 are given in Figure 3.8.

























Figure 3.8: Squared distance (dotted line) and CIBP criteria using a = 1 (dashed
line), a = 0.5 (solid line) for different values of p ∈ (0.05, 0.6). The target proba-
bility is γt = 0.3.
The CIBP criteria using both a = 1 and a = 0.5 go to infinity faster than the
squared distance as p approaches the lower bound. Moreover, for a = 1 the overly
toxic doses are penalised less than overly safe, because corresponding values are
located far from the upper bound. The asymmetric CIBP criterion solves this is-
sue and penalises probabilities above γt = 0.3 more severely than alternatives. All
criteria behave similarly in the neighbourhood of the target γt. Overall, the prop-
erties of the CIBP criterion allows to resolve the statistical and ethical concerns
by the use of an appropriate value of the asymmetry parameter a. The guidance
on the choice of a is given in the following section.
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Choice of the parameter of asymmetry Firstly, note that the denominator
alone is maximised at the point p = a/2. Then, if pˆ is an estimator of p (depending
on the approach, for instance, MLE or the Bayes optimal estimator) the “plug-in”




using a = 2γt leads to the same allocation as the plug-in estimator of the squared
distance criterion (3.5.1). Then, values a < 2γt lead to a more conservative allo-
cation of patients compared to the squared distance.
Secondly, the asymmetry parameter a represents the trade-off between the ethical
and uncertainty concerns. Then, a sensible choice of a should satisfy the following
conditions. Consider an interval (γt−ν, γt+ν). Assume that given two probability
estimates belonging to this interval and standing on the same squared distance
from γt, one would like to select the lower estimate due to the safety reasons. Then,
(γt−ν, γt+ν) defines an interval in which the safety is prioritised. Similarly, given
two estimates lying outside of the interval (γt − ν, γt + ν) for which the squared
distances are equal, one prefers decision with a greater uncertainty. Evidently, the
estimates on the bounds of the interval should correspond to the same value of the
CIBP criterion. Formally, solving
((γt − ν)− γt)2
(γt − ν)a (1− (γt − ν))2−a
=
((γt + ν)− ν)2
(γt + ν)a (1− (γt + ν))2−a












1− γt − ν
1− γt + ν
)
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For the fixed target values of the target γt and the half width ν, one can compute
the corresponding value of the asymmetry parameter a. Figure 3.9 shows values
of the asymmetry parameter for different half-widths ν and target values γt =
{0.20, 0.25, 0.30}, and provides a useful insight on the intuitive interpretation of
the parameter a.













Figure 3.9: Values of the parameter of asymmetry a for γt = 0.20 (dashed-dotted
line) , γt = 0.25 (solid line), γt = 0.30 (dashed line) and ν ∈ (0, 0.35). The
horizontal line corresponds to a = 0.30.
As ν → 0, a tends to 2γt corresponding to the squared distance allocation rule.
Increasing values of ν imply that an investigator prefers an interval in which a lower
estimate is selected to be wider, and consequently, more conservative allocations
and smaller values of a. Note that a corresponding to ν ≈ γt guarantees that for
any two estimates standing on the same squared distance from the target γt, the
dose corresponding to the lower toxicity will be selected. For example, for γt = 0.25
the corresponding value of a is close to 0.3 marked by the dotted horizontal line.
Novel Criterion in the CRM We incorporate the novel criterion (3.5.8) in
the CRM design. The design proceeds as described in Section 2.1.1, but replaces
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ψ(dj, θ)a(1− ψ(dj, θ))2−a
)
(3.5.10)
among all d1, . . . , dm is selected for the next group of patients where the expectation
is found with respect to the posterior probability fn given in Equation (2.1.2). The
procedure is repeated until the maximum number of patients, N , has been treated.
As the uncertainty and the conservatism is important in the allocation only, we
propose to use the conventional criterion (3.5.1) for the final MTD recommenda-
tion. Note that if the CIBP criterion (3.5.10) is used for the MTD recommendation
then the design might lead to the MTD underestimation (Appendix A).
3.5.3 Illustration
To illustrate the impact of the proposed escalation criterion, we revisit the results
of the actual clinical trial of Everolimus in patients with Metastatic Breast Cancer
(NCT00426556). The study considers three regimens of Everolimus given together
with Paclitaxel and Trastuzumab (PT):
1. Daily dosing of Everolimus 5mg plus PT (d1)
2. Daily dosing of Everolimus 10mg plus PT (d2)
3. Weekly dosing of Everolimus 30mg plus PT (d3)
The goal is to find the regimen corresponding to the target toxicity γt = 0.3.
Note that the amount of the complimentary drugs is fixed during the trial and a
clinician is confident in the monotonicity of toxicity probabilities corresponding to
d1, d2, d3. Thus, the trial can be analysed using the tools for single-agent trials.
The following aggregated data is available by the end of the trial.
We apply the CRM design using the 1-parameter power model (2.1.5) and the
robust operational prior distribution θ ∼ N (0, 1.34) used by O’Quigley and Shen
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Table 3.1: Aggregated data of the Everolimus trial
Dose d1 d2 d3
Number of Patients assigned 6 17 10
Number of DLTs 3 6 7
(1996) and the skeleton (0.20, 0.30, 0.40) implying that the prior MTD is d2. We
restrict the design such that the dose skipping is not allowed and enforce the
start from the lowest dose. Patients are enrolled in cohorts of three. Note that
the parameters of the design are the same for both the original CRM and the
proposed modification. The only difference is the allocation criterion: the original
CRM uses the squared distance criterion (3.5.1) while the proposed design uses the
CIBP criterion (3.5.10). Following the interpretation of the asymmetry parameter
we fix a = 0.3 to favour less toxic selections (see Figure 3.9). The designs are
implemented using the interactive functions of the bcrm-package by Sweeting et al.
(2013). We use the aggregated data from Table 3.1 to generate responses in a single
realisation of the trial. Clearly, DLTs indicated in Table 3.1 can appear in any
sequence. Therefore, we generate a random sample (without replacement) for each
dose to have a specific order of DLTs and fix it for both trials. The only exception
is that the realisation for the first cohort is chosen by us. We consider its influence
separately.
Allocation of Patients The first 3 patients are assigned to d1 by the restric-
tion. We begin by assuming that all 3 patients do not experience DLTs and
consider the behaviour of the designs. The sequential allocations of patients for
the CRM and CIBP designs in this case are given in Figure 3.10. Values of the
criteria after responses for each cohort are given in Table 3.2.
After no DLTs were observed for the first cohort, CRM and CIBP allocate the
second cohort of patients to d2 for which one patient experiences a DLT. Given
the toxic outcome, CRM recommends to stay at d2 for the third cohort. In contrast,
CIBP recommends to return to the previous dose level due to the conservatism of
















3 Individual trial (CIBP)
cohort















Figure 3.10: Allocations of 7 cohorts in the individual Everolimus trial.
both methods given a dose. Therefore, due to the construction of the illustration,
all patients in cohort 3 (using CIBP) experienced DLTs to consistent with the
aggregared data on d1. Then, the trial would be terminated by a clinician. At
the same time, the trial using the original CRM design proceeds as no DLTs were
observed for cohort 3 at dose d2. The dose d3 is recommended for cohort 4 in which
all patients have DLT. This leads to the de-escalation to d2 and after 2 cohorts
for which 3 patients (out of 6) had DLT and the further de-escalation to d1. All 3
patients in cohort 7 experienced DLTs and a clinician terminates the trial. Overall,
CRM assigned 21 patients and ten of them experienced DLTs which resulted in
the same conclusion as CIBP did after 9 patients with 4 toxicity outcomes only.
Table 3.2: Values of the squared distance criterion (2.1.4) used by CRM and of
the CIBP criterion (3.5.10) in the individual trial after responses for each cohort.
Value of criteria corresponding to the dose selected for a next cohort by are in
bold.
CRM CIBP
Cohort 1 0.031 0.012 0.002 0.62 0.47 0.45
Cohort 2 0.01 0.001 0.005 0.10 0.12 0.21
Cohort 3 0.03 0.013 0.001 0.30 0.67 1.41
Cohort 4 0.003 0.002 0.003
Cohort 5 0.003 0.002 0.024
Cohort 6 0.000 0.009 0.039
Cohort 7 0.014 0.048 0.096
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The illustration above demonstrates the allocation if no toxicity outcomes are
observed in cohort 1. Regarding all other possible outcomes (1, 2 or 3 toxicities),
one can find that both approaches result in the same conclusions, same numbers of
DLTs and the total number of patients. Therefore, the proposed approach results
in the same MTD recommendation, but in either a similar or safer allocation of
patients. This motivates a comprehensive simulation study of the novel allocation
criterion.
3.5.4 Comparison to the CRM
Setting Below we compare the performance of the proposed CIBP criterion
against the squared distance criterion both applied to the 1-parameter power
model. The single-agent Phase I trial with m = 6 doses and N = 30 patients
is considered. The goal is to find the MTD corresponding to the target γt = 0.25.
We consider 6 dose-toxicity scenarios with target doses located at positions corre-
sponding to scenario’s number. The dose-toxicity shapes are given in Figure 3.11.
Toxicity scenarios were chosen “equally difficult” in terms of the optimal non-
















































































































Figure 3.11: Six considered dose-toxicity scenarios for the comparison to the CRM.
The MTD is marked by a triangle.
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parametric benchmark (Section 2.1.2). It allows to compare the proportions of
correct selections between scenarios. We use function getprior from the dfcrm
R-package to specify the skeleton for the 1-parameter power choosing d2 to be
the prior MTD and the half width of the equivalent interval 0.05. The prior dis-
tribution of the parameter is chosen to be θ ∼ N (0, 1.34) (O’Quigley and Shen,
1996). Different skeletons corresponding to d3 and d4 being the MTD are also
investigated and the corresponding (quantitatively similar) results are given in
Appendix A. Again, both the standard CRM and its proposed modification use
the same model parameters and the only difference is the allocation rule. This al-
lows to connect observed differences to the choice of the allocation criterion only.
We study (i) the proportion of correct selections and (ii) the proportion of patients
experienced DLT. We consider different values of a = {0.3, 0.4, 0.5} corresponding
approximately to half widths of the interval ν ≈ {0.24, 0.20, 0.00}.
We denote CRM using the new allocation criterion with parameter a by CIBP(a).
The characteristics of both methods are evaluated in R (R Core Team, 2015) using
the bcrm-package by Sweeting et al. (2013). To accommodate the new criterion,
corresponding modifications to the package were made.
Operating Characteristics The proportions of each dose selections and the
proportion of patients experienced DLT for CRM, CIBP and the non-parametric
optimal benchmark (Section 2.1.2) are given in Table 3.3. We use 40, 000 replica-
tions to declare any differences above 1% as significant ones.
All considered designs lead to the PCS close to the characteristics of the bench-
mark in scenarios 1-5 and have some difficulties in selecting the highest dose in
scenario 6. Comparing the performance of the novel criteria for different values of
the asymmetry parameter, as one can expect, more conservative selections corre-
spond to CIBP(0.3). The greatest differences are in scenarios 1 and 6: the increase
in a from 0.3 to 0.5 leads to an increase in the PCS by 5% in the toxic scenario 1
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Table 3.3: Proportions of each dose selections and mean proportions of DLTs for
CRM, CIBP using a = {0.3, 0.4, 0.5}, and the non-parametric optimal benchmark.
Results are based on 40, 000 replications.
d1 d2 d3 d4 d5 d6 DLTs
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
Benchmark 70.12 16.23 7.31 4.23 1.61 0.50
CIBP(0.3) 69.18 21.65 6.18 2.27 0.61 0.11 28.31
CIBP(0.4) 66.40 22.20 7.25 3.08 0.91 0.16 29.46
CIBP(0.5) 64.12 22.25 8.49 3.80 1.15 0.18 30.58
CRM 65.59 21.16 8.22 3.79 1.07 0.17 30.17
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
Benchmark 21.01 50.18 19.91 6.25 2.10 0.55
CIBP(0.3) 24.06 47.88 21.98 5.00 0.93 0.15 23.33
CIBP(0.4) 24.00 46.95 22.28 5.39 1.19 0.19 24.87
CIBP(0.5) 23.97 46.12 22.20 6.02 1.46 0.24 26.45
CRM 25.41 45.76 21.36 5.96 1.27 0.24 26.10
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
Benchmark 2.49 19.24 50.37 24.08 3.28 0.44
CIBP(0.3) 4.26 25.61 46.48 20.20 3.16 0.28 20.91
CIBP(0.4) 4.08 25.53 46.25 20.57 3.23 0.34 22.56
CIBP(0.5) 3.77 25.64 46.49 20.46 3.31 0.32 24.21
CRM 3.91 26.66 45.62 20.37 3.06 0.37 23.97
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
Benchmark 0.10 2.58 19.13 50.37 23.96 3.85
CIBP(0.3) 0.22 5.01 27.27 44.62 19.65 3.23 19.36
CIBP(0.4) 0.17 4.78 26.64 45.66 19.59 3.15 20.99
CIBP(0.5) 0.18 4.74 27.16 45.74 19.36 2.83 22.43
CRM 0.18 4.50 27.82 45.32 19.15 3.03 22.43
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
Benchmark 0.00 0.00 2.39 19.23 50.57 27.73
CIBP(0.3) 0.00 0.34 6.54 27.67 43.34 22.11 17.71
CIBP(0.4) 0.00 0.31 5.89 27.77 44.12 21.89 19.24
CIBP(0.5) 0.00 0.33 5.50 28.06 44.84 21.28 20.73
CRM 0.01 0.27 5.46 28.89 44.10 21.28 20.56
Scenario 6
Toxicity 1.50 2.50 7.50 10.00 15.00 25.00
Benchmark 0.00 0.00 0.57 2.67 20.00 76.86
CIBP(0.3) 0.00 0.04 2.97 10.42 26.84 59.72 15.25
CIBP(0.4) 0.00 0.05 2.30 9.55 27.53 60.58 16.53
CIBP(0.5) 0.00 0.04 1.68 7.31 27.71 63.26 17.98
CRM 0.00 0.05 1.88 8.65 28.89 60.53 17.34
and to the decrease in the PCS by 3.5% in the flat scenario 6. The differences in
the rest of scenarios are smaller, but still significant. CIBP(0.3) has a greater PCS
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than CIBP(0.4) in scenarios 1 and 2, the same PCS in scenario 3 and a smaller in
scenario 4, 5 and 6. Overall, greater values of a favour the selection of higher doses
and lead to higher proportions of DLTs with the difference around 2-3% between
CIBP(0.3) and CIBP(0.5) under all scenarios.
Regarding the comparison of the novel criterion to the original CRM, one can
find that the CIBP(0.4) has a similar PCS, but smaller proportions of DLTs in all
considered scenarios. The CIBP(0.5) performs comparably to the CRM (scenarios
2-5) or better (scenario 6) than the CRM at the cost of 1% decrease in the PCS in
the toxic scenario 1. The CIBP(0.5) also results in a slight increase in the number
of toxic responses. The most noticeable difference can be observed by comparing
the CRM to the CIBP(0.3). In terms of the PCS, CIBP(0.3) outperforms the CRM
by 4% and 2% in toxic scenarios 1, 2 and shows the comparable performance in the
rest of scenarios. At the same time, CIBP(0.3) outperforms the CRM in terms of
the proportion of patients experienced a DLT in all considered scenario by nearly
3% in scenarios 2-5 and by 2% in scenarios 1 and 6. While the margin of these
differences might be seen to be negligibly small, this improvement results in nearly
one fewer patient experienced DLT. Therefore, the novel allocation rule is more
ethical as it exposes fewer patients to more toxic doses while leading to either no
changes or an increase in the PCS.
Another valuable feature of the novel approach is an additional flexibility which
allows controlling the mean number of DLTs directly. Clinicians can tailor the
parameter a based on their conservatism. For instance, they might be ready to
sacrifice the PCS in the flat scenario 6 for the sake of not giving overly toxic rec-
ommendation in the toxic scenario 1. The new criterion enables such an option.
At the same time, the design preserves its simplicity and does not result in ex-
tra computational costs. The comparison of the proposed design to alternative
methods is given in the following section.
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3.5.5 Comparison to Alternative Methods
Setting In this section, we compare CRM incorporating the CIBP allocation
criterion to alternative designs. We consider the setting by Wheeler et al. (2017)
for discrete dose levels. There are N = 40 patients and m = 6 doses in the
trial. The goal is to find the MTD corresponding to the target γt = 0.33. The
dose-toxicity scenarios are given in Figure 3.12.
















































































































































































Figure 3.12: Ten considered dose-toxicity scenarios for the comparison to EWOC.
The MTD is marked by a triangle.
We compare operating characteristics to the original EWOC design and its modifi-
cation (TAR and TDFB with parameters αmin = 0.25 and S = 12
2
3
) and to BLRM
using the loss function (3.5.6). All of alternative methods use the 2-parameter lo-
gistic model (2.1.6). The bivariate normal prior distribution for parameters of
BLRM suggested by Neuenschwander et al. (2008) is used. The parameters of
EWOC, TAR and TDFB are specified as by Wheeler et al. (2017). For the novel
design the prior distribution of θ as above is used. The only difference with the
previous section is the skeleton which is now set using the same information the
prior MTD as for the alternative methods - the skeleton is constructed using d3
as the prior MTD. Assuming that the ethical issue is of the great interest in this
trial we study different values of the asymmetry parameter a = {0.5, 0.25, 0.10}.
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We study the performance of designs in terms of (i) Accuracy
A = 1−m
∑m
j=1 (pj − γt)2 pij∑m
j=1 (pj − γt)2
where pj is the true toxicity probability for dj and pij is the probability to select
dj, and in terms of (ii) mean number of patients experience a DLT. Note that
the accuracy index A takes into account the selection at all dose levels. As many
different scenarios are considered, one can expect that one design can have a better
performance in one scenarios, but worse in others (Wages, 2015). Therefore, we
focus on the average performance: the (geometric) mean accuracy and the mean
number of DLTS across all scenarios.
Operating Characteristics Accuracy indices for the non-parametric opti-
mal benchmark, CIBP with asymmetry parameter a = {0.5, 0.25, 0.10}, TDFB,
































Figure 3.13: Accuracy indexes and mean accuracy indexes for the non-parametric
optimal benchmark, the CIBP using a = {0.5, 0.25, 0.10}, TDFB, EWOC, TAR
and BLRM designs. Upper dashed horizontal line corresponds to accuracy of the
TAR and the lower one to the accuracy of the TDFB. Results are based on 2000
simulations.
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All of the considered methods show the accuracy close to the accuracy of the
non-parametric optimal benchmark with EWOC being an exception. Comparing
CIBP approaches, one can see that the mean accuracy decreases as the parameter
a decreases. A more conservative allocation of patients results in smaller accuracy
indices in non-flat scenarios. The decrease in the mean accuracy index is, however,
rather small - from 0.87 using a = 0.5 to 0.83 using a = 0.1. The most noticeable
drop across scenarios can be found in scenario 5 - 0.20. Clearly, the variance of
the accuracy indices increases as a decreases - a more conservative design leads
to the better performance in toxic scenarios 1-3 for the cost of the less accurate
performance in flat scenarios 8-10.
Comparing different approaches, TAR, BLRM and CIBP(0.5) correspond to the
greatest mean accuracy. TDFB performs comparably to CIBP(0.25) both in terms
of the mean accuracy and its variability. As expected, EWOC results in the least
mean accuracy index due to the MTD underestimation in scenarios 5-7. The mean
accuracy index associated with the most conservative CIBP(0.10) is greater than
associate with the EWOC by 0.15.
The mean number of DLTs in all considered designs are given in Figure 3.14.
Regarding CIBP approaches, while lower values of a result in a lower accuracy
they also result in the fewer mean number of DLTs under all scenarios. The mean
number of DLTs across all scenarios is decreased by nearly 2 comparing CIBP(0.5)
and CIBP(0.10). Considering different designs, it is of interest to compare designs
which have comparable mean accuracy indices. TAR and BLRM result in 0.5
more DLTs on average than CIBP(0.5). TDFB that has the accuracy similar to
CIBP(0.25) results in nearly 1.5 more patients experienced DLT. Interestingly, the
EWOC, having the least mean accuracy index, results in the same mean number
of DLTs across all scenarios as CIBP(0.10).


























Figure 3.14: Mean number of DLTs for CIBP using a = {0.5, 0.25, 0.10}, TDFB,
EWOC, TAR and BLRM designs. The upper, middle and lower dashed horizontal
lines correspond to performance of TAR, CIBP(0.25) and EWOC, respectively.
Results are based on 2000 replications.
conservatism parameter as the trial progress which results in only one extra pa-
rameter to be specified. One can find a value of parameter a that leading to a
similar accuracy index, but a fewer mean number of DLTs. At the same time,
the safest version of the CIBP design results in comparable to the EWOC mean
number of DLTs across all scenarios, but also in the noticeably higher proportion
of correct MTD selections.
3.6 Discussion
In this chapter, we have introduced the unified definition of a symmetric loss
function in a restricted parameter space. Scale symmetric and interval symmetric
loss functions which are as simple as the squared loss function and which share
desirable properties are provided. On the basis of three examples, we show that
the corresponding Bayes estimators
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• perform well when compared to the squared error loss and other available
estimators;
• improve the estimation if the parameter lies away from bounds;
• allow to avoid boundary decisions and can be recommended in applications
where more conservative estimates are preferable.
We have subsequently shown how one can benefit from incorporating the novel
interval symmetric loss function as the allocation criterion in dose escalation trials.
The novel criterion
• requires only one additional parameter;
• has a clear intuitive interpretation;
• can be easily tuned according to the trial purposes.
A guideline on the choice of parameter is also given. We incorporated the criterion
into the Bayesian CRM method using the 1-parameter power model. The proposed
design results in a fewer mean number of patients experienced DLT with no loss in
the probability of correct selections compared to the original CRM design. Com-
paring the proposed design to other alternatives, it was shown that one can find
a value of the asymmetry parameter such that the novel design would result in
either
• a similar accuracy and a lower mean number of DLTs, or
• a higher accuracy and a similar number of DLTs.
Therefore, the new allocation criterion makes a model-based design a more ethical
option.
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Importantly, the novel criterion proposed in this work can be applied to any para-
metric model and is not limited to the 1-parameter one. Furthermore, the appli-
cation of the criterion was demonstrated in the context of a single-agent trial only,
but it is also of interest what benefits its application to the CRM generalisation
(e.g. to the time-to-event CRM by Cheung and Chappell (2000) or to the partial




Dose Finding Designs Which Do
Not Require Monotonicity
Assumptions
In the previous chapters, the contexts in which the monotonicity assumption is
satisfied (to various extents) were considered. It was shown that in case of known
monotonicity ordering, one can benefit from using a parametric model. There are,
however, many regimen finding clinical trials in which a monotonic ordering of
regimens with respect to increasing toxicity and (or) efficacy cannot be specified
prior to a study. This includes Phase I and Phase I/II combination trials, dose-
schedules trials and single drug studies of molecularly targeted agents (MTA). The
ability to find the target regimen (TR) using methods employing monotonicity
assumption is, however, rather limited if it is not satisfied (Shen and O’Quigley,
1996). There is also a broad class of clinical trials in which regimens are considered
as being independent, for example, many Phase II trials. In this section, we
propose a class of designs that do not require any parametric or monotonicity
102
assumptions and can be applied to different types of clinical trials.
4.1 Background
To overcome the issue of an unknown ordering in the context of Phase I trials, some
specialised approaches for dual agents combination trials have been proposed (e.g.
Thall et al., 2003; Wages et al., 2011; Riviere et al., 2015). The common feature of
the majority of novel Phase I designs relaxing the monotonicity assumption is that
they either rely on a complex parametric model or on an explicit set of orderings
of toxicity. While such methods can borrow information between regimens, they
might fail to find the TR if the model or orderings are misspecified. At the same
time, there is a growing interest in advanced trials with a large number of potential
orderings where specifying all of them (or a corresponding parametric model) is
infeasible. In addition, more complex endpoints than a binary one are becoming
more common in early phase trials (see e.g. Yuan et al., 2007; Lee et al., 2010, 2017)
as they can carry more information about drug’s mechanism of action. Despite this,
methods for studies with complex outcomes that do not require the monotonicity
assumption or a complex model are sparse to date.
Thinking more broadly about selecting one or more regimens during a trial (the
main objective of many Phase II studies), different methods that consider regi-
mens being independent have been proposed (see e.g. Stallard and Todd, 2003;
Koenig et al., 2008; Whitehead and Jaki, 2009; Magirr et al., 2012). Williamson
et al. (2017) have recently advocated designs maximising the expected number of
responses in small population trials. As a result, adaptive randomisation methods
and optimal Multi-Arm Bandit (MAB) approaches are starting to be considered in
Phase II trials. Although MAB designs outperform other well-established meth-
ods of randomisation (e.g. a fixed equal randomisation) in terms of the expected
number of successes, they can suffer a low statistical power for testing hypothe-
ses (Villar et al., 2015). This problem corresponds to the “exploration versus
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exploitation” (also known as “learn versus earn”) trade-off (Azriel et al., 2011).
Some rule-based modifications have been proposed to achieve a better balance of
these two objectives (see e.g. Villar et al., 2015; Williamson et al., 2017). They,
however, require calibration of additional parameters that should be carefully cal-
ibrated. Moreover, the majority of MAB approaches consider a univariate binary
endpoint only and hone in on the regimen (also called arm) with the largest ef-
fect by default. They cannot be applied to studies which aim to select the TR
corresponding to the target probability γe ∈ (0.7, 1).
Regarding regimen finding designs for Phase I/II clinical trials, Gooley et al. (1994)
was one of the first to consider two dose-outcome models simultaneously. Similar
to later works on Phase I/II designs (e.g. Thall and Russell, 1998; O’Quigley
et al., 2001; Braun, 2002; Thall and Cook, 2004; Yin et al., 2006, among others),
it is based on the monotonicity assumption for both toxicity and efficacy. As
discussed above, these assumptions can be violated for MTAs. Several designs for
either single agent or combination therapy trials that relax this assumption for
the dose-efficacy relationship have been proposed in the literature: see e.g. Cai
et al. (2014); Wages and Tait (2015); Riviere et al. (2016) for a binary efficacy
endpoint and Yeung et al. (2015, 2017) for a continuous efficacy endpoint. The
majority of novel designs are model-based and the selection of the TR (defined
as an optimal biologic regimen) is governed either by (i) a trade-off function (e.g.
Thall and Cook, 2004; Yeung et al., 2015, 2017) or (ii) a two-stage procedure
in which the safe subset is firstly defined and the most efficacious dose is then
estimated (e.g. Thall and Russell, 1998; Yin et al., 2013; Wages and Tait, 2015).
Regardless of the approach used, the number of parameters to be included in
the underlying model increases considerably if the monotonicity assumption is
relaxed. The design proposed by Wages and Tait (2015) uses the 1-parameter
model, but employs the idea of different orderings (Wages et al., 2011) to overcome
the uncertainty in efficacy ordering. This idea can be extended to a range of
problems (see e.g. Wages and Conaway, 2014, for cytotoxic drugs combination
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trials), although the extension to more complex settings, for instance, combination
studies or combination-schedule trials involving MTAs, can also be challenging due
to a large number of possible orderings. Consequently, designs for more complex
Phase I/II trials have not been extensively studied yet.
Overall, the research problems described above can be considered as a general
issue of correct selection of the TR whose response probability is the closest to
the percentile 0 < γ < 1 or, equivalently in the multidimensional case, whose
characteristics are the closest to the vector γ ∈ Sd where Sd is a d-dimensional
unit simplex. In this chapter, we propose a general experimental design for studies
with multinomial outcomes to solve this generic problem. Based on developments
in the information theory of context-dependent measures of information (Belis
and Guiasu, 1968; Kelbert and Mozgunov, 2015; Suhov et al., 2016; Kelbert and
Mozgunov, 2017), we derive a criterion which governs regimen selection in the
experiment. The criterion is based on the maximisation of the information gain
when considering an experiment with a particular interest in regimens whose re-
sponse probabilities are in the neighbourhood of γ. Recently other designs using
the information gain principle have been proposed (see e.g. Barrett, 2016; Kim
and Gillen, 2016). In contrast to these methods, the novel approach allows for the
incorporation of the context of outcomes (e.g. avoid high toxicity or low efficacy)
in the information measures themselves. This is achieved by assigning a greater
“weight” to the information obtained about regimens with characteristics close to
γ. Another difference to the majority of information-theoretic approaches is that
the design is based on the so-called “patients’ gain” and allocates each patient to
the regimen considered to be the optimal one while taking into account the uncer-
tainty. This leads to fulfilling of statistical goals of the experiment under ethical
constraints.
The proposed criterion is not restricted to a particular model and can be used,
for examples, to govern selection within traditional parametric designs. However,
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motivated by relaxing parametric and monotonicity assumptions, we demonstrate
that good operating characteristics of the design can be achieved without em-
ploying these assumptions. We study the asymptotic behaviour of the design and
compare the performance to the currently used methods in contexts of Phase I,
Phase II and complex combination-schedule Phase I/II clinical trials.
4.2 Information-Theoretic Criterion
The novel design is based on maximisation of the information gain in the experi-
ment with an interval of the specific interest (the neighbourhood of γ). Below, we
derive an explicit formula for the information gain in such a trial with multinomial
outcomes.
4.2.1 Derivation
Consider a discrete random variable taking one of d values and a corresponding
random probability vector Z =
[
Z(1), Z(2), . . . , Z(d)
] ∈ Sd defined on a unit simplex
Sd = {Z : Z(1) > 0, Z(2) > 0, . . . , Z(d) > 0;
d∑
i=1
Z(i) = 1}. (4.2.1)
Assume that Z has a prior Dirichlet distribution Dir(v + J) where parameters
v =
[
v(1), . . . , v(d)
]T ∈ Rd+, ∑di=1 v(i) = β and J is a d-dimensional unit vector.
After n realizations of a discrete random variable in which x(i) outcomes of i are
observed, i = 1, . . . , d, the random vector Zn has a Dirichlet posterior distribution
with a probability density function (pdf)
fn(p|x) = 1
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α(1), . . . , α(d)
]T ∈ Sd be the vector in the neighbourhood of which fn
concentrates as n → ∞. A classic question of interest in this setting is to esti-
mate the probability vector α. The information required to answer the estimation






with convention 0 log 0 = 0. The classic formulation of the estimation question,
however, does not take into account the fact that an investigator would like to find
the TR having characteristics γ =
[
γ(1), . . . , γ(d)
] ∈ Sd. Nor does it reflect that
one would like to have a more precise estimation of the vector α if it is close to γ
only. This is a consequence of the fact that the classic information measures do not
depend on the nature of outcomes p, but on their probabilities f(p) and, therefore,
are called context-free (Suhov et al., 2016). While it gives the notion of information
a great flexibility which explains its successful applications in various fields, the
context-free nature might be considered as a drawback in many application areas,
e.g. in clinical trials, as it is demonstrated below.
To take into account the context of the experiment and the nature of outcomes p,
one can consider an estimation experiment with “sensitive” area (i.e. the neigh-
bourhood of γ). The information required in such an experiment can be measured
by the weighted Shannon differential entropy (Belis and Guiasu, 1968; Clim, 2008;
Kelbert and Mozgunov, 2015; Suhov et al., 2016; Kelbert and Mozgunov, 2017) of





The crucial difference between the information measures given in Equation (4.2.3)
and Equation (4.2.4) is the weight function, φn(p), which emphasizes the interest
in the neighbourhood of γ rather than on the whole simplex Sd. It reflects that
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the information about the probability vector which lies in the neighbourhood of γ
is more valuable in the experiment.
Due to the limited sample size in actual studies, an investigator is typically in-
terested in answering the question: which regimen has an associated probability
vector closest to γ while ensuring an accurate estimation in the neighbourhood
of the TR only. For this question, the information gain from considering the
experiment with the sensitive area equals to
∆n = h(fn)− hφn(fn). (4.2.5)
Following the information gain approach, the first term in the equation above
is the information in a classic experiment using the context-free measure, while
the second (novel) term is the information when the context of events is taken
into account. Alternatively, ∆n can be considered as an average amount of the
additional statistical information required when considering the context-dependent
estimation problem instead of the traditional one.
The information gain in Equation (4.2.5) requires a weight function which defines
the “value” of the information in different areas of the simplex Sd to be speci-
fied. To track the influence of the weight function explicitly we consider a weight
function in the Dirichlet form:







where κ ∈ (0, 1) is a parameter and C(x,γ, n) is a constant which is chosen to
satisfy the normalization condition
∫
Sd φn(p)fn(p|x)dp = 1. The parameter κ is
restricted to the unit interval to ensure an asymptotically unbiased estimate of
the vector α: limn→∞
∫
Sd pφn(p)fn(p)dp = α. This emphasises the interest in the
identification of the TR for the small and moderate sample sizes typical for clinical
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trials. The form of the weight function for d = 2 is demonstrated in Figure 4.1.




















Figure 4.1: Weight function φn(p) given in Equation 4.2.6 in case d = 2 using
κ = 0.25 (solid line), κ = 0.50 (dashed line), κ = 0.75 (dotted line), the target
value γ = 0.25 and n = 20.
The asymptotic behaviour of the information gain, ∆n, for the family of weight
functions (4.2.6) is studied in Theorem 3.
Theorem 3. Let h(fn) and h
φn(fn) be the standard and weighted differential en-




for i = 1, 2, . . . , d and
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if κ ≥ 1
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where















and η = b(1− κ)−1c.
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The last term is the sum of integrals having the same structure. For the sake of
notations we assume x(i) + v(i) = x(i) which will not affect the asymptotic results
















Note that integrating over d − 1 variables does not change, the only difference is















)− ψ (n+ d)) , i = 1, 2, . . . , d,
where ψ(x) = d
dx
logΓ(x) is the digamma function. Putting all terms together,








To obtain the asymptotics of h(fn) as n→∞, the asymptotics of digamma func-
tion





















































































x(i) + γ(i)nκ + 1
)− ψ (n+ nκ + d)) .


































The first two terms are the same as in the differential entropy, and the third term,
the sum, is to be considered in more details. For j = 1, the constant in brackets







j−1 − 1 =
d∑
i=1
γ(i) − 1 = 0.
Then, if κ < 1
2
all terms decay to zero as n→ +∞. If κ ≥ 1
2
, first η = b(1− κ)−1c
terms are non-decaying and the rest goes to zero as n→ +∞. Finally, writing the
term of the sum for j = 2 separately, the result immediately follows.
The information gain, ∆n, tends to 0 for κ < 1/2 which implies that assigning
a value of information with a rate less than 1/2 is insufficient to emphasise the
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importance of the study context. However, the limit is non-zero for κ ≥ 1/2.
Following the conventional information gain approach, one would like to make
a decision which maximises the statistical information in the experiment. The
information gain ∆n is always non-positive and for any fixed n its asymptotics
achieves the maximum value 0 at the point α(i) = γ(i), i = 1, . . . , d (all constants
are cancelled out). Indeed, Theorem 3 implies that when maximising the informa-
tion gain ∆n, one tends to collect more information about the regimen which has
characteristics α closer to the target γ. To keep the solution easily interpretable
in applications, we construct the regimen selection criterion using the leading term














Note that maximising the leading term of the information gain asymptotics is
equivalent to minimising δ(κ)(α,γ). Criterion (4.2.7) can be considered as the
measure of the divergence between α and γ and the criterion which governs the
selection such that the information gain is maximised. The criterion (4.2.7) is
intuitive as it reflects explicitly the fact that an investigator tends to collect more
information about the regimen with the probability vector close to γ, and also
shares some desirable properties. Clearly, δ(κ)(·) ≥ 0 and δ(κ)(·) = 0 iff α = γ
for all κ and n. The boundary values α(i) = 0, i = 1, . . . , d correspond to infinite
values of δ(κ)(α,γ) which is one of the important properties for functions defined
on simplex Sd as advocated by Aitchison (1992) and in Chapter 3. We construct
the design based on the selection criterion (4.2.7) below.
4.2.2 Selection Criterion
Consider a discrete set of m regimens, T1, . . . , Tm, associated with probability
vectors α1, . . . ,αm and n1, . . . , nm observations. The regimen Tj is optimal if
it satisfies δ(κ)(αj,γ) = infi=1,...,m δ




ni ≡ δ(κ)(Zni , γ) is introduced where Zni has the Dirichlet distribution
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given in Equation (4.2.2). Let us fix a regimen Zni ≡ Zn and denote δ˜(κ)ni ≡ δ˜(κ)n .
It is a known that a Dirichlet random variable (after appropriate normalisation)
weakly converges to a multivariate normal distribution. In fact, a stronger result
can be shown using the Kullback-Leibler distance







where g and f are probability density functions.
Theorem 4. Let Z˜n = Σ
−1/2 (Zn −α) be a random variable with pdf f˜n where
pdf of Zn is given in Equation (4.2.2) with limn→∞
x(i)(n)
n
= α(i) for i = 1, 2, . . . , d,∑d
i=1 x
(i) = n and where Σ is a d-dimensional square matrix with elements Σ[ij] =
α(i)(1−α(i))
n
if i = j and Σ[ij] = −α(i)α(j)n if i 6= j. Let Z be the multivariate
Gaussian random variable MN (0, Id−1) (Id−1 is the (d− 1)-dimensional identity







Kullback-Leibler divergence of ϕ from f˜n tends to 0 as n→∞ which implies that
Z˜n weakly converges to Z.






















= h (fn) + log |det
(
Σ−1/2
) | (Cover and Thomas, 2012) where
det(A) is a determinant of the matrix A and






























































is the sum of the second moments.
Pinsker’s inequality (Csiszar and Ko¨rner, 2011) implies the convergence in the total
variation (Cover and Thomas, 2012) which implies the weak convergence.
Using Theorem 4 the following result can be obtained for the proposed criterion.








, Σ¯ = ∇TαΣ∇α, ∇α ≡





be a standard Gaussian RV. Then, under the assumptions of Theorem 4,
lim
n→∞





n weakly convergences to Z¯.
Proof. The statements about expectation and variance are straightforward to
prove by computing the first and the second moments of δ(κ)(Zn,γ). The weak con-
vergence result follows from Theorem 4 and by applying the delta method (Resnick,
2013).
A single summary statistic for δ(κ)(Zn,γ) is needed to select the most promising
regimen in the sequential experiment. We will focus on an intuitively clear and






, i = 1, . . . , d, the mode of the posterior Dirichlet distribution. The
















n2κ−1j , j = 1, 2, . . . ,m. (4.2.8)




nj ∈ [δˆ(κ)nj − ε, δˆ(κ)nj + ε]
)
= 1. The
statistic (4.2.8) is used to govern the selection among regimens during the exper-
iment. Note that the estimator above requires a vector of prior parameters vj,
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j = 1, . . . ,m to start the experiment. This choice implies an initial ordering in
which an investigator would like to test the regimens before the data is available.
4.2.3 Specific Assignment Rules
The criterion (4.2.7) summarizes the regimen’s characteristics and can be applied
to different types of sequential experiments. We consider two assignment rules:
Rule I which randomises between regimens and Rule II which selects the “best”
regimen. These rules follow the setting of the motivating clinical trials: Rule II is
widely used in Phase I trials where the randomisation to all doses is not ethical or
in the typical MAB setting where the primary goal is to maximise the number of
successes. On the other hand, Rule I is often used in Phase II trials to learn more
about all regimens allowing to decrease the probability of identifying a suboptimal
regimen (Thall and Wathen, 2007).
Rule I: Randomisation








, j = 1, . . . ,m. (4.2.9)
Note that P (w˜j = 0) = 0 meaning that there is a non-zero probability to assign a











When no observations have yet been collected, the procedure randomises according
to the criterion based on the prior distribution alone, δ˜
(κ)
βj
, j = 1, . . . ,m. Then,
given nj observations, xj outcomes for regimen Tj, j = 1, . . . ,m and using the












if δˆ(κ)ni > 0, i = 1, . . . ,m. (4.2.11)











is adopted for the final recommendation, where Nj is a total number of observation
on Tj, j = 1, 2, . . . ,m. The value κ = 0.5 in Equation (4.2.12) is used to ensure that
the final recommendation is not penalised by the sample size (see Section 4.2.4).
Rule II: Select the best




, j = 1, . . . ,m. Given nj observations, xj outcomes for the
regimen Tj, j = 1, . . . ,m and using the “plug-in” estimator, Tj is selected if
it satisfies δˆ
(κ)
nj = infi=1,...,m δˆ
(κ)
ni . The method proceeds until N observations are
assigned in the experiment. Again, we adopt Tj? as in Equation (4.2.12) for the
final recommendation.
4.2.4 Criterion in the Context of Clinical Trials
In examples, we apply the novel selection criterion to Phase I and Phase II clinical
trials. In these cases, the regimens are the different treatments (doses, combi-
nations, schedules, etc.) and the goal is to find the regimen corresponding to
the specific toxicity (efficacy) characteristics. As the proposed information gain
and the corresponding selection criterion tends to assign the next patients to the
best estimated TR during the trial, the criterion based on ∆n is the patient’s gain
(also known as best intention) criterion as classified by Whitehead and Williamson
(1998). The balance in the “exploration vs exploitation” trade-off is tuned by
the term n2κ−1j reflecting the penalty on the number of observations on the same
regimen (i.e. many observations on one regimen would favour selection of other
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regimens). This implies that the design will keep selecting a specific regimen only,
if the corresponding estimate, α is close to γ. As the trial progresses the design
requires an increasing level of confidence that the selected regimen is the TR.
Clearly, κ = 1/2 corresponds to no penalty and is of particular interest in trials
with small sample sizes while larger values of κ > 1/2 correspond to a greater
interest in the statistical power of the experiment. Importantly, the first term in
Equation (4.2.7) guarantees that the vast majority of patients will be assigned to
the TR even for κ > 1/2. Clearly, one is not interested in the penalty terms for
the final recommendations, therefore, κ = 1/2 is proposed in Equation (4.2.12).
As many Phase I and Phase II clinical trials consider a binary endpoint d = 2
(toxicity: yes/no or response: yes/no), we start with this case in applications of
the proposed design. In this case, the pdf (4.2.2) reduces to the Beta distribution
and criterion (4.2.8) takes the form







where α is the probability of event (toxicity/efficacy) and γ is the target. The
corresponding estimator takes the form











is a plug-in estimate, xj is number of toxicity/efficacy responses on regimen Tj after
nj patients were assigned to it and vj, βj are parameters of prior Beta distributions.
Note that the first term in the criterion (4.2.13) is the unit interval symmetric loss
function (3.3.4) which was shown to have desirable properties on a simplex. The
Euclidean distance term in the numerator of the criterion tends to assign patients
to the TR. At the same time, the denominator takes into account the uncertainty
117
in the denominator which is a variance of the probability of a binary event. In
the context of regimen finding trials, the denominator can be also considered as
a penalty term which “drives away” the allocation from the bounds (pˆnj = 0 and
pˆnj = 1) - the boundary values correspond to infinite values of the criterion. As
pointed out in Section 3.5, the maximum variance of the binary probability is
achieved at pˆnj = 0.5, so the criterion favours greater values of pˆnj which can be
unethical if the objective of a study is to control the toxicity. We will study whether
the construction of the criterion creates any practical limitation in the context of
Phase I clinical trial without the monotonicity assumption in Section 4.3.
Further, we also consider the case of d = 3 in the context of Phase I/II regimen
finding clinical trials with binary toxicity and binary efficacy endpoints. In this
case, there are three outcomes: (i) “efficacy and no toxicity”, (ii) “no efficacy and
no toxicity” and (iii) “toxicity”. Outcomes “toxicity and no efficacy” and “toxicity
and efficacy” are combined assuming that an efficacy response can only be observed
when no toxicity occurs. Due to the limited sample size, we will consider the case









(1− γ1 − γ2)2
1− α1 − α2 − 1, (4.2.15)
where α1, α2, α3 are the probabilities of the responding events and γ1, γ2 and γ3 are
the targets. The criterion (4.2.15) is the sum of three contributions correspond-
ing to each of three events considered. Terms in the criterion (4.2.15) have the
following interpretations:
• When α1 tends to 0 the regimen is either inefficacious or (and) highly toxic.
Then, the value of the trade-off function tends to infinity meaning that the
treatment should be avoided.
• When α2 tends 0 the regimen is either highly efficacious or (and) highly
toxic. Then, this term penalises a high toxicity regardless of a high efficacy
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as the trade-off function tends to infinity. This term prevents a too quick
escalation to highly toxic regimens.
• When 1 − α1 − α2 tends 0, the regimen is associated with nearly no toxic-
ity. However, the TR is expected to be associated with a non-zero toxicity.
Then, these terms drive the regimen allocation away from the under-dosing
regimens.
Note that all terms are dependent - an increase in one leads to decreases in others
and the optimal value is attained at the point of target characteristics only. Again,
the denominators “drive away” the selection from inefficacious and highly toxic
regimens and concentrate the allocation in the neighbourhood of the TR.
4.2.5 Asymptotic Behaviour
Considering the asymptotic behaviour of a procedure ensures that an experimental
design becomes more accurate as a sample size grows (Azriel et al., 2011). Recall
that the goal of the sequential experiment is to find the regimen j which corre-




(κ)(Zni ,γ), i = 1, . . . ,m. Denote the index of the regimen to
be selected by ν = arg mini=1,...,m δ˜
(κ)
i . Below, we consider the risk-adjusted aver-








where Ppij is the probability computed under the vector pij = [α1,j, . . . , αm,j]T ,
1 ≤ j ≤ m, which assumes that αj,j corresponds to the TR. We would say that
the design is consistent if limN→∞AN = 1. The main result of this section is
formulated in Theorem 6.
Theorem 6. Let us consider the experimental design with the selection criterion
based on δ˜
(κ)
ni , m regimens and true probabilities vectors αi, i = 1, . . . ,m. Then,
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(a) The design is consistent under assignment Rule I for κ ≥ 0.5.
(b) The design is consistent under assignment Rule II for κ > 0.5.
Proof. (a) Rule I. Under Rule I proportions of observations on each regimen
converges to a constant as follows from Equation (4.2.10). Therefore, one can
assume that it is fixed and the probability measure below is conditional on a
non-zero allocation proportion.
We start from κ = 1/2 and adopt notation δ˜
(1/2)
ni ≡ δ˜i. Denoting
C¯k,k+1 ≡ {δ˜k < δ˜k+1} and Ck,k+1 ≡ {δ˜k > δ˜k+1}
we find that
{ν = k} ⇔ {C¯k,1 ∩ C¯k,2 ∩ . . . ∩ C¯k,k−1 ∩ C¯k,k+1 ∩ . . . ∩ C¯k,m} ⇔ {∩mi=1,i 6=kC¯k,i}.
Using DeMorgan’s law and Boole’s inequality (Resnick, 2013), one can obtain
P(ν = k) = 1− P (∪mi=1,i 6=kCk,i) ≥ 1− m∑
i=1,i 6=k





























k,i (δk − δi)
)
(4.2.17)





and Σ¯k is the covariance matrix corresponding to the regimen k
as in Theorem 5. As regimens k and i are independent, there are two independent
random variables in the left-hand side of the second term in Equation (4.2.17)
and each of them converges to normal random variables (Theorem 5). Therefore,
the sum converges to a standard Gaussian random variable after an appropriate
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normalisation. Consequently, for j = 1, . . . ,m







j,i (δj,j − δi,j)
)
(4.2.18)
By the construction of the vector pij, δj,j−δi,j < 0. The number of observations on
each regimen Nj is proportional to the total sample size N under Rule I: Nj ' wjN
where an ' bn means that limn→∞ anbn = 1, j = 1, . . . ,m. Thus,
Σ¯
−1/2
j,i (δj,j − δi,j) ' c
√
N (4.2.19)
where c is a negative constant. Plugging-in terms in the accuracy formula, we
obtain that limN→∞AN ≥ 1.
For κ > 1/2, the probability of the final selection in the experiment is given
by Equation (4.2.16) for κ = 1/2 as the penalty term is not taken into account
for the final recommendation. Therefore, the Inequality (4.2.18) holds. The only
difference is the number of observations on each regimen which is now proportional
to the total number of patients Nj ' lj(N)N with lj depending on N . This results
in a different constant c < 0 in Equation (4.2.19), but in the unchanged rate
√
N
due to the same rate in both nominator and denominator of Equation (4.2.9) with
respect to the total number of patients N .
Binary outcomes
While the asymptotic result in Equation (4.2.17) is given in general terms of Σ¯k,i,
it can be written explicitly for d = 2. In the special case of binary outcomes,

























nkni (δk − δi)√
nkαi(1− αi)(δi′)2 + niαk(1− αk)(δk ′)2
)
. (4.2.20)
The number of patients nk and ni are proportional to the total number of patients
by the construction of Rule I. Therefore, the result in Equation (4.2.19) becomes
explicit.
(b) Rule II. Consider κ = 1
2
. The design based on this measure and on its point
estimate is inconsistent as it does not guarantee an infinite number of patients on all
regimens as required under the assumption of the regimens independence (Robbins,
1952). Let us consider a counterexample with two regimens and the regimen
T1 being the TR. Suppose that prior parameters are specified such that δˆβ2 
δˆβ1 and δ2  δˆβ1 , so T2 is selected initially. While the number of observations
on T2 increases and the estimate δˆ2 approaches the true value δ2 (Theorem 5),
the estimate δˆ1 remains unchanged. One can find prior values δˆβ1  δ2 such
that T1 is never selected, because the point estimate δˆ2 would not go below δˆβ1 .
Consequently, the selection would “lock-in” at the suboptimal regimen regardless
of further outcomes. Therefore, the number of patients on both regimens do not
tend to infinity as N →∞.
For 1
2
< κ < 1, let Lj(t) be the indicator function such that
Lj(t) =

1 with probability P(δ˜(κ)j (t) = mini δ˜
(κ)
i (t))
0 with probability 1− P(δ˜(κ)j (t) = mini δ˜(κ)i (t))
where δ˜
(κ)
j (t) is a random variable corresponding to the posterior density function
after t observations in the experiment. Let nj(t) =
∑t
i=1 Lj(i) be the number of
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Note, that P(δ˜(κ)j (u) = mini δ˜
(κ)
i (u)) has already been studied in (a) (see e.g.
Equation (4.2.20) for the expression in the binary case). The mean of δ˜
(κ)
j (u)
associated with Tj to be selected is an increasing polynomial with respect to N .
The probability to be the minimum decreases for j and increases for i = 1, . . . , j−











The final selection is the regimen satisfying (4.2.12). Consequently, the number of
observations on each regimen tends to infinity and we obtain that limN→∞AN = 1
using the arguments of (a).
Note that there is no explicit general expression for P(δ˜(κ)j (u) = mini δ˜
(κ)
i (u)) and,
consequently, for the PCS as it depends on the whole history of events. To study
the asymptotic behaviour of the novel design under Rule II for different choice of κ,
we propose an approximation procedure in Appendix B.1-B.3. It demonstrates
that the design is indeed inconsistent for κ = 0.5 and provides insights on the
convergence for different values of the penalty parameter κ.
Below, the performance of the proposed experimental design is studied in contexts
of Phase I (Section 4.3), Phase II (Section 4.4) and Phase I/II (Section 4.5) regimen
finding clinical trials. We will refer to our proposal as the Weighted Entropy
(WE) design (WEI under Rule I and WEII under Rule II) and compare it to well-
established alternative approaches. All computations have been conducted using
R (R Core Team, 2015).
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4.3 Application to Phase I Clinical Trials
4.3.1 Setting
To study the WE design in the context of Phase I clinical trials, let us consider
m = 7 regimens, N = 20 patients and the regimen selection allowed after each
patient. The goal is to find the regimen (which could be combination, schedule
or combination-schedule) with the toxicity probability closest to γt = 0.25. In
these studies randomisation to all regimens is not ethical for safety reasons and
therefore, Rule II is used. We would like to emphasise that we do not consider the
classic dose escalation problem in which the doses can be ordered according to the
increasing toxicity. We focus on the setting in which clinicians do not know the
toxicity ordering. While clinicians will be able to provide a presumed ordering of
the regimens, this order might be misspecified.
We consider scenarios in which the prior order chosen by a clinician is either
correct or misspecified. Scenarios with correctly specified ordering have monotonic
regimen-toxicity relationships and scenarios with misspecified ordering have non-
monotonic relationships. The investigated scenarios are shown in Figure 4.2 and
include a variety of monotonic and non-monotonic shapes as well as one scenario
with highly toxic regimens only. Note that when studying regimens, it is likely that
several of them would have similar toxicity. Therefore, scenarios with probabilities
of toxicity outcome close to each other are considered.
It is assumed that limited information about regimens is available and a linear
increase in toxicity probabilities is expected such that
pˆβ1 < pˆβ2 < . . . < pˆβ7
where pˆ is given in Equation (4.2.14). For safety reasons, the trial is required
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Figure 4.2: Toxicity scenarios. The target regimen is marked by a triangle and
the maximum tolerated toxicity γt = 0.25 is marked by a dashed horizontal line.
The monotonic scenarios 1-3, 6 correspond to a correctly prespecified ordering of
regimens according to increased toxicity and non-monotonic scenarios 4 and 5 to
a misspecified ordering of regimens.
to start at T1. An “operational” prior, a prior that gives good operating char-
acteristics under different scenarios, is calibrated over set of different scenarios
and the details on the calibration are given in Appendix B.4. The prior uses
β1 = . . . = β7 = 1 and the prior toxicity probability modes of
pˆ = [0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55]T.
The penalty parameter is fixed at κ = 0.5 due to the small sample size.
4.3.2 Comparators
The WE design is compared to common Phase I dose escalation designs. Specifi-
cally, we consider the Bayesian CRM (Section 2.1.1) and EWOC designs (Section
3.5) that assume a monotonic regimen-toxicity relationship. These designs are
chosen to illustrate the consequences of the monotonicity assumption violation.
We would also consider the partial ordering CRM (POCRM, Wages et al., 2011)
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which relaxes the monotonicity assumption but uses the same model-based nature
as CRM. The POCRM design is briefly summarised below.
If a single order of doses according to increasing toxicity cannot be specified,
clinicians can often provide several orderings which are considered as feasible ones.
Assume that there are R possible monotonic orderings. Under ordering r the DLT
probability has a parametric form pj = ψ
(r)(dj, θ). Then, after n patients were
assigned to dose levels d(1), . . . , d(n) and outcomes y1, . . . , yn were observed, the





as in the original CRM approach with the only difference in the model function
φ(r)(d(i), yi, θ) = ψ
(r)(d(i), θ)yi(1− ψ(r)(d(i), θ))1−yi .
Following the original CRM, the posterior distribution for parameter θ can be
computed by Equation (2.1.2) under all orderings r = 1, . . . , R. This results
in R fitted CRM models. Given prior distribution of orderings {q(1) . . . , q(R)},
where 0 ≤ q(r) ≤ 1 and ∑Rr=1 q(r) = 1, the posterior probability of ordering r after










The next group of patients is allocated based on ordering r? corresponding to
the maximum value of pi
(r)
n , r = 1, . . . , R. For chosen model r?, let f ?n be the
corresponding posterior distribution in Equation (2.1.2). Using estimate in Equa-
tion (2.1.3) for the toxicity probability, the next group of patients is assigned the
dose level minimising the criterion (2.1.4). The procedure is repeated until the
maximum number of patients N has been treated.
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The POCRM requires ordering of regimens to be specified prior to a trial. In the
comparison the correct orderings only are included to allow for the best possible
performance of the POCRM under the evaluated scenarios. The orderings are given
in Table 4.1. The same prior toxicity probabilities pˆ and rough prior distributions





of the model parameters were chosen for the model-based alternatives. Finally, we
include the non-parametric optimal benchmark (Section 2.1.2).
The main characteristics to consider are: (i) the proportion of correct selections
and (ii) the average number of toxic responses. The bcrm package (Sweeting et al.,
2013) is used for the CRM and the EWOC and the pocrm package (Wages and
Varhegyi, 2013) is used for POCRM. For all methods 104 simulations are used.
4.3.3 Safety Constraint
For ethical reasons an escalation procedure should be planned so that only a few
patients are assigned to highly toxic regimens. This is typically achieved by the
use of a safety constraint. The majority of existing safety constraints are based
on the assumption of monotonicity and hence are not suitable for the proposed
design. We adopt the following safety constraint instead. The regimen Tj is safe
if after n patients ∫ 1
γ∗
fnj(p)dp ≤ θnj
where γ∗ is an upper toxicity threshold, θnj controls the overdosing probability
and fnj is the posterior Beta distribution of the toxicity probability. Note that
the overdosing threshold θnj changes as the trial progresses. We require it to be
a decreasing function of n with θ0 = 1 to give a possibility to test all regimens (if
data suggests so) and θfinal ≤ 0.3 to ensure that the final recommendation is safe.
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As an illustration, the linearly non-increasing
θn = max(1− rn, θfinal)
is used with r > 0. We have calibrated the parameters of the safety constraints
(details are given in Appendix B.4) and used γ∗ = 0.45 and r = 0.035 in the
simulations. Safety constraints of a similar form were incorporated in the model-
based methods.
4.3.4 Operating Characteristics
The simulation results in monotonic scenarios 1-3 are given in Table 4.2.
Table 4.2: Operating characteristics of WE, CRM, POCRM and EWOC designs
in scenarios 1-3. Term, DLT and N¯ correspond to termination proportion, average
number of toxic responses and average number of patients, respectively. The most
likely recommendation is in bold, the TR is in italics. Results are based on 104
replications.
T1 T2 T3 T4 T5 T6 T7 Term DLT N¯
Scenario 1. Linear response
Scenario 0.06 0.12 0.15 0.18 0.24 0.36 0.40
Optimal 0.92 9.12 10.60 14.44 31.54 27.50 5.87
WE 7.03 14.72 23.33 30.11 23.34 1.39 0.05 0.03 3.3 20.0
CRM 2.66 7.21 14.17 20.58 26.62 15.95 12.53 0.3 4.38 19.9
POCRM 2.69 11.25 22.30 15.73 22.60 20.62 4.60 0.2 4.94 20.0
EWOC 8.06 13.80 20.30 23.70 20.20 9.62 3.88 0.4 3.76 18.8
Scenario 2. Logistic shape
Scenario 0.10 0.18 0.25 0.32 0.50 0.68 0.82
Optimal 6.05 29.03 30.12 28.27 6.48 0.05 0.00
WE 17.78 27.43 27.54 22.51 3.76 0.11 0.00 0.9 5.23 20.0
CRM 17.24 25.88 28.70 19.37 6.24 0.56 0.04 1.9 4.84 19.7
POCRM 14.98 27.32 27.89 18.50 6.70 1.04 1.86 1.7 5.54 20.0
EWOC 28.72 27.66 24.32 13.65 4.21 0.00 0.00 1.4 3.27 18.0
Scenario 3. J shape
Scenario 0.15 0.20 0.50 0.55 0.60 0.65 0.70
Optimal 42.40 45.79 11.49 0.25 0.06 0.01 0.00
WE 38.07 44.65 6.59 3.44 1.48 0.28 0.02 5.5 5.94 19.8
CRM 37.47 37.85 17.41 2.92 0.36 0.07 0.00 3.9 5.10 19.4
POCRM 33.57 37.76 13.27 2.55 0.54 1.33 6.04 4.9 6.06 19.8
EWOC 51.00 26.11 11.01 0.88 0.13 0.00 0.00 10.9 3.60 16.8
The WE design performs comparably to CRM and POCRM designs and selects
the TR with the probability nearly 0.25 and 0.30 in scenarios 1-2. In scenario 1
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the WE design underestimates the target treatment and recommends a less toxic
treatment more often due to the safety constraint. Despite that, the performance
of all methods is not far from the non-parametric optimal benchmark which shows
that the selection of the TR is challenging in these scenarios. Proportions of
terminations are close to 0 and the average number of toxic responses is largely
the same for all considered methods. As expected, EWOC underestimates the TR
in both scenarios.
In scenario 3, the WE design shows a better performance than the model-based
alternatives with nearly 45% of correct selections against below 40% by CRM and
POCRM, respectively. The safety constraint allows to prevent the recommenda-
tion of highly toxic regimens and controls the total number of toxic responses.
Again, EWOC underestimates the TR but results only in 3 toxic responses com-
pared to 5 for CRM and 6 toxicities for WE and POCRM. Clearly, the methods
relaxing the monotonic assumption result in more toxic responses.
The results for non-monotonic scenarios 4-5 and unsafe scenario 6 are given in
Table 4.3. As expected, the designs based on the monotonicity assumption are
not able to find the TR in the non-monotonic settings. Comparing other designs,
WE has a substantial advantage. It finds the TR with the probability nearly
0.28 comparing to 0.20 by POCRM while exposing nearly the same number of
patients to toxic regimens. The time-varying safety constraint allows the selection
of the TR even in non-monotonic scenarios where the TR lies beyond the toxic
treatments (T3 − T4 in scenario 4 and T1 − T4 in scenario 5).
Considering scenario 6, the benchmark chooses the first regimen in 99.5% of repli-
cated trials as the safety constraint is not incorporated in it. WE terminates
earlier with probability 0.8 and performs similarly to POCRM and EWOC. It
outperforms CRM which recommends a highly toxic regimen with a larger prob-
ability (32.56% against 19.16%). However, methods that relax the monotonicity
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Table 4.3: Operating characteristics of WE, CRM, POCRM and EWOC designs.
Term, DLT and N¯ correspond to termination proportion, average number of toxic
responses and average number of patients, respectively. The most likely recom-
mendation is in bold, the TR is in intalics. Results are based on 104 replications.
T1 T2 T3 T4 T5 T6 T7 Term DLT N¯
Scenario 4. Inverted-U shape
Scenario 0.05 0.10 0.40 0.35 0.25 0.15 0.12
Optimal 0.88 7.36 19.12 18.96 38.47 13.64 1.57
WE 14.11 19.13 11.77 18.27 27.90 8.50 0.23 0.1 4.26 20.0
CRM 4.26 19.90 17.70 6.31 2.84 3.00 46.10 0.3 3.26 19.9
POCRM 2.87 11.39 11.75 9.32 19.11 33.94 11.62 0.2 4.29 20.0
EWOC 7.18 24.90 18.60 3.79 2.52 3.79 30.60 6.6 2.73 18.9
Scenario 5. Inverted-U shape
Scenario 0.35 0.40 0.40 0.35 0.25 0.15 0.10
Optimal 16.18 3.01 3.01 16.18 39.46 18.65 3.51
WE 15.57 12.65 13.31 18.27 27.92 8.90 0.58 9.9 5.81 19.7
CRM 47.41 2.51 0.97 0.48 0.72 0.40 30.10 27.3 4.27 16.0
POCRM 16.81 5.98 5.66 12.42 20.10 23.13 10.23 9.7 5.14 19.5
EWOC 30.75 1.26 0.78 0.47 0.47 0.31 9.78 56.2 3.30 11.0
Scenario 6. Unsafe
Scenario 0.50 0.55 0.60 0.65 0.70 0.75 0.80
Optimal 99.53 0.35 0.10 0.02 0.00 0.00 0.00
WE 13.63 5.53 2.45 0.88 0.27 0.06 0.00 77.2 8.02 14.2
CRM 32.24 0.32 0.08 0.00 0.00 0.00 0.00 67.4 5.33 10.3
POCRM 13.18 0.57 0.12 0.04 0.01 2.06 0.08 83.9 7.12 12.5
EWOC 16.17 0.00 0.12 0.00 0.00 0.00 0.00 83.7 3.07 6.1
assumption result in more toxic responses and require more patients on average
to come to the termination conclusion. While CRM and EWOC require 5 and 6
patients only, it takes nearly 14 and 13 patients for WE and POCRM due to the
consideration of non-monotonic orderings.
Summarising, the proposed design can perform comparably to the model-based
approaches in trials with small sample size and with correctly specified ordering.
At the same time, it can outperform them in cases when the ordering is misspeci-
fied. The time-varying safety constraint achieves the goals motivated by the ethical
concerns while not preventing the TR selection in safe and non-monotonic scenar-
ios. Therefore, one can conclude that the design is ethical and can be applied
in practice if there is an uncertainty in the monotonicity ordering of regimens.
Importantly, while a moderate number of regimens is considered in the example
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above, similar results can be obtained for smaller number of regimens. As the pro-
posed design does not fit any model to link the regimens, it will not experience the
overfitting problem as model-based approaches, and can find the TR with fewer
number of regimens.
4.4 Application to Phase II Clinical Trials
4.4.1 Setting
Consider a Phase II clinical trial investigatingm regimens and in which the primary
endpoint is a binary measure of efficacy (e.g. a response to the treatment). The
goals of the study are (i) to find the most effective regimen (TR) and (ii) to treat as
many patients as possible on it. Clearly, Rule I is preferable for the first goal and
Rule II for the second one. We consider two hypothetical trials, each with m = 4
regimens, investigated by Villar et al. (2015) for Multi-Arm Bandit models (MAB).
We compare the performance of the proposed approach to the MAB design based
on the Gittins index (Gittins and Jones, 1979), which is the nearly optimal design
in terms of maximising the expected number of successes (ENS), and to the fixed
and equal randomisation (FR) which is expected to have a high statistical power.
Trial 1 investigates N1 = 423 and efficacy probabilities are (0.3, 0.3, 0.3, 0.5) while
Trial 2 considers N2 = 80 and the scenario is (0.3, 0.4, 0.5, 0.6). Following the
original application we consider the hypothesis H0 : p0 ≥ pi for i = 1, 2, 3 with
the family-wise error rate calculated at p0 = . . . = p3 = 0.3, where p0 corresponds
to the control treatment efficacy probability. The Dunnett test (Dunnett, 1984)
is used for the hypothesis testing in the FR setting. The hypothesis testing for
MAB and WE designs is performed using an adjusted Fisher’s exact test (Agresti,
1992). The adjustment chooses the cutoff values to achieve the same type-I error
as FR. The Bonferroni correction is used for MAB and WE designs to correct for
the multiple testing and the family-wise error rate is set to be less or equal to
0.05. Characteristics of interest are (i) the type-I error rate (α), (ii) statistical
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power (1 − η), (iii) the expected number of successes (ENS) and (iv) the average
proportion of patients assigned to the TR (p∗).
The WE design requires specification of the target value γe which can be defined
in many trials by clinicians. This can be a maximum efficacy that they expect to
see for the particular diseases. Below we consider the most challenging setting in
which no target value is specified. Then, we set the target probability γe = 1 which
corresponds to the aim “to find the regimen with the highest efficacy probability”.
The vector of the prior mode probabilities
p(0) = [0.99, 0.99, 0.99, 0.99]T
is chosen to reflect no prior knowledge about which regimen has the highest suc-
cess probability and that each treatment is considered as highly efficacious until
data suggests otherwise. This choice of prior reflects the equipoise principle (Djul-
begovic et al., 2000). We choose β0 = 5 to ensure enough observations on the
control regimen and β1 = β2 = β3 = 2 to reflect no prior knowledge for competing
regimens. We fix κ = 0.5 for WEI and investigate the influence of different values
of κ on WEII.
The trade-off between the expected number of successes (ENS) and the statistical
power for different values of the penalty parameter κ under Rule II is illustrated
in Figure 4.3.
In both trials, greater values of κ correspond to a greater power and a lower
ENS as the increase in penalty tends to switch more often and leads to more
spread allocation of patients. The exception is κ ∈ (0.5, 0.55) in Trial 1 where
the inconsistency for κ = 0.5 leads to “locking-in” on the suboptimal regimen.
We choose two values of κ for the subsequent comparison to alternatives. These
choices correspond to (i) high ENS, but unacceptable power (dashed line) and (ii)
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Figure 4.3: ENS and power (using a fixed cutoff value) for the WE design under
the Rule II and different κ. Dashed lines correspond to the values chosen for the
subsequent study. Results are based on 104 replications.
reduced ENS, but high power (dotted line).
4.4.2 Operating Characteristics
The operating characteristics of designs in Trial 1 are given in Table 4.4.
Table 4.4: Operating characteristics of the WE design under Rule I (WEI), under
Rule II (WEII) for different κ (in brackets), MAB design and FR in Trial 1 with
N = 423 under the null and alternative hypothesises. Results are based on 104
replications.
Method
H0 : p0 = p1 = p2 = p3 = 0.3 H1 : p0 = p1 = p2 = 0.3, p3 = 0.5
α p∗(s.e) ENS(s.e.) (1− η) p∗(s.e.) ENS (s.e.)
MAB 0.05 0.25 (0.18) 126.68 (9.4) 0.43 0.83 (0.10) 198.25 (13.7)
FR 0.05 0.25 (0.02) 126.91 (9.4) 0.82 0.25 (0.02) 147.91 (9.6)
WEI (0.50) 0.05 0.24 (0.05) 126.84 (9.5) 0.88 0.39 (0.06) 159.90 (11.0)
WEII (0.55) 0.05 0.21 (0.20) 126.89 (9.4) 0.55 0.83 (0.18) 197.13 (17.8)
WEII (0.65) 0.05 0.23 (0.13) 126.86 (9.4) 0.87 0.74 (0.10) 189.26 (13.7)
Under the null hypothesis, the performance of all methods is similar and the
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type-I error is controlled. Under the alternative hypotheses, the WEII design
with κ = 0.55 performs comparably to the MAB in terms of the ENS, but yields
almost 10% points increase in the power. Nevertheless, it has an unacceptable
low statistical power which, however, can be increased by using higher values of
the penalty parameter (κ = 0.65). It leads to an increase in the power from 0.53
to 0.86 at the cost of the slight (≈ 4%) decrease in the ENS. In fact WEII then
has comparable power to FR, while resulting in 42 more patients responded to the
treatment. Another way to increase the statistical power is to use WEI for which
both the associated power and the ENS is higher than for FR.
The operating characteristics of the designs in Trial 2 with fewer patients and
a linearly increasing trend is given in Table 4.5. Under the null hypothesis, all
Table 4.5: Operating characteristics of the WE design under the Rule I (WEI),
under the Rule II (WEII) for different κ (in brackets), MAB design and FR in Trial
2 with N = 80 under the null and alternative hypothesises. Results are based on
104 replication.
Method
H0 : p0 = p1 = p2 = p3 = 0.3 H1 : pi = 0.3 + 0.1i, i = 0, 1, 2, 3
α p∗(s.e) ENS(s.e.) (1− η) p∗(s.e.) ENS (s.e.)
MAB 0.00 0.25 (0.13) 23.97 (4.10) 0.01 0.49 (0.21) 41.60 (5.4)
FR 0.05 0.25 (0.04) 24.02 (4.10) 0.50 0.25 (0.04) 35.98 (4.3)
WEI (0.50) 0.05 0.23 (0.07) 23.92 (4.11) 0.59 0.33 (0.10) 37.55 (4.7)
WEII (0.55) 0.01 0.20 (0.15) 24.01 (4.10) 0.11 0.50 (0.27) 40.72 (5.9)
WEII (0.65) 0.05 0.22 (0.12) 23.96 (4.08) 0.52 0.47 (0.21) 40.19 (5.4)
designs perform similarly and type-I errors are controlled at the 5% level. Under
the alternative hypothesis, MAB and WEII with κ = 0.55, again, yield the highest
(and similar) ENS among all alternatives, but also a low statistical power. WEI
or increased κ for WEII result in a noticeable power increase - 0.59 and 0.52,
respectively. Comparing to FR, both designs have a greater (or similar) power
and result in more ENS.
Overall, WE designs can perform comparably to the nearly optimal MAB design
in terms of the ENS, but with a greater statistical power for both large and small
sample sizes. They have similar statistical power to FR, but with the considerably
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greater ENS. The ENS and power trade-off can be tuned via the built-in parameter
κ. Although, some modification to the MAB designs were proposed (e.g. see Villar
et al., 2015) to prevent the lower statistical power, the majority of those are ruled-
based. The proposed approach allows to avoid any algorithm-based rules and keeps
the procedure fully adaptive. Additionally, the computation of the Gittens index
for the MAB design is not trivial, requires more attention and is widely discussed
in the literature (e.g. see Villar et al., 2015, and reference therein). Some of them
require calibration and can be computationally intensive. The proposed criterion,
in contrast, is extremely simple and easy to compute. While the proposed designs
are compared for the target γe = 1, a similar performance can be expected for the
problem of seeking the regimen associated with γe ∈ (0.7, 1).
4.5 Application to Phase I/II Clinical Trials
4.5.1 Motivating Trial
This section is motivated by an ongoing Phase I/II clinical trial at the Hospital
Gustave Roussy for patients with high-risk neuroblastoma. Both binary toxicity
and efficacy endpoints are evaluated during the trial. The goal is to find the optimal
biological regimen (OBR) defined as the safest regimen with a toxicity probability
below the upper toxicity bound φ and a maximum efficacy above the lowest efficacy
bound ψ. It is, however, expected to be challenging to find a single regimen having
the safest toxicity and maximum efficacy simultaneously. Therefore, clinicians are
also interested in finding “correct” regimens defined as regimens with the highest
efficacy rate while still safeguarding patients.
Neuroblastoma is the most frequent individual type of a solid tumour in children
(Steliarova-Foucher et al., 2017). Although different chemotherapy regimens of
increasing intensities have been evaluated, the 5-years overall survival remains
around 50% for the high risk group (Kreissman et al., 2013). A recent pre-clinical
study has suggested that the use of a particular immunotherapy targeting the
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disialoganglioside GD2 which is expressed in all neuroblastoma cells, in combina-
tion with conventional chemotherapy (etoposide and cisplatin) can improve the in-
duction treatment. The first part of the high-risk neuroblastoma treatment aims to
reduce the tumour burden to facilitate surgery and subsequent treatments. Combi-
nations of the newly developed immunotherapy and chemotherapy are given under
different schedules:
• Immunotherapy for 2 days after the chemotherapy (S1)
• Immunotherapy for 3 days after the chemotherapy (S2)
• Immunotherapy for 4 days with the chemotherapy. Overlap 1 day (S3)
• Immunotherapy for 4 days with the chemotherapy. Overlap 2 days (S4)
The combination of treatments is given for two cycles (three weeks). In each cycle
the combination is given under one of schedules S1, . . . , S4. Six different regimens
are considered in the study and are given in Table 4.6. The toxicity outcome is
evaluated by the end of the second cycle (after three weeks from the treatment
start). The efficacy data is available after two more cycles (after six weeks from the
start of the treatment) only. If a patient has experienced toxicity he will be treated
off the protocol and the efficacy outcome cannot be observed. A maximum of 40
patients will be recruited to the study and it is anticipated that two patients can
be recruited each month. Consequently, it is expected that the next two patients
are assigned to a regimen before efficacy outcomes for the previous two patients
are observed.
Table 4.6: The range of considered regimens in the motivating trial.
Regimen T1 T2 T3 T4 T5 T6
Cycle 1 S1 S2 S3 S3 S4
Cycle 2 S1 S2 S2 S3 S4 S4
A clinician is certain that toxicity probabilities of T3, T4 and T5 are greater than
of T1, T2 and smaller than of T6. However, toxicity probabilities of T3, T4 and T5
136
cannot be ordered according to increasing toxicity levels before the trial. Therefore,
there are 6 possibilities how regimens T1, . . . , T6 can be ordered with respect to
the toxicity probabilities
1) T1, T2, T3, T4, T5, T6
2) T1, T2, T3, T5, T4, T6
3) T1, T2, T4, T3, T5, T6
4) T1, T2, T4, T5, T3, T6
5) T1, T2, T5, T3, T4, T6
6) T1, T2, T5, T4, T3, T6.
(4.5.1)
Additionally, a plateau or umbrella shape for the efficacy is plausible due to the
action mechanism of the immunotherapy. This results in 48 efficacy orderings
to be considered so that traditional designs cannot be applied directly. We il-
lustrate how the proposed design can be applied in the context of the complex
combination-schedule clinical trial. We also discuss practical and ethical issues
such as coherence, delayed and missing efficacy responses, ethical constraints.
4.5.2 Practical Considerations
Re-parametrisation The selection criterion in Equation (4.2.15) depends on
probabilities α1 and α2 corresponding to “efficacy and no toxicity” and “no effi-
cacy and no toxicity” events, respectively. However, the goal of Phase I/II clin-
ical trials is conventionally formulated in terms of toxicity (pt) and efficacy (pe)
probabilities and corresponding targets γt and γe. Thus, we re-parametrise the
criterion (4.2.15) using α1 = (1 − pt)pe, α2 = (1 − pt)(1 − pe), γ1 = (1 − γt)γe
and γ2 = (1− γt)(1− γe) and denote the selection criterion (trade-off function) by
δ (pt, pe, γt, γe). This measure can be computed for each of m regimens with toxic-
ity probabilities pt,1, . . . , pt,m and efficacy probabilities pe,1, . . . , pe,m, respectively.
Given δ(pt,j, pe,j, γt, γe), j = 1, . . . ,m, the TR j
? satisfies
δ(pt,j? , pe,j? , γt, γe) = min
j=1,...,m
δ(pt,j, pe,j, γt, γe). (4.5.2)
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Contours of the efficacy-toxicity trade-off function for different combinations of
toxicity and efficacy probabilities and γt = 0.01, γe = 0.99 are given in Figure 4.4.
The most desirable point pt = 0.01, pe = 0.99 (right bottom corner) corresponds


























Figure 4.4: Contours of the efficacy-toxicity trade-off function δ(pt, pe, γt, γe) for
pt ∈ (0, 0.85) and pe ∈ (0.15, 1), γt = 0.01, γe = 0.99.
to the minimum of the trade-off function. As probabilities move away from this
point the trade-off function grows with an increasing rate that can be seen by
contours located closer to each other.
Estimation The proposed trade-off function for regimen j depends on unknown
parameters pt,j and pe,j. While these could be estimated using model-based ap-
proaches such as the CRM, we can also consider each toxicity and efficacy probabil-
ity independently as a Beta random variable estimated directly from the observed
number of toxicities/efficacies. This allows the design to avoid the monotonicity
assumption.
Let us consider an estimator for regimen j. The toxicity probability has prior
distribution B(νt,j + 1, βt,j − νt,j + 1), νt,j, βt,j > 0. After nj patients and xt,j
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toxicities, we obtain Beta posterior B(xt,j + νt,j + 1, nj − xt,j + βt,j − νt,j + 1)
which concentrates in the neighbourhood of 0 < pt,j < 1. Similarly, given prior
Beta parameters νe,j, βe,j > 0, after nj patients and xe,j efficacy responses the Beta
posterior, B(xe,j + νe,j + 1, nj − xe,j + βe,j − νe,j + 1), for the efficacy probability
















e,j , γt, γe) = δˆ
(nj)
j as
the criterion that governs the selection of a subsequent regimen to be studied in
Phase I/II regimen finding trials.
Note that the trade-off function (4.2.15) is derived in the general form without
assuming independence between toxicity and efficacy. While the estimators (4.5.3)
does not account for the interaction between toxicity and efficacy, the derived
trade-off function does.
Hybrid Randomised design Given unknown toxicity rates for regimens and
a limited sample size, the assignment Rule I randomising between all regimens is
not ethical to apply. Therefore, we consider the non-randomised version of the
design under the assignment Rule II. At the same time, under this assignment rule
the design can “lock-in” which means that one regimen would be tested regardless
of further outcomes and the true optimal regimen can be never tested. In this case
the design can benefit from the assignment rule based on a randomisation (Thall
and Wathen, 2007; Wages and Tait, 2015).
We propose the randomisation within a safety set with probabilities proportional
to the inverse of the trade-off function. For ethical considerations we restrict
randomisation to the two best regimens only. Formally, assume that regimen j? is
the estimated best regimen (has the minimum value of δˆ
(nj? )
j? ) and l is the second
best regimen (i.e. has the second smallest value of δˆ
(nl)




























The method proceeds until the maximum number of patients, N , have been
treated. The regimen j? satisfying criterion (4.5.2) is adopted as the final rec-
ommendation. We refer to this design as “WE(R)”. This randomisation technique
allows to get more spread allocation, while assigning only few patients to subop-
timal regimens. We will focus on these two allocation rules only although other
alternatives are possible. For instance, one might assign the first patients using
randomisation and the rest using allocation to the “best” as suggested by Wages
and Tait (2015).
Delayed responses So far, it was implied that efficacy responses are available
at the same time as the toxicity information is. However, this is unlikely to be true
in practice. While toxicity is usually quickly ascertainable, an efficacy endpoint
may take longer to be observed (Riviere et al., 2016) and waiting for both endpoints
increases the length of a trial substantially. However, the proposed criterion still




e,i can be estimated
based on a different number of observations. Consequently, the design can proceed
before the full response is observed and would only use the information available
at the time the regimen for the next cohort is selected.
For instance, it takes twice as long to observe the efficacy outcome than the tox-
icity outcome (six weeks versus three weeks) in the motivating trial. To conduct
the trial in a timely manner, the next cohort of patients is expected to be assigned
based on the toxicity data only for the previous cohort and both toxicity and ef-
ficacy data for earlier patients. For instance, the recommendation for the third
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cohort is based on both toxicity and efficacy outcomes for cohort 1 but only the
toxicity outcomes for cohort 2. The proposed design accommodates this by com-
puting toxicity and efficacy estimates based on different numbers of observations
but on all the available information up to the time of the next patient allocation.
Note that if an efficacy outcome is available earlier, it can (and should) be included
in the design. Doing so can improve the performance of the design as illustrated in
Appendix C.4. Note also that there may be situations in which auxiliary informa-
tion about efficacy is available (e.g. through a short-term endpoint). Accounting
for this information is beyond the scope of this section.
Coherence In practice, a clinician might be very cautious about further esca-
lation if a DLT was observed in the previous cohort. For this reason, we force the
WE design to satisfy principles of the coherent escalation/de-escalation (Cheung,
2005) with respect to known orderings. Assume that there are S known mono-
tonic partial orderings. Denote the position of a regimen for cohort i in the partial
ordering s by [s]T
(i) and the sum of the corresponding toxicity outcomes by Q(i).




(i) −[s] T (i−1) > 0|Q(i−1) ≥ q
)
= 0, s ∈ S (4.5.5)
where q is a threshold number of toxicities after which the escalation should be




(i) −[s] T (i−1) < 0|Q(i−1) < q
)
= 0, s ∈ S. (4.5.6)
For instance, in the motivating example the following partial orderings are known
pt,1 ≤ pt,2 ≤ pt,3 ≤ pt,6
pt,1 ≤ pt,2 ≤ pt,4 ≤ pt,6 (4.5.7)
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pt,1 ≤ pt,2 ≤ pt,5 ≤ pt,6.
It follows that if more than q toxicity outcomes are observed for T3 the next
cohort can be still allocated to T4. Moreover, these coherence principles are used
to incorporate the information about pairs of regimens that can be ordered (for
example, T1 and T2). While it is not taken into account in the estimation step of
the original design, it is reflected in allocation restrictions.
4.5.3 Illustration
Below, we demonstrate the performance of the non-randomised WE design in the
context of the motivating trial. The major challenge of the motivating trial is
the uncertainty in the regimen-toxicity relation for T3, T4, T5 which results in six
possible toxicity orderings given in Equation (4.5.1). Furthermore, for each of
these toxicity orderings either a monotonic, plateau or umbrella regimen-efficacy
relationship can be expected. Despite this complex setting, the WE design can be
applied as both toxicity and efficacy endpoints are binary.
We consider the regimen-finding clinical trial with m = 6 regimens, T1, . . . , T6,
N = 36 patients and cohort size c = 2. The regimens are ordered (on the basis of
clinician’s beliefs) with increasing toxicity and efficacy. The trial is to be started
at regimen T1 and no regimen-skipping is allowed. The coherence parameter is
fixed to be q = 1 and the escalation/de-escalation is required to be coherent
with respect to known partial orderings (4.5.7). Following the motivating trial,
toxicity is evaluated after two cycles of treatment (three weeks) and efficacy data
is available after four cycles (six weeks) only. Since it is expected to recruit one
patient per month, we assume that the next patient is assigned after the toxicity
outcome is available for the previous patient. Moreover, efficacy is only observed
for patients without toxicity.
True probabilities of toxicity and efficacy are pt = [0.05, 0.10, 0.45, 0.15, 0.30, 0.55]
T
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and pe = [0.10, 0.40, 0.70, 0.70, 0.70, 0.70]
T. This scenario corresponds to a plateau
in the regimen-efficacy relationship starting at T3 and to the misspecified ordering
of toxicities − regimen T3 is more toxic than regimens T4 and T5. We study
the ability of the WE design to recommend the optimal and correct regimens
which are define as follows. The safest regimen with a toxicity probability below
the upper toxicity bound φ and a maximum efficacy above the lowest efficacy
bound ψ is called optimal and the regimen with the highest efficacy rate while
still safeguarding patients (irrespective of it also having lowest toxicity) is called
correct. Then, for a maximum toxicity probability bound φ = 0.35 and a minimum
efficacy probability bound ψ = 0.20, regimen T4 is the optimal one and regimens
T4 and T5 are correct ones. To ensure that a regimen with the same efficacy
but a lower toxicity is preferred over one with a higher toxicity we set γt = 0.01
and, similarly, we set γe = 0.99 to prefer a regimen with a higher efficacy if the
toxicity is the same. To see that T4 is indeed the OBR using these targets, one can
compute the true values of the trade-off function [9.48,1.77,1.59,0.67,1.03,2.16]T.
The minimum among all regimes corresponds to T4 as desired and the second
smallest value corresponds to the correct regimen T5.
Prior parameters of toxicity pˆ
(0)




e = [0.60, 0.65, 0.70, 0.75, 0.80, 0.85]T and βt,j = βe,j = 1, j = 1, . . . , 6 are chosen.
Note that the purpose of this priors is to specify in which order the regimens
are trialled. The allocation of 18 cohorts in a single simulated trial is given in
Figure 4.5. Note that “no toxicity and efficacy” and “no toxicity and no efficacy”
outcomes in Figure 4.5 can be observed after four cycles only. Until an efficacy
outcome is available the design uses information about “no toxicity” only.
The allocation starts at T1 with no toxicities. As no efficacy responses have been
observed yet and T1 has the “promising” prior efficacy probability, it is selected
again. Following no efficacies for cohort 1, cohort 3 is assigned to T2 at which




























No Toxicity + Efficacy
Figure 4.5: Allocation of 18 cohorts in the invididual trial.
data are available. After no toxicity (cohort 4) and no efficacy (cohort 3), cohort 5
is assigned to T3 for which both patients experience toxicities. As there is the
uncertainty whether T3 is more toxic than T4 and (or) T5, cohort 6 is assigned
to T4. After no toxicity outcomes are observed, cohort 7 is allocated to regimen
T4 again. Due to no toxicities (cohort 7) and one efficacy (cohort 6), regimen
T4 is chosen for cohort 8 as well. However, after no efficacy for cohort 7, the
design escalates to regimen T5. Again, as no toxicity outcomes are observed for
cohort 9, cohort 10 is assigned to T5 too at which one patient experiences a toxicity.
However, by the time cohort 11 is allocated, efficacy outcomes for cohort 9 become
available and the allocation remains at regimen T5. As no further efficacies have
been observed for regimen T5, design escalates further to regimen T6 for which
two toxicities are observed. Then, the design de-escalates to the optimal regimen
T4 for which one efficacy and no toxicity has been previously observed (against 1
efficacy and 1 toxicity for regimen T5). All the consequent patients (up to cohort
18) are assigned to the optimal regimen T4 which is finally selected in the trial.
Clearly, a delayed efficacy response requires two cohorts to be assigned to each dose
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conditionally on ‘no toxicity‘. It leads to fewer patients at the optimal regimen
but also to more reliable selection due to a better exploration of regimes.
While the regimen-finding algorithm in the individual trial is considered above,
allocation probabilities for each cohort in 106 replicated trials are given in Fig-

































Figure 4.6: Probabilities to allocate each of 18 cohorts to T1 (solid green), T2
(dashed green), T3 (dashed red), T4 (solid blue), T5 (dashed blue) and T6 (solid
red) in the motivating trial setting. The optimal regimen is Regimen T4 and the
correct regimens are Regimens T4 and T5). Results are based on 10
6 replications.
first regimen with probability 1. As illustrated above, the design stays at T1 if
no toxicity was observed (due to a “promising” efficacy) or if a toxicity is ob-
served (due to the coherence principle). The probability to allocate a cohort to
the optimal regimen T4 starts to increase after cohort 5 and reaches nearly 60% for
cohort 18. Considering the probability of regimen recommendations, we compare
the performance to an equal allocation of 6 patients per each regimen. For the
equal allocation, the trade-off functions for each regimen are estimated at the end
of the trial and the regimen corresponding to the smallest value is selected. The
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optimal regimen T4 is recommended in 62.5% of trials and the correct regimen T5
in 18.6% of trials by the WE design against 31% and 29% by the equal allocation,
respectively. It means that the proposed design recommends one of the correct
regimens in more than 80% of the trials and clearly favours the optimal one.
Overall, the proposed design appears to be able to recommend the optimal regimen
with a high probability and the escalation/de-escalation algorithm in the individ-
ual trial is intuitive. A comprehensive study comparing the proposed method to
alternative approaches and across different scenarios is given below.
4.5.4 Ethical Constraints
Not borrowing information across regimens is a key feature of the proposed design.
However, some regimens might have high toxicity and/or low efficacy. Then, a
design can result in a high (small) number of toxicity (efficacy) responses or in
unsafe/inefficacious selections. For ethical reasons it is required to control the
number of patients exposed to such regimens and two time-varying constraints are
introduced.
Safety constraint An absence of the monotonicity assumption for toxicity
makes the problem of the highly toxic regimen selection even more crucial. As
stated above, a conventional (constant) safety constraint (e.g. as in Riviere et al.,
2016) cannot be applied because no parametric model is used. On the one hand,
a reliable safety constraint should give the hypothetical possibility to test all regi-
mens if data suggests so. On the other hand, the final recommendation should be
made with a high confidence in safety. Following the argument for Phase I clinical
trials above, a time-varying safety constraint meets both of these requirements. A









t,j is the Beta posterior density function of the toxicity probability, φ
∗ is
the toxicity threshold and ζnj is the probability that controls overdosing. As infor-
mation increases, we gain confidence about a regimen’s safety and hence consider
the constraint that becomes more strict as the trial progresses. We therefore use
a non-increasing function of nj for ζ
(nj). We choose ζ(0) = 1 initially to allow all
regimens to be tested while the final recommendation is made with probability ζN .
Subsequently we use a linearly decreasing function ζ(ni) = max(1−rtnj, ζN) where
rt > 0. These safety constraint parameters can either be specified by experts or
alternatively calibrated with respect to trial’s goals using simulations.
Futility Constraint The same reasoning is applied to a time-varying futility





e,j (p)dp ≥ ξ(nj) (4.5.9)
where f
(nj)
e,j is the Beta posterior density function of the efficacy probability, ψ
∗ is
the efficacy threshold and ξ(nj) is the controlling probability. This probability is
an increasing function of nj and the recommendation is made with probability ξN .
We use a linearly increasing function ξ(nj) = min(renj, ξN) where re > 0.
4.5.5 Simulation Setting
Scenarios In this section, we study the performance of the proposed design
in the context of the motivating trial under various different scenarios. Following
the motivating trial, we consider m = 6 regimens and N = 36 patients which
are enrolled in cohorts of c = 2. The setting as stated in Section 4.5.3 remains
unchanged. The upper toxicity and the lowest efficacy bounds are φ = 0.35 and
ψ = 0.20, respectively. The goal is to study the ability of the WE design to identify
the optimal and correct regimens as defined above.
The major challenge of the motivating trial is the uncertainty in both regimen-
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Table 4.7: Six permutations of scenario 1. The optimal regimen is in bold and
correct regimens are underlined.
T1 T2 T3 T4 T5 T6
Sc 1.1 (.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
Sc 1.2 (.005;.01) (.01;.10) (.02;.30) (.10;.80) (.05;.50) (.15;.80)
Sc 1.3 (.005;.01) (.01;.10) (.05;.50) (.02;.30) (.10;.80) (.15;.80)
Sc1.4 (.005;.01) (.01;.10) (.10;.80) (.02;.30) (.05;.50) (.15;.80)
Sc 1.5 (.005;.01) (.01;.10) (.05;.50) (.10;.80) (.02;.30) (.15;.80)
Sc 1.6 (.005;.01) (.01;.10) (.10;.80) (.05;.50) (.02;.30) (.15;.80)
toxicity and regimen-efficacy relations. This increases the number of possible sce-
narios to be investigated enormously. Therefore, we start by defining scenarios
on which the assessment will be based. Firstly, we specify 14 scenarios with in-
creasing regimen-toxicity relations and different shapes of regimen-efficacy curves
given in Figure 4.7: eight plateau regimen-efficacy scenarios (1-8) by Riviere et al.
(2016), four umbrella shaped scenarios (9-12) by Wages and Tait (2015), and two
scenarios with no optimal and correct regimens (13-14, due to inefficacy and tox-
icity, respectively). These scenarios were initially used to test the performance of
the WE design in a context of Phase I/II single MTA trial and compare it to the
methods by Wages and Tait (2015) and Riviere et al. (2016). The results of this
evaluation are given in Appendix C. Secondly, to allow for the uncertainty in the
toxicity ordering, we consider six permutations of each scenario with respect to
toxicity orderings (4.5.1). For instance, six permutations of scenario 1 are given
in Table 4.7. Overall, this results in 84 scenarios that cover a large variety of
possibilities and allows the proposed design to be assessed in the setting of the
motivating trial adequately. In the analysis we focus on (i) the proportion of opti-
mal/correct selection, (ii) the average number of toxic responses, (iii) the average
number of efficacy responses. The study is performed using R (R Core Team, 2015)
and 10,000 replications for each scenario.
Design Specification As in the illustrative example above, we use the target
toxicity of γt = 0.01 and the target efficacy of γe = 0.99. This implies that an
investigator targets the most efficacious yet the least toxic regimen. The design
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Figure 4.7: Eight plateau regimen-efficacy (blue triangles) scenarios (1-8), four
umbrella regimen-efficacy scenarios (9-12) and two scenarios with no correct regi-
mens (13-14) in the trial with m = 6 regimens. Toxicity and efficacy probabilities
are marked by red circles and blue triangles, respectively. The red dotted hori-
zontal line corresponds to the upper toxicity bound φ = 0.35 and the blue dotted
horizontal line corresponds to the lowest efficacy bound ψ = 0.20. A dashed black
vertical line corresponds to the optimal regimen.
was restricted to satisfy the coherence conditions (4.5.5) - (4.5.6) with respect to
partial orderings and q = 1. The randomised design is presented here as it has
been shown in the evaluations of single agent trials (see Appendix C) to have more
potential benefits when more than one correct regimen is expected in the trial.
Parameters βt,j = βe,j = 1 of the prior Beta distributions (4.5.3) are chosen for
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all regimens j = 1, . . . , 6 to emphasize a limited amount of information avail-
able. Parameters νt,j and νe,j (which coincide with prior toxicity efficacy prob-
abilities for chosen values of βt,j, βe,j) are calibrated such that the optimal regi-
men can be found in various different scenarios with high probability. Note that
the design is fully driven by the values of the trade-off function and, therefore,
there are two requirements for the prior parameters. The prior should dictate
to start the trial at the lowest regimen T1 and the design should follow the es-
calation order of regimens specified by clinicians (with no regimen-skipping). To
preserve a gradual escalation, the prior should assume that the higher regimens
have greater efficacy but also greater toxicity. To restrict the number of prior
parameters to be calibrated, we would assume a linear increase in prior toxicity
and efficacy probabilities. Through extensive calibration, prior vectors of toxi-
city probabilities pˆ
(0)
t = [0.10, 0.14, 0.18, 0.22, 0.26, 0.30]
T and efficacy probabili-
ties pˆ(0)e = [0.60, 0.62, 0.64, 0.66, 0.68, 0.70]
T were chosen for subsequently analysis.
Note that despite the increasing prior probabilities, the ordering of the regimens is
not fixed and can change as the trial progresses. Regarding the ethical constraint,
parameters of the safety constraint ζN = 0.30, rt = 0.02, φ
∗ = 0.4 and of the futil-
ity constraint ξN = 0.50, re = 0.05, ψ
∗ = 0.35 were calibrated. A further guideline
on the choice of the operational prior and the parameters of safety and futility
constraints are given in Appendix C.
Competing method We compare the performance of the novel approach to
the extension of the design by Wages and Tait (2015) which was originally proposed
for the fixed toxicity ordering. The original design employs the idea of partial
orderings as in the POCRM by Wages et al. (2011) with respect to the various
efficacy orderings. We extend the original design to allow for several toxicity






for a class of working dose-toxicity models where dk,w w = 1, . . . ,W is a skeleton
for model w, W is a number of working models and θt is an unknown parameter.
One parameter power model is also used for the dose-efficacy relation
pek = q
exp(θe)
k,s , s = 1, . . . , S,
for a class of working dose-efficacy models where qk,s, s = 1, . . . , S is a skeleton
for model s, S is a number of working models and θe is an unknown parame-
ter. The working model is selected using the posterior model probabilities as for
the POCRM (Section 4.3.2) - the model corresponding to the highest posterior
probabilities is selected.
Following Wages and Tait (2015), a trial involving MTA with a monotonic regimen-
toxicity relation and 6 regimens is associated with 11 efficacy orderings: one strictly
monotonic, five cases of a plateau location and 5 cases of umbrella peaks. Similarly,
one can deduce all possible efficacy orderings associated with each toxicity ordering.
For instance, for the toxicity ordering T1, T2, T3,T5,T4, T6 we specify the following
ordering (Figure 4.8)
1. 0.10, 0.20, 0.30, 0.50, 0.40, 0.60 (monotonic with respect to regimen-toxicity)
2. 0.20, 0.30, 0.40, 0.60, 0.50, 0.60 (plateau starting at T4)
3. 0.30, 0.40, 0.50, 0.50, 0.60, 0.40 (peak at T5)
4. 0.20, 0.30, 0.40, 0.60, 0.50, 0.50 (peak at T4)
5. 0.40, 0.50, 0.60, 0.40, 0.50, 0.30 (peak at T3)
6. 0.50, 0.60, 0.50, 0.30, 0.40, 0.20 (peak at T2)
7. 0.60, 0.50, 0.40, 0.20, 0.30, 0.10 (peak at T1)
Note that other orderings as a “plateau starting at T1/T2/T3/T5” are already in-
cluded in the first regimen-toxicity case. Applying the same procedure to the rest
of toxicity orderings (4.5.1) leads to 48 unique efficacy orderings. The design pro-
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ceeds as follows. Firstly, given the available data, one of 6 toxicity orderings is
selected as proposed by Wages et al. (2011). Secondly, one of 48 efficacy orderings
is chosen as in the original design. The parameters of the designs are chosen as
in the original specification by Wages and Tait (2015) with an exception of using
cohort size c = 2 and 80% confidence intervals for stopping rules.The design waits
for both toxicity and efficacy responses to allocated the next cohort and assumes
that an efficacy outcome is observed regardless the toxicity outcome.We refer to
this design as WT.



























































































































Figure 4.8: Seven efficacy orderings corresponds to the the toxicity ordering
T1, T2, T3, T5, T4, T6.
Different variations of the extended WT design were also explored. A reduced
number of efficacy orderings (plateau cases only) were investigated, but no signif-
icant difference was found, and the specification with the full number of orderings
was found to be more robust. Additionally, the ‘conditional‘ choice of the effi-
cacy orderings was also studied. Using this approach, once the toxicity ordering
is selected, that choice of the efficacy orderings is restricted to 11 orderings with
respect to the toxicity profile. However, it was found to result in less accurate
optimal and correct regimen recommendations across all scenarios.
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4.5.6 Operating Characteristics
The results of the comparison in scenarios 1-12 using 6 permutations are summa-
rized in Figure 4.9. The length of the bar corresponds to the proportion of the




























































































































Figure 4.9: Proportion of optimal (bright) and correct (transparent) selections by
WE(R) (black) and WT (red) designs in scenarios 1-12 across six permutations.
Results are based on 104 replications.
optimal (solid) and correct (transparent) regimen selections by WE(R) (black)
and WT (red). Overall, both designs are robust to toxicity ordering permutations
under all scenarios. The difference of minimum and maximum proportions of the
optimal and correct selections within one scenario does not exceed 5% and 8% for
153
WE and WT designs, respectively. Regarding the proportion of correct selections,
the designs perform comparably (no more than 5% difference) in scenarios with
several correct regimens (scenarios 2-5, 7 and 8) with scenario 1 being an exception
(8% difference in favour to WT design). Regardless the large number of orderings,
WT design preserves it accuracy in terms of the correct regimen selections.
Comparing optimal regimen selections, WE(R) favours the optimal regimen over
other correct regimens systematically. It results in superior characteristics in half
of all scenarios: 1, 3, 4, 7-9 with the minimum difference across permutations
ranging from 7% (scenario 7) up to 45% (scenario 1) and the maximum difference
varying between 11% and 52%, respectively. Generally, WT is less conservative as
it favours safe regimens with higher toxicity that results in a lower proportion of
optimal selections in these scenarios. Both designs perform comparably in scenar-
ios 2, 5, 10 and 11 within the maximum difference of 2-4%. At the same time, a
less conservative nature of WT allows outperforming WE(R) by 3-8% under sce-
nario 6 in which the optimal regimen is the highest safe one. WT also shows a
better performance in scenario 12 with the difference in the proportion of optimal
selections ranging in 10-13%. The regimen 1 is optimal and 36 patients are not
enough for WE(R) to investigate all regimens and come back to T1 but it is enough
for the WT to identify the decreasing ordering.
Investigating ethical aspects of the designs, the average numbers of toxicity and
efficacy responses across all permutations in scenarios 1-12 are given in Table 4.8.
The WE(R) design is generally safer and results in at least nearly one less toxic
response in scenarios 1, 3-8 with the largest difference of 2.7 in scenario 4. WT
design results in fewer toxicities in scenarios where the target regimen is among the
first ones (scenarios 2, 10, 12). While the prior toxicity vector chosen for WE(R)
suggests proceeding escalation, the model-based approach is able to identify the
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Table 4.8: Mean number of toxicity and efficacy responses in scenarios 1 − 12
across six permutations using N = 36 patients and m = 6 regimens. Results are
based on 104 replications.
Sc 1 2 3 4 5 6 7 8 9 10 11 12
Toxicity responses
WE(R) 2.5 6.4 3.2 4.4 7.0 7.7 5.1 5.1 3.9 5.9 7.8 2.4
WT 4.1 5.0 4.5 7.1 7.9 8.7 5.9 6.0 3.3 4.2 7.5 1.5
Efficacy responses
WE(R) 19.8 14.4 20.8 19.5 18.2 12.5 22.8 22.8 15.4 13.7 16.7 18.1
WT 24.5 14.4 21.0 21.4 19.0 13.8 23.4 23.5 15.8 14.4 16.7 21.5
correct ordering faster. The average number of efficacy outcomes does not differ
by more than one in the majority of scenarios (2, 3, 5, 7-11). Due to the fact that
WT waits for the complete efficacy response and due to model-based nature, it
results in 1-5 more average efficacy responses in scenarios 1, 4, 6 and 12. At the
same time, WE(R) waits for the efficacy outcome and escalates slower as it was
shown in Section 4.5.3.
Regarding scenarios 13 and 14 with no correct and no optimal regimens due to
futility and high toxicity, WE(R) terminates the trial earlier in nearly 72% and
85% of the trials against 68% and 79%, respectively. WE(R) results in 10.5 and
10.3 toxic responses on average in scenarios 13 and 14 against 10.4 and 10.5 by
WT, respectively. Regarding the efficacy outcomes, WE(R) results in 7.0 and 8.7
responses versus 7.4 and 9.0 by WT. This follows that both designs are able to
terminate the trial with high probability and prevent unethical patient allocations.
Summarising, the proposed design is robust to the possible true toxicity and effi-
cacy orderings. WE(R) is found to be a good and comparative alternative to the
model-based design when a large number of orderings is to be considered. While
all possible toxicity and efficacy orderings are still feasible to specify, it can be
challenging to convince a clinician to randomise between them given the limited
sample size of N = 36 patients. WE(R) is able to identify optimal and correct reg-
imens with high probability while being safer than model-based design and leads
to a comparable number of efficacy responses in the majority of scenarios.
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Table 4.9: Operating characteristics of WE (R) design in scenarios 1-12: pro-
portion of optimal and correct rselections for different correlation values r =
{−0.8, 0.0, 0.8}. The largest deviations are in bold. Results are based on 104
replications.
Scenario 1 2 3 4 5 6 7 8 9 10 11 12
WE (R) Proportion of optimal selections
ρ = −0.8 70.7 22.5 37.7 59.8 40.0 52.8 36.2 24.7 51.1 45.9 45.1 56.0
ρ = 0.0 66.5 31.0 39.5 59.3 40.5 46.8 33.2 32.8 44.8 47.7 38.5 59.1
ρ = 0.8 65.5 41.2 42.4 61.4 42.7 47.5 33.5 38.3 43.6 51.4 37.3 63.6
Proportion of correct selections
ρ = −0.8 90.9 81.2 91.4 91.8 78.0 52.8 91.6 75.4 51.1 45.9 48.1 56.0
ρ = 0.0 88.1 89.7 87.2 86.7 73.2 46.8 86.7 77.5 44.8 47.7 38.5 59.1
ρ = 0.8 88.4 96.6 84.8 84.5 73.6 47.5 86.2 80.9 43.6 51.4 37.3 63.6
4.5.7 Sensitivity Analysis
In the simulation study above, the toxicity and efficacy outcomes were assumed
to be uncorrelated which may not hold in an actual trial. In this section, we
investigate the robustness of the WE(R) design to the correlation in toxicity and
efficacy under scenarios given in Figure 4.7. The study was also conducted for
different toxicity orderings permutations and the same qualitative results were
obtained (not shown).
We follow the procedure proposed by Tate (1955) to generate correlated binary
toxicity and efficacy outcomes. The procedure generates a binary normal vector
with unit variances and pre-specified correlation coefficient ρ. The generated ran-
dom variable is then transformed to a binary response by applying the cumulative
distribution function and a quantile transformation, subsequently.
The results of WE(R) performance in cases of high negative correlation (ρ = −0.8),
absence of correlation (ρ = 0.0) and high positive correlation (ρ = 0.8) under
scenarios 1-12 are summarised in Table 4.9.
In the majority of scenarios, WE(R) is robust to both negative and positive cor-
relations. The proportions of optimal selection in correlated cases never differ by
more than 10% compared to the uncorrelated case. Moreover, the differences be-
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tween the proportions of optimal selections in positively and negatively correlated
cases do not exceed 8% in 10 out of 12 scenarios with scenarios 2 and 8 being
exceptions. A noticeable difference in the performance can be seen in plateau sce-
narios 2 and 8 in which the optimal regimens are among low regimens (T1 and
T2, respectively). In these scenarios, efficacy probabilities are nearly the same and
the negative correlation biases the selection to higher regimens which worsen the
proportion of optimal selections by nearly 9% in scenarios 2 and 8. In contrast,
the positive correlation biases the selection to lower regimens and leads to an in-
crease by 10% and 6% in the proportion of optimal selection in these scenarios,
respectively. There are no noticeable changes in the rest of scenarios as the bias
caused by the correlation is smaller than the difference in toxicity and probability
estimates.
Overall, the proposed design is robust to the highly correlated toxicity and efficacy
outcomes. The proportion of optimal and correct selections in the correlated cases
never differs by more than 10% compared to the uncorrelated case and mainly
unchanged in the majority of scenarios. Despite assumed independence in the
estimates, WE(R) is able to find the optimal and correct regimens in highly cor-
related cases.
4.6 Discussion
In this chapter, we have proposed a family of criteria for selecting the target
regimen in experiments with multinomial outcomes. The novel criterion
• has an intuitively clear interpretation and can be easily computed by non-
statisticians;
• leads to an accurate selection without the need for parametric or monotonic-
ity assumptions;
• drives the allocation away from the bounds of spaces to the neighbourhood
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of the target regimen;
• preserves flexibility and allows to tailor the design parameters in a light of
the investigation goal.
The consistency conditions of the design based on the novel criterion are obtained.
The application of the novel design was also demonstrated in the context of the
Phase I, Phase II and Phase I/II clinical trials. The simulation results demonstrate
that the proposal
• has comparable or better characteristics than other alternatives in Phase I
and Phase II clinical trials with binary outcomes;
• can identify the optimal and correct regimens with high probability and leads
to an ethical allocation of patients in the context of Phase I/II trials;
• is a good alternative to model-based designs when the ordering specification
is challenging.
It is important to emphasize that the derived selection criterion can be also applied
in conjunction with a parametric model which also expands its possible applica-
tions. This, in fact, was already demonstrated in Section 3.5 where the novel
information-theoretic criterion in case of binary outcomes d = 2 and κ = 0.5 was
incorporated into the one-parameter CRM model to govern the allocation of pa-
tients. This expands potential applications of the novel criteria. Moreover, the
same form of the information-theoretic criterion and unit interval symmetric loss
function suggests a link in the properties of the information gain and loss function
on restricted parameters space which is subject of further research.
Despite clinical trials being used as the main motivation throughout, the design
can be applied to a wide range of problems of a similar nature. For example,
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applications where the MAB approach has found application: online advertising,
portfolio design, queuing and communication networks, etc. (see Gittins et al.,
2011, and references there in). On top of that, the proposed design can be used in
more general problems of a percentile estimation rather than the identification of




In this work, we have considered various settings of complex regimen finding clini-
cal trials which involve novel compounds. It was found in Section 2.2 that one can
benefit from the monotonicity assumption in specific type of Phase I combination
trials, but existing models should be appropriately adapted for the combination
setting. It is also emphasized that the goals beyond the standard maximum toler-
ated regimen identification are of interest for molecularly targeted compounds and
the designs should be tailored for them as well. To address objectives specific to
combination trials with immunotherapies, we have proposed to include a control
arm (standard of care) in the escalation trial and randomise patients between the
control and the estimated MTC. We have also advocated the use of more com-
plex combination-toxicity model in such trials. The proposed design, however,
can face the same problem of “locking-in” on suboptimal combinations as other
model-based designs (Azriel et al., 2011). While being one of the main concerns
regarding the model-based designs, this problem has received limited attention in
the literature and is the direction of the future research.
Motivated by a growing interest in more complex designs, we have proposed the
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extension of the non-parametric benchmark in Section 2.3 which can be applied
in the vast majority of novel early phase contexts. The novel tool allows for
the assessment of the performance of many designs and two recently proposed
methods were compared to the respective benchmarks as examples. Importantly,
the novel tool provides the information on the proportion of correct selections, but
not on other important characteristics in the regimen finding trials, for example,
the average number of toxic responses and allocation proportions. These aspects
remain unstudied and provide a valuable direction for the future research in terms
of the non-parametric optimal designs.
In Chapter 3, we have considered a regimen finding trial as a generic problem of
estimation on restricted parameter spaces in a Bayesian setting. While the problem
has appeared to have quite a long historical record, it has received limited attention
in the applications. Motivated by this, simple loss functions were proposed. It was
found that they can lead to particular improvements when dealing with estimation
on restricted spaces. A further consideration in the setting of the multivariate
estimation is required and is an topic for further work. In Section 3.5, the new loss
function was used as the allocation criterion incorporated into the 1-parameter
CRM design. It has led to the same proportion of correct selections as the original
allocation criterion, but to a lower average number of toxicities and imposing fewer
patients to more toxic doses. Comparison to alternative methods has also revealed
that the proposed criterion can lead either to the same accuracy and fewer toxicities
or to a greater accuracy and the same number of toxicities. Therefore, such a design
should be recommended for the application as leading to a more ethical patient
allocation. This opens a door for further applications of the proposed loss function
beyond the regimen finding studies.
In Chapter 4 we have considered a more general problem of the regimen finding
in complex trials with the violated monotonicity assumption. The information-
theoretic consideration of the problem lead to the class of novel criteria for studies
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with multinomial outcomes. The proposal was demonstrated to have comparable
or better characteristics than alternative methods and to preserve a flexibility by
being applied in various setting with unknown monotonicity ordering. There are,
however, important practical considerations that should be studied further with
respect to the novel designs. Particularly, the influence of various implementation
techniques of the missing and delayed outcomes which are common in regimen
finding trials can be of interest in the setting with no parametric model. Fur-
thermore, the proposed design assumes that outcomes of interest have a discrete
distribution, but there is a growing interest in continuous endpoints. As an exam-
ple, a continuous efficacy endpoint becomes a more common choice in a clinical
practice (Hirakawa, 2012; Yeung et al., 2015, 2017). An extension of the proposed





A Modified Allocation Rule for
the CRM
In Section 3.5.4, the comparison of the CRM and CIBP designs is presented.
For the simulation results in the main text the skeleton with equivalent interval
0.05 and the prior MTD d2 is used. In fact, the same qualitative results can
be obtained for other skeletons. The performance of the CRM and CIBP if the
skeleton is constructed using the prior MTD d3 and d4 are given in Table A.1
and Table A.2, respectively. The operating characteristics in case if the proposed
allocation criterion (3.5.10) is used for the final selection are given in Table A.3.
One can find that in this case the CIBP underestimates the MTD in the majority
of the scenarios.
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Table A.1: Proportions of dose selections and mean proportions of DLTs for CRM
and the CIBP using a = {0.3, 0.4, 0.5} and the prior distribution as described in
Section 3.5, but the prior MTD d3 is used for the skeleton construction. Results
are based on 40000 replications.
d1 d2 d3 d4 d5 d6 DLTs
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP(0.3) 67.59 22.50 6.44 2.60 0.74 0.13 28.73
CIBP(0.4) 64.12 22.53 8.29 3.77 1.08 0.21 29.98
CIBP(0.5) 61.78 22.23 9.61 4.80 1.30 0.28 31.31
CRM 63.27 21.28 9.45 4.52 1.28 0.21 31.02
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP(0.3) 22.86 47.00 23.37 5.45 1.15 0.17 23.94
CIBP(0.4) 22.89 45.59 23.64 6.25 1.40 0.23 25.64
CIBP(0.5) 23.47 44.65 23.12 6.97 1.49 0.29 27.14
CRM 24.38 44.26 22.64 6.81 1.64 0.27 27.23
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP(0.3) 3.76 23.83 46.95 21.62 3.51 0.33 21.74
CIBP(0.4) 3.84 23.95 46.45 21.98 3.47 0.32 23.25
CIBP(0.5) 3.53 23.99 46.36 22.17 3.56 0.40 25.09
CRM 3.52 24.57 46.51 21.54 3.50 0.37 25.17
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP(0.3) 0.17 4.45 25.60 46.06 20.42 3.29 20.10
CIBP(0.4) 0.16 4.15 25.51 46.38 20.60 3.20 21.62
CIBP(0.5) 0.15 4.00 25.66 46.66 20.38 3.14 23.37
CRM 0.18 4.08 26.25 46.39 20.24 2.85 23.40
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP(0.3) 0.00 0.27 5.71 27.24 44.13 22.64 18.39
CIBP(0.4) 0.00 0.24 5.06 26.41 45.88 22.41 19.96
CIBP(0.5) 0.00 0.27 4.97 27.23 45.48 22.05 21.41
CRM 0.00 0.25 4.58 27.98 45.88 21.31 21.56
Scenario 6
Toxicity 1.50 2.50 10.00 10.00 15.00 25.00
CIBP(0.3) 0.00 0.02 2.42 9.37 26.83 61.36 15.83
CIBP(0.4) 0.00 0.02 1.74 7.62 27.18 63.44 17.20
CIBP(0.5) 0.00 0.05 1.74 7.75 27.89 62.58 18.20
CRM 0.00 0.04 1.29 6.63 28.55 63.49 18.36
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Table A.2: Proportions of dose selections and mean proportions of DLTs for CRM
and CIBP using a = {0.3, 0.4, 0.5} and the prior distribution as described in
Section 3.5, but the prior MTD d4 is used for the skeleton construction. Results
are based on 40000 replications.
d1 d2 d3 d4 d5 d6 DLTs
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP(0.3) 64.38 23.48 7.74 3.21 1.03 0.15 29.25
CIBP(0.4) 62.80 22.43 9.04 4.15 1.35 0.24 30.56
CIBP(0.5) 59.16 22.61 10.51 5.68 1.73 0.31 31.93
CRM 60.09 21.50 10.73 5.63 1.74 0.30 31.96
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP(0.3) 21.23 46.23 24.93 6.07 1.36 0.18 24.61
CIBP(0.4) 21.78 44.21 25.04 6.94 1.74 0.29 26.46
CIBP(0.5) 22.46 43.10 24.44 7.82 1.87 0.31 27.91
CRM 23.79 42.60 23.60 7.78 1.92 0.32 28.17
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP(0.3) 3.50 22.07 47.11 23.09 3.92 0.31 22.38
CIBP(0.4) 3.37 21.87 46.68 23.73 3.97 0.38 24.31
CIBP(0.5) 3.54 22.51 46.14 23.47 3.93 0.41 25.67
CRM 3.53 23.31 45.96 22.88 3.89 0.44 26.19
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP(0.3) 0.13 3.62 23.72 47.04 22.04 3.44 20.85
CIBP(0.4) 0.16 3.71 23.79 47.30 21.75 3.29 22.57
CIBP(0.5) 0.15 3.67 24.02 47.06 21.78 3.31 23.99
CRM 0.15 3.56 24.48 47.12 21.39 3.30 24.57
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP(0.3) 0.00 0.20 4.69 25.61 45.86 23.64 19.11
CIBP(0.4) 0.00 0.22 4.35 25.54 46.44 23.44 20.82
CIBP(0.5) 0.00 0.21 4.14 25.68 46.36 23.61 22.10
CRM 0.00 0.23 4.09 26.50 46.24 22.94 22.45
Scenario 6
Toxicity 1.50 2.50 10.00 10.00 15.00 25.00
CIBP(0.3) 0.00 0.03 1.74 8.63 26.63 62.97 16.33
CIBP(0.4) 0.00 0.03 1.33 6.53 25.96 66.16 18.01
CIBP(0.5) 0.00 0.02 1.24 6.20 26.59 65.94 18.88
CRM 0.00 0.05 1.17 6.44 27.95 64.38 18.88
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Table A.3: Proportions of dose selections and mean proportions of DLTs for CRM
and CIBP using a = {0.3, 0.4, 0.5, 0.6} and the prior distribution as described in
Section 3.5, but the prior MTD d3 is used for the skeleton construction and the
MTD is selected using the novel criterion (3.5.10). Results are based on 40000
replications.
d1 d2 d3 d4 d5 d6 DLTs
Scenario 1
Toxicity 25.00 35.00 37.50 40.00 45.00 50.00
CIBP(0.3) 74.85 17.07 5.36 2.07 0.57 0.08 28.73
CIBP(0.4) 69.02 19.12 7.49 3.33 0.87 0.17 29.98
CIBP(0.5) 64.28 20.65 9.12 4.52 1.19 0.23 31.31
CIBP(0.6) 58.83 22.17 10.90 5.97 1.82 0.30 32.63
CRM 63.27 21.28 9.45 4.52 1.28 0.21 31.02
Scenario 2
Toxicity 15.00 25.00 35.00 40.00 45.00 50.00
CIBP(0.3) 32.69 44.56 17.77 4.03 0.83 0.10 23.94
CIBP(0.4) 28.78 44.97 19.72 5.25 1.10 0.18 25.64
CIBP(0.5) 26.61 44.34 21.09 6.35 1.35 0.24 27.14
CIBP(0.6) 23.71 42.91 23.30 7.82 1.94 0.31 28.82
CRM 24.38 44.26 22.64 6.81 1.64 0.27 27.23
Scenario 3
Toxicity 10.00 15.00 25.00 35.00 45.00 50.00
CIBP(0.3) 6.25 30.85 44.27 16.23 2.22 0.18 21.74
CIBP(0.4) 5.29 29.01 45.06 17.95 2.45 0.25 23.25
CIBP(0.5) 4.21 26.71 45.62 20.13 3.02 0.32 25.09
CIBP(0.6) 3.81 24.55 45.84 21.84 3.60 0.36 26.39
CRM 3.52 24.57 46.51 21.54 3.50 0.37 25.17
Scenario 4
Toxicity 5.00 10.00 15.00 25.00 35.00 45.00
CIBP(0.3) 0.43 6.82 32.95 42.94 15.05 1.80 20.10
CIBP(0.4) 0.28 5.75 30.69 44.37 16.70 2.21 21.62
CIBP(0.5) 0.21 4.72 28.28 45.80 18.49 2.49 23.37
CIBP(0.6) 0.19 3.86 26.35 46.51 20.24 2.85 24.61
CRM 0.18 4.08 26.25 46.39 20.24 2.85 23.40
Scenario 5
Toxicity 2.50 5.00 10.00 15.00 25.00 35.00
CIBP(0.3) 0.00 0.60 8.54 34.20 41.13 15.53 18.39
CIBP(0.4) 0.01 0.43 6.88 31.60 43.16 17.93 19.96
CIBP(0.5) 0.00 0.39 5.67 30.01 44.74 19.19 21.41
CIBP(0.6) 0.00 0.22 4.63 27.74 45.66 21.73 22.62
CRM 0.00 0.25 4.58 27.98 45.88 21.31 21.56
Scenario 6
Toxicity 1.50 2.50 10.00 10.00 15.00 25.00
CIBP(0.3) 0.00 0.12 3.31 12.32 33.03 51.22 15.83
CIBP(0.4) 0.00 0.08 2.27 9.30 31.25 57.11 17.20
CIBP(0.5) 0.00 0.10 1.96 8.59 30.63 58.72 18.20
CIBP(0.6) 0.00 0.03 1.29 6.25 27.43 65.00 19.36
CRM 0.00 0.04 1.29 6.63 28.55 63.49 18.36
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Appendix B
Weighted Entropy design for
trials with a binary endpoint
It was shown in Section 4.2.5 that the probability of the correct selection P (ν = j)
under Rule II has no analytical expression as it depends on the whole history of
events. Instead, the exact characteristics can be found computationally as de-
scribed in Appendix B.1. It will be shown that the computational approach is
time-consuming even for moderate sample sizes and cannot be used to investigate
the asymptotic behaviour. An approximation procedure for computing the ex-
pected sample size at each regimen is subsequently introduced in Appendix B.2.
We use this approximation to investigate asymptotic properties of the design un-
der Rule II in Appendix B.3. Below, we focus on the case of binary outcomes as
in the examples for Phase I and Phase II clinical trials.
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B.1 Computing Exact Operating
Characteristics
B.1.1 Exact Algorithm
Below we describe an algorithm for computing proportions of each regimen selec-
tion for the WE design under Rule II using the “plug-in” estimator (4.2.14). As
before we consider the sequential experiment with m regimens, N patients and
a binary endpoint in which the regimen selection is allowed to change after each
observation.
The “plug-in” estimator δκ(pˆnj , γ) = δˆ
κ
nj
for regimen Tj given in Equation (4.2.13)
after t observations enrolled in the experiment can be written as a function of the
number of responses xj(t) and observations nj(t). We denote it by
δˆκ(xj(t), nj(t), γ) = δˆ
κ(xj(t), nj(t)).
The selection probability is then determined by the number of responses and ob-
servations on all regimens. As the method does not use the information borrowing
between regimen, there are only two possibilities after an outcome of a current
patient is observed: to stay at the estimated target regimen Tj or to switch to
regimen Ti (which was the “second best” before). Either of these events can hap-
pen with probabilities {0, 1, αj, 1 − αj} where αj is the probability of response
associated with regimen Tj. For instance, probability 1 corresponds to regimen Tj
being selected for the next subject regardless the previous observation. Assume
that t subjects are already assigned in the experiment. Before the t+ 1th selection
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is made, the transition matrix takes the form
Pt =















0m,1 . . . 1m,j . . . 0m,i . . . 0m,m

where it is assumed that j < i and j, i 6= 1, the double lower index corresponds to
the position of the element,
Pj,j = P
(
δˆ(κ)(xj(t) +Xj, nj(t) + 1) < δˆ
(κ)(xi(t), ni(t))
)
and Xj is a binary random variable that takes value 0 with probability 1−αj and
1 with probability αj. The transition probability then is Pj,j =

0, if δˆ(κ)(xj, nj + 1) > δˆ
(κ)(xi, ni) and δˆ
(κ)(xj + 1, nj + 1) > δˆ
(κ)(xi, ni)
1, if δˆ(κ)(xj, nj + 1) < δˆ
(κ)(xi, ni) and δˆ
(κ)(xj + 1, nj + 1) < δˆ
(κ)(xi, ni)
αj, if δˆ
(κ)(xj, nj + 1) > δˆ
(κ)(xi, ni) and δˆ
(κ)(xj + 1, nj + 1) < δˆ
(κ)(xi, ni)
1− αj, if δˆ(κ)(xj, nj + 1) < δˆ(κ)(xi, ni) and δˆ(κ)(xj + 1, nj + 1) > δˆ(κ)(xi, ni)
Using the transition matrix, probabilities of all paths (all possible outcomes in the
trial) can be computed. There are, however, 2N possibilities that makes the pro-
cedure computationally costly for moderate values of N . At the same time, paths
that reach the same number of outcomes x1, . . . , xm and observations n1, . . . , nm,
can be united to reduce the computational cost. However, the search and union
of these paths can be costly as well. A trade-off is sought between merging paths
often, in which case a little computational gain is expected and merging paths
infrequently which means that many paths need to be searched over increasing




Table B.1 provides the comparison of proportions of each regimen selections using
the exact algorithm against 106 replicated trials in scenario 1 (Section 4.3) with
N = 20.
Table B.1: Proportions of each regimen selections in scenario 1 (Section 4.3) using
the exact computation and 106 replications.
Toxicity 0.06 0.12 0.15 0.18 0.24 0.36 0.40
Prior 0.25 0.30 0.35 0.40 0.45 0.50 0.55
Exact 4.04 10.09 18.85 22.09 26.52 12.97 5.42
Simulations 4.14 10.20 19.09 22.65 26.37 12.60 4.95
As expected, proportions of selections obtained by the exact algorithm are close
to those obtained by simulations. The difference are minor and the simulation
setting gives a good understanding of the design behaviour. The computational
time for different sample sizes N = {10, 20, 25, 30} using the paths unions is given
in Table B.2. The paths are not united for N = 10 and united after selections 11,
11− 15 and 11− 23 for N = 20, 25, 30, respectively.
Table B.2: Average computational time (min) for the exact algorithm and the
simulations approach in a scenario with 7 regimens and total sample sizes N =
{10, 20, 25, 30}.
Sample size All paths United paths 106 replications
N = 10 0.001 - 16.33
N = 20 0.92 0.64 27.95
N = 25 24.44 10.60 32.58
N = 30 942.08 372.78 38.43
The exact algorithm becomes infeasible for N > 25 while it takes much less time
for smaller sample sizes. The union procedure decreases the computation time for
all sample sizes and makes the computation for N = 25 three times faster than
the simulation approach and more than 2 times faster than the exact algorithm
without united paths. For N = 30 the exact computation takes nearly 10 more
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time than the simulation study. Therefore, the former one seems to be a reasonable
substitution for larger sample sizes.
B.2 Approximation Procedure for Expected
Number of Observations
B.2.1 Approximation
Both exact algorithm and simulation approach are computationally infeasible for
large sample sizes. Therefore, these approaches cannot be effectively used to study
the large samples behaviours, for example, using different values of parameter κ
in many different scenarios. The main challenge of the exact procedure is to trace
all possible trajectories and to estimate the expected sample size at each regimen.
We propose the following procedure that approximates the expected number of
patients at each regimen and allows computing the selection proportions.
The core idea of the approximate is to replace the exact values xj(t) and nj(t)
































Using the law of the total probability and the transition matrix
[φ1(t) . . . φm(t)] = [φ1(t− 1) . . . φm(t− 1)]Pt
where the only non-trivial quantity of transition matrix Pt
Pj,j = P
(














. This allows computing the expected number of obser-
vations and expected number of responses at all regimens.It is demonstrated below
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that the approximate procedure can be effectively used to study the behaviour of
the WE design under Rule II.
B.2.2 Illustration
We consider two scenarios with two regimens only. In scenario 1, the target per-
centile is γ = 0.20 and the prior probabilities of response are pˆ = [0.20, 0.20]T.
In scenario 2, the target is γ = 0.99 and the prior is pˆ = [0.99, 0.99]T. In both
examples we fix β = 5, the probability associated with regimen 2, α2 = 0.40, and
N = 50. We study how the expected number of observations on regimen 1 depends
on parameter α1. The results for the approximation and the simulations approach

































Figure B.1: Expected number of observations at regimen 1 using different values of
α1 obtained by the approximation (dashed line) and by 10
6 simulations (solid line).
Left panel: the target probability γ = 0.20. Right panel: the target probability
γ = 0.99.
In scenario 1, both the approximation and the simulation approach have a peak
at the point α1 = γ = 0.2 and the overall dependence on the probability α1 is
represented correctly by the approximation. However, the exact values obtained
by the approximation are largely overestimated in the neighbourhood of γ. The
number of observations by both approaches is the same for α1 = α2 = 0.4 and
the approximation is accurate for α1 > 0.4. Regarding scenario 2, the expected
number of observations by both methods reaches the peak at α1 = 0.99 and has
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the half total sample size for α1 = 0.4. The expected number of observations by
the approximation is very close to ones obtained by simulations for all values of α1.
Importantly, the computational time for the simulated results in one scenario takes
nearly 18 hours (106 replications for values α1 on a grid (0.05, 0.95) with step 0.05),
while the approximation procedure takes less than one second. Due to this gain,
the approximation is used to demonstrate the asymptotic behaviour of the PCS
in the following section.
B.3 Asymptotic Behaviour of the Weighted
Entropy Design Using the Approximation
We use the approximation of the expected number of observations under Rule II
and Equation (4.2.20) to find the lower bound of the PCS in Equation (4.2.18) in
Theorem 6 and to investigate the asymptotic properties of the design for different
values of the parameter κ.
To demonstrate the large sample behaviour an illustrative trial with two regimens
is considered. The true probabilities of responses are (0.3, 0.5) for regimen 1 and
regimen 2, respectively. The goal of the trial is to find the regimen corresponding
to the maximum probability of response γ = 1. Following Section 4.4, we fix
prior parameters β1 = β2 = 2 and v1 = v2 = 0.99 × 2. The expected number
of observations on the suboptimal arm, the proportion of observations on the
suboptimal arm and the lower bounds of the PCS for different values of N and κ
are given in Figure B.2.
As it was shown in Theorem 6, the total number of observations on the subopti-
mal regimen locks-in for κ = 1/2 which results in the design’s inconsistency. For
κ > 1/2 the total number of observations on the suboptimal regimen is a non-
decreasing function of the number of observations. “Jumps” in the graph of the
expected number of observations correspond to the sample size when the subop-
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Figure B.2: Operating characteristics of the approximation: (i) Expected number of
observations on suboptimal regimen, (ii) expected proportion of observations on sub-
optimal regimen, and (iii) the normal approximation for the PCS lower bound (4.2.18)
for different sample sizes N and κ = 0.5 (solid), κ = 0.55 (dashed), κ = 0.60 (dotted),
κ = 0.70 (dotted-dashed).
timal regimen is selected. The jumps become more regular as κ increases. For a
given κ the number of observations between jumps increases with a sample size
due to the decreasing rate of the penalty term.
B.4 Calibration of the Design Parameters for
Phase I Clinical Trials
The WE design applied in the context of Phase I clinical trials (Section 4.3) requires
specification of the prior distributions and the parameters of safety constraint. We
would like to find the operational parameters, the parameters for which the WE
design selects the TR with a high probability in many different scenarios. We
provide a guideline how these parameters can be calibrated below.
B.4.1 Operational Prior




. It is assumed that an investigator has the same (limited)
knowledge about all regimens and β1 = . . . = β7 are chosen. Then, the problem
reduces to the choice of ν1, . . . , ν7 which are equal to pˆβ1 , . . . , pˆβ1 in this case,
respectively. To guarantee the procedure to start from T1 we set pˆβ1 = γ. Although
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the initial ordering (with respect to increasing toxicities) might be misspecified, a
clinician would like to test the regimen in the specific order. Therefore, increasing
values of pˆβ1 < . . . < pˆβ7 are required. For simplicity, we would consider the prior
parameters which assume a linear increase in toxicity probabilities.
To calibrate the operational parameters of prior distributions, we consider six
scenarios with different locations of the TR given in Figure B.3. Given m = 7,
we set the difference between prior toxicities at the first regimen T1 and the last
regimen T7 and, then, interpolate the linear curve for the rest. We would define
step = pˆβ7 − pˆβ1 . Then, we vary values of step and β in each scenario. Larger
values of β and the step correspond to more conservative escalation schemes as
an investigator needs more observations on each particular regimen to escalate.
Therefore, one can expect a set of prior parameters that lead to similar proportions
of correct selections. The proportion of correct selections (PCS) using different
values of step and β is given in Figure B.3.
Figure B.3: Proportion of correct selections by WE design using different values of
β (vertical axis) and step (horizontal axis). Results are based on 106 replications.
Brighter colours correspond to higher values of the PCS. A conservative prior (top
right corner of the grid) prevents the WE design from correct selections in upper
line graphs scenarios as higher regimens can be hardly reached. At the same time,
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it leads to accurate selections in scenarios with highly toxic regimens (lower line
scenarios). In contrast, less conservative choices result in higher PCS in upper line
scenarios and lower PCS in lower line ones. There is a clear trade-off between the
ability to investigate higher regimen and the desire to prevent the high number of
toxic selections. Therefore, the geometric mean of the PCS over all scenarios is
chosen as the criterion for the operational prior choice. The geometric mean for
different values of parameters is given in the Figure B.4.




















Figure B.4: Geometric mean of proportions of correct selections by WE design
using different values of parameters β (vertical axis) and step (horizontal axis) in
six scenarios. Results are based on 106 replications.
There is a set of the prior parameter leading to the same geometric mean of the
PCS. We choose a prior that carries a limited information β = 1 and seek for
the rate maximising the geometric mean. Thus, the following vector of modes is
chosen
pˆ = [0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55]T.
We also consider the case of the larger sample size N = 25 using the same sce-
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narios to illustrate the choice of prior in trials with a slightly greater sample. The
geometric mean of proportions of correct selection using N = 25 is given in Fig-
ure B.5. There is a similar dependence pattern on β and step. As one would
expect, the set of the equivalent operational prior parameters is now wider. This
means that the importance of the prior distribution choice decreases as the sample
size increases.
Figure B.5: Geometric mean of proportions of correct selections by WE design
using different values of β (vertical axis) and step (horizontal axis). The total
sample size N = 25 is used. Results are based on 106 replications.
B.4.2 Safety Constraint
Parameters r and γ∗ define the strictness of the safety constraint. Greater values
of r and smaller values of γ∗ would lead to a more conservative escalation. While it
would help to avoid high risk in unsafe scenarios, it would also prevent the correct
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selections in flat safe scenarios. There is a clear trade-off in the choice of these
parameters that is precisely studied below.
Let us consider two extreme scenarios: a linear flat regimen response shape (sce-
nario 1 in Section 4.3) with the TR far from the bottom (T5) and the scenario
with no safe regimens at all (scenario 6 in Section 4.3). The proportion of correct
selections (scenarios 1) and the proportion of early terminations (scenario 6) by
WE design using different values of γ∗ and r are given in Table B.3.
Table B.3: Operating characteristics of WE design in linear and unsafe scenarios
using different parameters of the safety constraint. Figures in the upper line cor-
respond to termination proportions in the unsafe scenario 6. Figures in the lower
cells correspond to the PCS in the flat scenario 1. Subsequently used parameters
of the safety constraint are in bold. Results are based on 106 replications.
r
0.010 0.015 0.020 0.025 0.030 0.035 0.040 0.045
γ∗ = 0.55
0.00 0.32 4.32 18.47 36.15 49.06 61.49 75.70
26.47 26.65 26.40 26.05 26.85 25.03 24.10 20.23
γ∗ = 0.50
0.15 2.50 17.76 38.75 52.74 63.06 74.94 87.22
26.27 26.22 26.53 27.24 25.46 23.30 20.35 17.10
γ∗ = 0.45
1.13 12.72 35.72 56.49 67.16 77.55 86.53 93.49
26.15 26.02 26.81 25.18 24.26 23.15 18.16 11.05
γ∗ = 0.40
7.47 37.95 59.49 70.52 80.53 88.32 94.18 97.63
26.04 25.91 24.90 21.98 17.66 17.47 11.05 3.51
γ∗ = 0.35
33.98 58.22 74.42 84.14 90.52 94.86 97.90 99.20
25.65 24.54 20.45 15.55 13.77 9.21 6.25 0.70
γ∗ = 0.30
55.51 77.02 87.21 92.99 96.50 98.55 99.37 99.83
24.21 18.09 14.40 11.42 7.13 0.95 0.08 0.04
The upper line corresponds to the proportion of times the WE design terminates
the trial early in the unsafe scenario 6. The lower line corresponds to the proportion
of trials the TR is selected in the linear scenario 1. The most relaxed safety
constraint corresponds to the left upper corner: no trials are terminated in the
highly toxic scenario and the PCS in the linear scenario is relatively high. The
right lower corner corresponds to the strictest safety constraint: nearly all trials
are terminated in the unsafe scenario, but the method will often not find TR in the
linear scenario. Therefore, the trade-off is to sacrifice the accuracy of the method
when the TR is far from the bottom in order to prevent the selection of a highly
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toxic regimen. Consequently, γ∗ = 0.45 and r = 0.035 are used.
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Appendix C
Weighted Entropy Design for
Single Agent Phase I/II Trials
with trinary outcomes
The proposed WE design can be applied to a wide range of Phase I/II clinical trials.
While the performance of the WE design was demonstrated in the context of the
motivating combination-schedule trial, it can be also applied to single agent dose
finding Phase I/II trials of molecularly targeted agents for which several model-
based designs were recently proposed (see e.g. Wages and Tait, 2015; Riviere et al.,
2016). Here we show the comparison of the proposed design to the currently used
and provide a step-by-step algorithm how the parameters of the novel design can
be calibrated.
C.1 Simulation Setting
We consider m = 6 doses and N = 60 patients. The dose-toxicity relationship is
known to be a non-decreasing function, but a clinician expects either a plateau or
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an umbrella shape for the dose-efficacy curve. As before we would assume that it
takes twice longer to evaluate an efficacy response than a toxicity response. To
conduct the trial in a timely manner, the next cohort of patients is allocated after
the toxicity data for the previous cohort are available. The upper toxicity and
the lowest efficacy bounds are φ = 0.35 and ψ = 0.20. The goal is to study the
ability of the WE design to identify the optimal and correct doses. A dose is
called optimal if it is safe, has maximal efficacy and minimal toxicity while a safe
dose with maximum efficacy (irrespective of it also having lowest toxicity) is called
correct.
We consider 14 scenarios (Figure 4.7) that were used for the motivating trial simu-
lations: eight plateau scenarios (1-8) suggested by Riviere et al. (2016), 4 umbrella
shaped scenarios (9-12) studied by Wages and Tait (2015) and two scenarios with
no correct doses (13-14, due to inefficacy and toxicity, respectively)
In the analysis we focus on (i) the proportion of optimal/correct selections, (ii) the
average number of toxic responses, (iii) the average number of efficacy responses.
The study is performed using R (R Core Team, 2015) and 10,000 replications for
each scenario. We compare the characteristics with the “RIV” design proposed by
Riviere et al. (2016) and the “WT” design developed by Wages and Tait (2015).
Parameters of the designs are chosen as in the original proposals with an exception
of using cohort size c = 3 and 80% confidence intervals for stopping rules for the
WT design.
C.2 Design Specifications
As before, we use the target toxicity γt = 0.01 and the target efficacy γe = 0.99.
Due to the known toxicity ordering, the design is restricted to satisfy the coherence
principals given in Equation (4.5.5) and Equation (4.5.6) with q = 1. We consider
non-randomised and hybrid randomised versions of the WE design to study an
allocation rule impact. As design specifications for both variants of the design are
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similar, we provide the algorithm for the non-randomised WE design only.
C.2.1 Operational Prior
Parameters βt,i = βe,i = 1 of the prior Beta distribution in (8) are chosen for all
dose levels i = 1, . . . ,m to emphasize a limited available information. Parame-
ters νt,i and νe,i (which coincide the prior probabilities of toxicity and efficacy for
βt,i = βe,i = 1) are specified such that the WE design leads to accurate optimal
dose selection in many different scenarios. The prior values of νt,i and νe,i are cali-
brated over scenarios 1-8 with different locations of the optimal and correct doses.
There are two restrictions on the prior parameters: the escalation should start
at the first dose and no dose skipping is allowed. To restrict number of possible
parameters to be calibrated over, we assume that prior efficacy and toxicity prob-
ability increases linearly as νt,i = startt +wt × i and νe,i = starte +we × i. Then,
we search for the values of startt, starte, wt, we such that the geometric mean of
the proportion of optimal selection over all scenarios is maximised.
Prior vectors of toxicity probabilities
pˆ
(0)
t = [0.05, 0.14, 0.23, 0.32, 0.41, 0.50]
T
and efficacy probabilities
pˆ(0)e = [0.55, 0.58, 0.61, 0.64, 0.67, 0.70]
T
are subsequently used for the non-randomised WE design.
Similarly, vectors of prior toxicity
pˆ
(0)




pˆ(0)e = [0.65, 0.69, 0.73, 0.77, 0.81, 0.85]
T
efficacy probabilities are used for the randomised WE(R) design. It was found that
the randomised WE(R) design is more robust to the choice of the prior parameter
than non-randomised WE.
C.2.2 Safety Constraint
To set the time-varying safety constraint, we use ζN = 0.30 and calibrate φ
∗, rt
using the highly toxic scenario 14 and the flat scenario 6. These two scenarios
are chosen to represent the trade-off in the safety constraint. The proportion of
correct selections (terminations) and the mean number of patients involved in a
trial for different parameters values are given in Figure C.1. The mean number






























































Figure C.1: Safety constraint parameters calibration: φ∗ ∈ (0.3, 0.5), rt ∈ (0, 0.05)
in scenarios 6 and 14. The proportion of correct selections (terminations) and the
mean number of patients in a trial (scenario 14). The final choice is marked by a
black frame. Results are based on 104 replications.
of patients in scenario 6 does not vary a lot and the corresponding graph is not
shown. In scenario 6 the highest proportion of the optimal selections corresponds
to the least strict safety constraint (right bottom corner), but only 35% of trials
in scenario 14 are then terminated. At the same time, the most strict rule (left
top corner) results in 100% of terminations in scenario 14, but only in 5% of
correct selection in scenario 6. Parameters rt = 0.0125 and φ
∗ = 0.4 are chosen
for subsequent study as a reasonable trade-off. The same parameters of the safety
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constraints are used for the randomised design.
C.2.3 Futility Constraint
We calibrate the futility constraint by fixing ξN = 0.50 and tuning ψ
∗ and re using
two opposite scenarios - 2 and 13. In scenario 2 all doses have the same efficacy
probability. In scenario 13 there are no correct doses as all efficacious doses have
unacceptable toxicity. The proportion of correct selections (terminations) and the
mean number of patients are given in Figure C.2. Since the mean number of

























































Figure C.2: Futility constraint parameters calibration: ψ∗ ∈ (0.1, 0.5) and re ∈
(0, 0.05) in scenarios 2 and 13. The proportion of correct selections (terminations)
and the mean number of patients in a trial (scenario 13). The final choice is in the
black frame. Results are based on 104 replications.
patients in scenario 2 does not vary this graph is not shown. A stricter constraint
is favourable in scenario 13 and less favourable in scenario 2 while the opposite is
true for less strict constraints. Subsequently, parameters ψ∗ = 0.3 and re = 0.05
are used for both non-randomised and randomised designs.
C.3 Operating Characteristics
The results of the comparison in scenarios 1-8 with plateau dose-efficacy relation
and in scenarios 13-14 with no correct doses are summarised in Table C.1 and
Table C.2. Each figure in Table C.1 corresponds to proportions of optimal or
correct dose selections. The detailed results, such as the selection proportions and
mean number of patients on each dose, are given in Table C.4 and Table C.5.
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Table C.1: Proportion of optimal and correct dose selections in scenarios 1-8 and
13-14 using N = 60 patients and m = 6 doses. Results are based on 104 replica-
tions.
Scenario 1 2 3 4 5 6 7 8 13 14
Proportion of the optimal dose selections
WE 58.8 30.3 65.8 71.1 60.3 53.5 60.0 37.8 95.2 96.9
WE (R) 72.0 35.0 51.0 69.9 54.5 56.7 48.5 36.4 93.2 97.4
RIV 57.0 60.2 48.4 53.7 55.3 55.9 37.9 43.0 91.9 91.0
WT 19.6 41.9 29.3 25.3 27.0 65.2 27.1 26.1 91.5 90.4
Proportion of the correct dose selections
WE 60.3 90.0 87.5 79.8 89.7 53.5 77.8 91.5 - -
WE (R) 89.3 97.0 92.8 89.1 87.5 56.7 88.3 91.1 - -
RIV 94.1 96.6 83.8 82.3 80.6 55.9 89.9 77.4 - -
WT 98.1 97.6 93.6 86.5 80.0 65.2 93.3 81.1 - -
With respect to the optimal dose selections, both versions of the proposed design
perform comparably or better than model-based designs in the majority of scenar-
ios. The WE design without randomisation leads to a considerable improvement
in scenarios 3-5, 7 and 13-14 and outperform the best model-based alternative
by up to 20%. While the randomised WE(R) shows the comparable to the best
model-based alternative performance in scenarios 3,5 and 6, it also results in more
accurate optimal dose selections in scenarios 1, 4, 7, 13-14. However, both WE
and WE(R) are outperformed by RIV in scenarios 2 and 8 in which dose-toxicity
and dose-efficacy curves are flat in the neighbourhood of the optimal dose. While
RIV recommends the lowest dose by default, such small differences in toxicity and
efficacy probabilities are difficult to be found using the small sample size. At the
same time, the absence of a parametric model is not found to be a problem in
any other cases. WT design outperforms all other designs in scenario 6 with the
optimal dose being the highest safe one. Generally, WT is less conservative as it
favours safe doses with higher toxicities that results in a low proportion of optimal
selections if the optimal dose is not the highest safe one (see also Table C.4 and
Table C.5).
Considering the proportion of the correct selections, WT outperforms RIV in all
scenarios and has the best performance among all alternatives in scenarios 1-3
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Table C.2: Mean number of toxicity and efficacy responses in scenarios 1 − 8
and 13 − 14 using N = 60 patients and m = 6 doses. Results are based on 104
replications.
Scenario 1 2 3 4 5 6 7 8 13 14
Toxicity responses
WE 3.1 6.0 2.8 4.5 7.9 11.0 5.9 5.6 11.7 11.0
WE (R) 4.0 6.9 4.3 6.0 8.7 10.8 6.9 6.9 13.0 10.9
RIV 5.5 8.1 6.0 10.0 12.1 13.2 9.6 9.3 11.0 11.5
WT 6.8 6.7 7.3 13.2 13.5 14.7 10.0 9.1 11.2 12.1
Efficacy responses
WE 28.5 24.0 33.0 30.0 29.8 19.4 34.6 28.9 6.0 9.1
WE (R) 27.4 24.0 34.5 32.2 29.8 19.2 36.5 29.2 7.1 8.9
RIV 38.0 24.0 34.6 35.0 29.4 21.4 39.1 29.3 6.2 9.6
WT 41.5 24.0 35.5 37.0 32.3 24.4 39.9 29.2 5.4 9.7
and 6-7. In the rest of scenarios, WT has either comparable or worse performance
than the randomised WE(R). Comparing WE and WE(R), the randomised design
is more robust in terms of correct selections with the largest difference in scenario 1.
Here, the chosen prior would not escalate to dose 6 once the optimal is already
found at dose 5 if no randomisation is used.
In terms of toxicities we find that the non-randomised WE design results in a
considerably lower number of toxicities in almost all scenarios with the largest
difference observed in scenario 4. As the WT approach is less conservative, it
results in a greater number of toxicities, but also leads to the highest average
number of efficacies in all scenarios. In contrast, the cost of the WE’s lowest
number of toxicities is a smaller number of efficacies. In scenarios 13 and 14 with
no optimal and correct doses, all alternatives result in nearly the same average
number of toxicities and efficacies.
The results of the comparison in scenarios 9-12 with an umbrella-shaped dose-
efficacy relationship and only one correct dose are given in Table C.3. Overall, WE
designs lead to more robust optimal dose selections in non-monotonic scenarios.
The WE design with no randomisation outperforms RIV by up to 35% and WT by
up to 6%. WT has the highest proportion of the optimal dose selection in scenarios
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Table C.3: Proportions of optimal dose selections, mean number of toxicity and
efficacy responses in scenarios 9-12 using N = 60 patients and m = 6 doses.
Results are based on 104 replications.
Scenario 9 10 11 12 9 10 11 12 9 10 11 12
Optimal selection Toxicity responses Efficacy responses
WE 54.7 55.9 46.5 80.1 4.5 5.7 10.0 1.8 29.7 25.6 27.4 35.4
WE(R) 56.7 56.2 47.9 70.9 5.5 6.7 10.0 3.3 28.4 24.6 27.1 32.7
RIV 20.3 35.3 46.0 96.1 5.0 6.3 12.8 2.6 26.3 23.9 28.7 35.5
WT 50.1 49.3 56.9 75.9 5.5 5.9 12.2 2.4 27.9 24.8 29.4 36.3
11 with nearly 10% difference compared to the non-randomised WE. The RIV
design is more conservative and recommends d1 with the highest probability that
results in the best performance in scenario 12, but poor performance in other cases.
The non-randomised WE is more favourable compared to the randomised version
due to a single correct dose in each scenario. The average number of toxicities of
the WE design is again the safest alternative. In contrast to the scenarios with
a plateau, it can now also result in a larger number of efficacy responses (e.g. in
scenario 9) due to the non-monotonic shape of the dose-efficacy curve.
Overall, the proposed approaches have better or comparable operating charac-
teristics in 9 out of 14 considered scenarios even with less information used in a
trial. Comparing two assignment rule of the WE design, the non-randomised WE
is always less accurate in terms of the correct dose selection. As the result, the
WE design without randomisation should be preferred if only one correct dose is
expected or a clinician is cautious about the toxicity profile, while the randomised
WE is a robust choice if multiple correct doses are expected.
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Table C.4: Operating characteristics of WE, WE(R), RIV and WT designs in sce-
narios 1-4: selection proportions, mean number of patients assigned to a dose (in
brackets), termination proportion (Term), mean number of toxicity (T) and effi-
cacy (E) responses. The optimal dose is in bold and correct doses are underlined.
Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 1
(.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
WE 0.0 0.1 2.3 37.4 58.8 1.5 0.0 3.1 28.5
(6.1) (6.3) (9.5) (20.5) (17.4) (0.3)
WE(R) 0.0 0.2 1.0 9.5 72.0 17.3 0.0 4.0 27.4
(5.1) (5.0) (8.2) (13.8) (21.7) (6.2)
RIV 0.0 0.0 0.7 4.5 57.0 37.1 0.7 5.5 38.0
(3.3) (3.7) (4.8) (7.7) (21.5) (19.0)
WT 0.0 0.1 0.4 1.3 19.6 78.5 0.1 6.8 41.5
(3.9) (1.6) (2.4) (3.6) (11.4) (37.1)
Scenario 2
(.01;.40) (.04;.40) (.10;.40) (.25;.40) (.50;.40) (.70;.40)
WE 30.3 26.3 20.8 12.5 6.3 3.7 0.2 6.0 24.0
(18.3) (17.0) (13.7) (7.9) (2.7) (0.4)
WE(R) 35.0 29.0 21.5 11.5 2.8 0.2 0.1 6.9 24.0
(15.0) (15.7) (15.7) (10.0) (3.3) (0.4)
RIV 60.2 20.3 8.8 7.3 2.6 0.3 0.6 8.1 24.0
(18.8) (13.0) (10.7) (10.7) (5.8) (0.8)
WT 41.9 24.5 16.9 14.2 2.4 0.0 0.0 6.7 24.0
(23.1) (13.0) (10.7) (8.6) (3.4) (1.3)
Scenario 3
(.01;.25) (.02;.45) (.05;.65) (.10;.65) (.20;.65) (.30;.65)
WE 0.6 12.6 65.8 18.2 2.8 0.1 0.0 2.8 33.0
(7.2) (15.9) (29.2) (6.7) (0.9) (0.0)
WE(R) 0.7 6.6 51.0 30.5 10.6 1.2 0.0 4.3 34.5
(6.4) (9.6) (21.3) (16.1) (5.8) (0.9)
RIV 2.0 14.3 48.4 19.2 9.8 6.4 0.0 6.0 34.6
(6.3) (9.8) (15.5) (12.9) (10.4) (5.1)
WT 1.4 4.9 29.3 29.9 22.6 11.8 0.0 7.3 35.5
(6.1) (5.0) (13.8) (14.8) (12.0) (8.3)
Scenario 4
(.01;.05) (.02;.25) (.05;.45) (.10;.70) (.25;.70) (.50;.70)
WE 0.0 0.5 19.6 71.1 8.5 0.3 0.0 4.5 30.0
(6.2) (7.9) (17.8) (25.2) (2.9) (0.1)
WE(R) 0.0 1.3 9.2 69.9 18.5 1.0 0.0 6.0 32.2
(5.4) (6.9) (13.4) (24.1) (9.2) (0.8)
RIV 0.0 0.7 8.2 53.7 28.6 8.5 0.4 10.0 35.0
(3.8) (5.0) (9.1) (19.0) (15.9) (7.0)
WT 0.0 0.4 2.1 25.3 61.2 10.8 0.2 13.2 37.0
(4.5) (2.4) (4.0) (13.5) (24.7) (10.9)
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Table C.5: Operating characteristics of WE, WE(R), RIV and WT designs in sce-
narios 5-8: selection proportions, mean number of patients assigned to a dose (in
brackets), termination proportion (Term), mean number of toxicity (T) and effi-
cacy (E) responses. The optimal dose is in bold and correct doses are underlined.
Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 5
(.01;.10) (.05;.35) (.15;.60) (.20;.60) (.45;.60) (.60;.60)
WE 0.1 6.2 60.3 28.9 3.6 0.8 0.1 7.9 29.8
(6.4) (12.3) (29.4) (10.5) (1.3) (0.1)
WE(R) 0.1 7.3 54.5 35.4 4.2 0.2 0.3 8.7 29.8
(6.1) (12.9) (23.0) (14.8) (3.0) (0.2)
RIV 0.0 8.5 55.3 25.3 9.7 1.2 0.1 12.1 29.4
(5.0) (8.7) (18.5) (15.6) (10.1) (2.0)
WT 0.1 2.7 27.0 53.0 16.9 0.2 0.1 13.5 32.3
(5.2) (4.4) (14.3) (22.3) (11.0) (2.8)
Scenario 6
(.01;.05) (.05;.10) (.10;.20) (.20;.35) (.30;.55) (.50;.55)
WE 0.4 0.8 3.7 18.9 53.5 18.9 4.7 11.0 19.4
(6.6) (7.4) (10.0) (15.7) (16.8) (2.8)
WE(R) 0.4 0.8 4.8 25.4 56.7 7.1 4.4 10.8 19.2
(6.3) (7.7) (11.1) (16.3) (15.2) (2.9)
RIV 0.1 0.7 4.5 17.0 55.9 13.7 8.3 13.2 21.4
(4.5) (5.5) (7.9) (12.4) (19.0) (7.8)
WT 0.2 0.9 3.8 21.4 65.2 5.8 2.7 14.7 24.4
(5.0) (3.0) (5.3) (13.0) (25.1) (7.9)
Scenario 7
(.02;.30) (.07;.50) (.13;.70) (.17;.73) (.25;.76) (.30;.77)
WE 0.5 21.4 60.0 16.2 1.7 0.0 0.0 5.9 34.6
(8.7) (20.6) (25.3) (5.1) (0.4) (0.0)
WE(R) 0.8 10.9 48.5 31.9 7.2 0.6 0.0 6.9 36.5
(8.6) (13.8) (22.0) (12.5) (2.9) (0.3)
RIV 1.4 8.7 37.9 24.5 16.4 11.1 0.0 9.6 39.1
(6.2) (8.9) (14.6) (14.0) (11.3) (5.1)
WT 1.6 5.2 27.1 29.8 24.7 11.7 0.0 10.0 39.9
(6.7) (5.4) (13.7) (14.8) (12.1) (7.3)
Scenario 8
(.03;.30) (.06;.50) (.10;.52) (.20;.54) (.40;.55) (.50;.55)
WE 3.2 37.8 34.7 19.1 4.2 1.0 0.0 5.6 28.9
(9.4) (23.9) (17.8) (7.1) (1.5) (0.1)
WE(R) 3.9 36.4 33.8 20.9 4.4 0.4 0.0 6.9 29.2
(9.2) (16.9) (18.7) (11.7) (3.2) (0.3)
RIV 12.8 43.0 21.7 12.7 8.2 1.7 0.1 9.3 29.3
(10.1) (14.3) (12.8) (12.3) (8.5) (2.0)
WT 7.1 26.1 27.0 28.0 11.3 0.4 0.0 9.1 29.2
(9.9) (13.0) (13.9) (13.8) (7.1) (2.2)
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Table C.6: Operating characteristics of WE, WE(R), RIV and WT designs in sce-
narios 9-12: selection proportions, mean number of patients assigned to a dose (in
brackets), termination proportion (Term), mean number of toxicity (T) and effi-
cacy (E) responses. The optimal dose is in bold and correct doses are underlined.
Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 9
(.01;.30) (.05;.50) (.10;.60) (.15;.40) (.20;.25) (.25;.15)
WE 3.0 34.7 54.7 5.8 1.3 0.5 0.0 4.4 29.7
(8.9) (23.1) (22.5) (3.9) (1.4) (0.4)
WE(R) 4.1 31.4 56.7 6.5 1.1 0.1 0.0 5.5 28.4
(8.5) (15.6) (22.0) (9.1) (3.6) (1.2)
RIV 24.2 54.7 20.3 0.6 0.0 0.0 0.2 5.0 26.3
(13.2) (18.3) (14.1) (8.5) (4.7) (1.2)
WT 7.3 30.9 50.1 8.8 2.1 0.7 0.2 5.5 27.9
(9.8) (15.4) (22.1) (7.1) (3.3) (2.2)
Scenario 10
(.02;.38) (.06;.50) (.12;.40) (.30;.30) (.40;.25) (.50;.20)
WE 18.4 55.9 15.9 3.9 3.2 2.7 0.1 5.7 25.6
(14.7) (27.4) (11.0) (4.3) (2.1) (0.5)
WE(R) 22.7 56.2 17.0 2.5 1.2 0.2 0.1 6.7 24.6
(13.4) (21.4) (14.9) (6.6) (3.0) (0.6)
RIV 60.4 35.3 2.8 0.4 0.1 0.1 1.0 6.3 23.9
(20.2) (17.6) (10.1) (8.0) (3.3) (0.5)
WT 29.0 49.3 15.8 4.9 0.9 0.1 0.1 5.9 24.8
(19.5) (21.6) (10.5) (4.8) (2.3) (1.2)
Scenario 11
(.03;.25) (.09;.35) (.16;.48) (.28;.65) (.42;.52) (.56;.39)
WE 2.2 9.8 30.4 46.5 8.6 2.8 0.2 10.0 27.4
(9.3) (13.5) (19.4) (15.1) (2.4) (0.3)
WE(R) 3.6 12.0 30.9 47.9 5.3 0.5 0.2 10.0 27.1
(10.2) (13.9) (18.0) (14.5) (3.0) (0.2)
RIV 6.7 14.0 27.0 46.0 5.6 0.3 0.3 12.8 28.7
(8.1) (10.2) (14.1) (17.0) (8.7) (1.7)
WT 6.9 9.4 23.2 56.9 3.5 0.0 0.1 12.2 29.4
(9.9) (7.9) (13.8) (22.2) (4.6) (1.6)
Scenario 12
(.02;.68) (.05;.56) (.07;.49) (.09;.40) (.11;.33) (.13;.26)
WE 80.1 14.5 3.9 1.1 0.3 0.1 0.0 1.8 35.4
(44.8) (10.0) (3.4) (1.1) (0.5) (0.1)
WE(R) 70.9 18.7 7.1 2.4 0.9 0.2 0.0 3.3 32.7
(20.5) (15.1) (11.8) (7.0) (3.6) (1.9)
RIV 96.1 3.2 0.6 0.1 0.0 0.0 0.0 2.6 35.5
(34.6) (10.1) (6.4) (4.8) (2.8) (1.4)
WT 75.9 17.1 5.1 1.2 0.6 0.2 0.0 2.4 36.3
(37.0) (11.0) (5.4) (3.0) (2.1) (1.4)
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Table C.7: Operating characteristics of WE, WE(R), RIV and WT designs in
scenarios 13-14: selection proportions, mean number of patients assigned to a
dose (in brackets), termination proportion (Term), mean number of toxicity (T)
and efficacy (E) responses. The optimal dose is in bold and correct doses are
underlined. Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 13
(.05;.01) (.10;.02) (.25;.05) (.55;.35) (.70;.55) (.90;.70)
WE 0.0 0.0 0.2 2.9 0.6 1.1 95.2 11.7 6.0
(6.7) (7.6) (10.9) (12.2) (1.6) (0.1)
WE(R) 0.1 0.0 0.2 4.4 1.1 0.2 93.9 13.0 7.1
(6.9) (7.7) (10.6) (12.1) (3.2) (0.4)
RIV 0.0 0.0 2.3 5.8 0.0 0.0 91.9 11.0 6.2
(5.8) (5.9) (7.7) (11.0) (2.7) (0.3)
WT 0.0 0.1 5.5 3.1 0.0 0.0 91.5 11.2 5.4
(6.3) (6.5) (14.8) (7.9) (1.5) (1.2)
Scenario 14
(.50;.40) (.60;.55) (.69;.65) (.76;.65) (.82;.65) (.89;.65)
WE 2.2 0.2 0.1 0.3 0.2 0.0 96.9 11.0 9.1
(17.6) (2.8) (0.6) (0.1) (0.0) (0.0)
WE(R) 1.9 0.5 0.3 0.2 0.0 0.0 97.4 10.9 8.9
(17.6) (2.4) (0.8) (0.1) (0.0) (0.0)
RIV 8.8 0.2 0.0 0.0 0.0 0.0 91.0 11.5 9.6
(16.0) (4.3) (1.1) (0.2) (0.0) (0.0)
WT 9.5 0.0 0.0 0.0 0.0 0.0 90.4 12.1 9.7
(23.0) (0.4) (0.1) (0.1) (0.1) (0.1)
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C.4 Early Efficacy Data
In the setting above, it is assumed that it takes twice as long to observe the efficacy
outcome than the toxicity endpoint. It is, however, possible that an efficacy (or
lack of efficacy) can be observed at the time of the interim analysis for some of
the patients. As the proposed design includes all available information, it can also
accommodate earlier efficacy (no efficacy) data. This section we study how the
operating characteristics of the non-randomised WE design are affected if a certain
proportion of “no efficacy” responses can be observed earlier.
The setting above remains unchanged with the following exception: if the patient
has observed no DLT and will have “no efficacy”, it is assumed that the outcome
can be observed at the time of toxicity evaluation with probability pi. If observed
earlier, the WE design uses this information for the next patient allocation. We
consider two cases: pi = 0 (the original setting) and pi = 1/2 (half of “no efficacy”
responses can be observed earlier). The results are given in Table C.8.
As expected, the availability of some of the efficacy information earlier leads to a
less conservative design that allows a more rapid escalation. Earlier “no efficacy”
data even in half of the patients lead to more ethical patient allocation. This can be
seen by increased numbers of efficacy responses almost in all scenarios with the cost
of a reasonable increase in the average number of toxicity responses. The largest
increase can be seen in scenario 1 where the average number of efficacy response
increase by nearly 7, while toxicity increases only by 1. The information about
earlier efficacy also improves the proportion of optimal selections in the scenarios
where the target dose is high - by 6% in scenario 1 and by 4% in scenario 6. As
the design being less conservative it favours higher doses among correct ones. This
decreases the proportion of optimal selections in scenario 3, 5, 7 and 12 by 3-7%.
At the same time, the proportion of correct selections is either unchanged (scenario
5 and 8) or increased by at least 5% (all the rest plateau scenarios). This confirms
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Table C.8: Operating characteristics of WE in scenarios 1-12 with no early efficacy
data available (pi = 0) and with half “no efficacy” outcomes (pi = 1/2) available
at the time of toxicity evaluation: selection proportions, mean number of toxicity
(T) and efficacy (E) responses . The optimal dose is in bold and correct doses are
underlined. Results are based on 104 replications.
WE d1 d2 d3 d4 d5 d6 T E
Sc.1 (.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
pi = 0 0.0 0.1 2.3 37.4 58.8 1.5 3.1 28.5
pi = 1/2 0.0 0.0 1.5 23.5 64.9 10.0 4.3 34.8
Sc. 2 (.01;.40) (.04;.40) (.10;.40) (.25;.40) (.50;.40) (.70;.40)
pi = 0 30.3 26.3 20.8 12.5 6.3 3.7 6.0 24.0
pi = 1/2 33.2 27.1 21.9 12.2 3.7 1.6 7.2 24.0
Sc. 3 (.01;.25) (.02;.45) (.05;.65) (.10;.65) (.20;.65) (.30;.65)
pi = 0 0.6 12.6 65.8 18.2 2.8 0.1 2.8 33.0
pi = 1/2 0.9 9.4 57.7 24.0 6.8 1.1 3.7 34.8
Sc. 4 (.01;.05) (.02;.25) (.05;.45) (.10;.70) (.25;.70) (.50;.70)
pi = 0 0.0 0.5 19.6 71.1 8.5 0.3 4.5 30.0
pi = 1/2 0.0 0.9 14.6 68.0 15.8 0.7 5.9 33.9
Sc. 5 (.01;.10) (.05;.35) (.15;.60) (.20;.60) (.45;.60) (.60;.60)
pi = 0 0.1 6.2 60.3 28.9 3.6 0.8 7.9 29.8
pi = 1/2 0.1 6.3 56.8 32.8 3.3 0.7 9.2 31.5
Sc. 6 (.01;.05) (.05;.10) (.10;.20) (.20;.35) (.30;.55) (.50;.55)
pi = 0 0.4 0.8 3.7 18.9 53.5 18.9 11.0 19.4
pi = 1/2 1.4 1.4 4.9 22.2 57.2 10.0 13.1 22.2
Sc. 7 (.02;.30) (.07;.50) (.13;.70) (.17;.73) (.25;.76) (.30;.77)
pi = 0 0.5 21.4 60.0 16.2 1.7 0.0 5.9 34.6
pi = 1/2 0.9 16.4 53.4 23.2 5.5 0.6 6.9 37.0
Sc. 8 (.03;.30) (.06;.50) (.10;.52) (.20;.54) (.40;.55) (.50;.55)
pi = 0 3.2 37.8 34.7 19.1 4.2 1.0 5.6 28.9
pi = 1/2 3.0 37.8 34.0 20.1 4.0 1.1 6.9 29.5
Sc. 9 (.01;.30) (.05;.50) (.10;.60) (.15;.40) (.20;.25) (.25;.15)
pi = 0 3.0 34.7 54.7 5.8 1.3 0.5 4.4 29.7
pi = 1/2 3.8 34.2 54.6 6. 1.1 0.2 5.1 29.7
Sc. 10 (.02;.38) (.06;.50) (.12;.40) (.30;.30) (.40;.25) (.50;.20)
pi = 0 18.4 55.9 15.9 3.9 3.2 2.7 5.7 25.6
pi = 1/2 20.2 57.1 17.2 2.8 1.6 1.0 6.3 25.5
Sc. 11 (.03;.25) (.09;.35) (.16;.48) (.28;.65) (.42;.52) (.56;.39)
pi = 0 2.2 9.8 30.4 46.5 8.6 2.8 10.0 27.4
pi = 1/2 3.5 10.8 31.7 45.5 6.3 1.8 11.4 28.8
Sc. 12 (.02;.68) (.05;.56) (.07;.49) (.09;.40) (.11;.33) (.13;.26)
pi = 0 80.1 14.5 3.9 1.1 0.3 0.1 1.8 35.4
pi = 1/2 74.1 17.5 5.8 1.8 0.6 0.1 2.2 36.8
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that the WE design in the setting with no earlier efficacy information is more
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